
<html lang="en"     class="pb-page"  data-request-id="9c32fe94-c278-4de9-ae1e-bef09681a43e"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.5b01052;website:website:acspubs;issue:issue:10.1021/jmcmar.2015.58.issue-23;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway" /></meta><meta name="dc.Creator" content="Yong  Ling" /></meta><meta name="dc.Creator" content="Chenjun  Xu" /></meta><meta name="dc.Creator" content="Lin  Luo" /></meta><meta name="dc.Creator" content="Jingyi  Cao" /></meta><meta name="dc.Creator" content="Jiao  Feng" /></meta><meta name="dc.Creator" content="Yu  Xue" /></meta><meta name="dc.Creator" content="Qing  Zhu" /></meta><meta name="dc.Creator" content="Caoyun  Ju" /></meta><meta name="dc.Creator" content="Fengzhi  Li" /></meta><meta name="dc.Creator" content="Yihua  Zhang" /></meta><meta name="dc.Creator" content="Yanan  Zhang" /></meta><meta name="dc.Creator" content="Xiang  Ling" /></meta><meta name="dc.Description" content="A novel series of hybrids from β-carboline and hydroxamic acid were designed and synthesized. Several compounds (5m, 11b–d, and 11h) not only exerted significant antiproliferation activity against ..." /></meta><meta name="Description" content="A novel series of hybrids from β-carboline and hydroxamic acid were designed and synthesized. Several compounds (5m, 11b–d, and 11h) not only exerted significant antiproliferation activity against ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 24, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01052" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01052" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01052" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01052" /></link>
        
    
    

<title>Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01052" /></meta><meta property="og:title" content="Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0013.jpeg" /></meta><meta property="og:description" content="A novel series of hybrids from β-carboline and hydroxamic acid were designed and synthesized. Several compounds (5m, 11b–d, and 11h) not only exerted significant antiproliferation activity against four human colorectal cancer (CRC) cell lines but also showed histone deacetylase inhibitory effects in vitro. The most potent compound, 11c, exhibited anticancer potency sevenfold higher than that of SAHA. 11c triggered more significant cancer cell apoptosis than did SAHA by cleavage of both PARP and caspase 3 in a dose-dependent manner. Furthermore, 11c simultaneously increased the acetylation of histone H3 and α-tubulin, enhanced expression of DNA damage markers histone H2AX phosphorylation and p-p53 (Ser15), and activated p53 signaling pathway in HCT116 cells. Finally, 11c showed low acute toxicity in mice and inhibited the growth of implanted human CRC in mice more potently than did SAHA. Together, 11c possessed potent antitumor activity and may be a promising candidate for the potential treatment of human CRC." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01052"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01052">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01052&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01052&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01052&amp;href=/doi/10.1021/acs.jmedchem.5b01052" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2015</span><span class="cit-fg-volume">, 58</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 9214-9227</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/58/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01047" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01125" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yong++Ling">Yong Ling</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chenjun++Xu">Chenjun Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lin++Luo">Lin Luo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jingyi++Cao">Jingyi Cao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jiao++Feng">Jiao Feng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yu++Xue">Yu Xue</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qing++Zhu">Qing Zhu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Caoyun++Ju">Caoyun Ju</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengzhi++Li">Fengzhi Li</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yihua++Zhang">Yihua Zhang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yanan++Zhang">Yanan Zhang</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Xiang++Ling">Xiang Ling</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1a"><span class="aff-text"><sup>†</sup>School of Pharmacy and Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P.R. China</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">§</span> <span class="aff-text">Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#760c1e1718110f1718171836111b171f1a5815191b"><span class="__cf_email__" data-cfemail="73091b121d140a121d121d33141e121a1f5d101c1e">[email protected]</span></a>. Phone: +86-513-85051892.</div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#0e76676f606920606f607a6160694e69636f6762206d6163"><span class="__cf_email__" data-cfemail="8df5e4ece3eaa3e3ece3f9e2e3eacdeae0ece4e1a3eee2e0">[email protected]</span></a>. Phone: +86-513-85051749.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01052&amp;href=/doi/10.1021%2Facs.jmedchem.5b01052" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2015</span></span><span class="cit-volume">, 58</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 9214–9227</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 10, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>6 July 2015</li><li><span class="item_label"><b>Published</b> online</span>24 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2015</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01052" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01052</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9214%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYong%2BLing%252C%2BChenjun%2BXu%252C%2BLin%2BLuo%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D58%26issueNum%3D23%26contentID%3Dacs.jmedchem.5b01052%26title%3DNovel%2B%25CE%25B2-Carboline%252FHydroxamic%2BAcid%2BHybrids%2BTargeting%2BBoth%2BHistone%2BDeacetylase%2Band%2BDNA%2BDisplay%2BHigh%2BAnticancer%2BActivity%2Bvia%2BRegulation%2Bof%2Bthe%2Bp53%2BSignaling%2BPathway%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9227%26publicationDate%3DDecember%2B2015">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01052"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2625</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">45</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01052" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel β-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yong&quot;,&quot;last_name&quot;:&quot;Ling&quot;},{&quot;first_name&quot;:&quot;Chenjun&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Lin&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Jingyi&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Jiao&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Yu&quot;,&quot;last_name&quot;:&quot;Xue&quot;},{&quot;first_name&quot;:&quot;Qing&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Caoyun&quot;,&quot;last_name&quot;:&quot;Ju&quot;},{&quot;first_name&quot;:&quot;Fengzhi&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Yihua&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Yanan&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Xiang&quot;,&quot;last_name&quot;:&quot;Ling&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;58&quot;,&quot;pages&quot;:&quot;9214-9227&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01052&quot;},&quot;abstract&quot;:&quot;A novel series of hybrids from β-carboline and hydroxamic acid were designed and synthesized. Several compounds (5m, 11b–d, and 11h) not only exerted significant antiproliferation activity against four human colorectal cancer (CRC) cell lines but also showed histone deacetylase inhibitory effects in vitro. The most potent compound, 11c, exhibited anticancer potency sevenfold higher than that of SAHA. 11c triggered more significant cancer cell apoptosis than did SAHA by cleavage of both PARP and caspase 3 in a dose-dependent manner. Furthermore, 11c simultaneously increased the acetylation of histone H3 and α-tubulin, enhanced expression of DNA damage markers histone H2AX phosphorylation and p-p53 (Ser15), and activated p53 signaling pathway in HCT116 cells. Finally, 11c showed low acute toxicity in mice and inhibited the growth of implanted human CRC in mice more potently than did SAHA. Together, 11c possessed potent antitumor activity and may be a promising candidate for the potential treatment of human CRC.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01052&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01052" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01052&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01052" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01052&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01052" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01052&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01052&amp;href=/doi/10.1021/acs.jmedchem.5b01052" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01052" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01052" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01052%26sid%3Dliteratum%253Aachs%26pmid%3D26555243%26genre%3Darticle%26aulast%3DLing%26date%3D2015%26atitle%3DNovel%2B%25CE%25B2-Carboline%252FHydroxamic%2BAcid%2BHybrids%2BTargeting%2BBoth%2BHistone%2BDeacetylase%2Band%2BDNA%2BDisplay%2BHigh%2BAnticancer%2BActivity%2Bvia%2BRegulation%2Bof%2Bthe%2Bp53%2BSignaling%2BPathway%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D58%26issue%3D23%26spage%3D9214%26epage%3D9227%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/58/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/jmcmar.2015.58.issue-23/20151210/jmcmar.2015.58.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of hybrids from β-carboline and hydroxamic acid were designed and synthesized. Several compounds (<b>5m</b>, <b>11b</b>–<b>d</b>, and <b>11h</b>) not only exerted significant antiproliferation activity against four human colorectal cancer (CRC) cell lines but also showed histone deacetylase inhibitory effects in vitro. The most potent compound, <b>11c</b>, exhibited anticancer potency sevenfold higher than that of SAHA. <b>11c</b> triggered more significant cancer cell apoptosis than did SAHA by cleavage of both PARP and caspase 3 in a dose-dependent manner. Furthermore, <b>11c</b> simultaneously increased the acetylation of histone H3 and α-tubulin, enhanced expression of DNA damage markers histone H2AX phosphorylation and p-p53 (Ser15), and activated p53 signaling pathway in HCT116 cells. Finally, <b>11c</b> showed low acute toxicity in mice and inhibited the growth of implanted human CRC in mice more potently than did SAHA. Together, <b>11c</b> possessed potent antitumor activity and may be a promising candidate for the potential treatment of human CRC.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31857" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31857" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Colorectal cancer (CRC) is currently the third most common cancer worldwide and the second leading cause of cancer death in both men and women in the United States. Despite the advances in the diagnosis and treatment of CRC that have resulted in significant improvement on management of this malignancy, significant challenges remain in the treatment of CRC. In particular, many patients with advanced and metastatic tumors still succumb to the disease.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Alternative and novel molecular-targeted therapeutic approaches are urgently needed. Traditionally, agents designed to hit single biological targets have been the main approach in therapeutics development. However, it becomes apparent that these magic bullet drugs often have limited clinical utility and might not be the answer to treating complex illnesses such as cancer. This is because tumors normally harbor multiple misregulated growth and survival pathways, which can easily evolve during drug treatment.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Therefore, single drugs with multiple biological targets have increasingly attracted interest in cancer treatment.</div><div class="NLM_p">Natural products have been a rich source of compounds for drug discovery, and the majority of anticancer drugs currently used in clinical settings are derived from natural product scaffolds such as paclitaxel and vincaleukoblastine. β-Carbolines are a class of naturally occurring alkaloids that contain a planar tricyclic pyrido-[3,4-<i>b</i>]indole ring structure and are widely distributed in plants, marine creatures, insects, and mammals as well as human tissues and bodily fluids.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> β-Carboline alkaloids such as harmine and its derivatives have shown a variety of pharmacological activities, particularly antitumor effects (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> These compounds have been shown to inhibit cancer cell growth and lead to apoptosis through multiple mechanisms such as inhibition of DNA topoisomerases I and II, CDK, PLK, and MAO.<a onclick="showRef(event, 'ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9 ref10">(7-10)</a> In particular, β-carbolines can intercalate with DNA, alter DNA replication fidelity, and influence enzymatic activities in DNA repair processes because of the presence of polycyclic aromatic planar pharmacophore, which is capable of stacking between DNA base pairs.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> In fact, several β-carbolines including harmane, norharman, and β-carboline–benzimidazole conjugates have been reported to intercalate into DNA, leading to altered DNA replication fidelity or to influencing of enzymatic activities in DNA repair processes.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a></div><div class="NLM_p">Inhibition of histone deacetylases (HDACs) has emerged as a promising therapeutic approach to the treatment of cancer. It has been shown that HDAC inhibitors (HDACi) significantly suppress cancer cell proliferation, angiogenesis, and metastasis and induce apoptosis through multiple mechanisms, including changes in gene expression and alterations of both histone and nonhistone proteins such as p53 and heat shock protein 90.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> Several HDAC inhibitors have been approved to date. Despite promising results in the treatment of cutaneous T-cell lymphoma, the two U.S. FDA-approved HDACi’s, Vorinostat (SAHA)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and romidepsin,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> have not proven effective in clinical trials involving solid tumors.<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19-21)</a> Other HDACi’s that have recently been approved include belinostat (PXD101), panobinostat (LBH589), and chidamide (Epidaza) for the treatment of PTCL or multiple myeloma,<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22-24)</a> but their effects on solid tumors have not been examined.</div><div class="NLM_p">Interestingly, recent results from in vitro and in vivo studies have demonstrated that HDACi’s possess synergistic or additive antitumor effects in combination with several classes of anticancer drugs.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25-27)</a> For instance, several reports suggest a synergy between HDACi’s and DNA damage reagents cisplatin, topotecan, or etoposide.<a onclick="showRef(event, 'ref3 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref3 ref28 ref29 ref30">(3, 28-30)</a> Therefore, given the DNA damage effects of β-carbolines, the combination of HDACi’s and β-carboline alkaloids may represent a promising strategy to achieve increased anticancer efficacy (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). In this first proof-of-principle study, we aimed to simultaneously target multiple pathways by integrating the key structural elements of β-carboline alkaloids and HDACi’s into one single structure to form hybrids.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative β-carboline derivatives, HDAC inhibitor SAHA, and designed β-carboline/hydroxamic acid hybrids <b>5a</b>–<b>o</b> and <b>11a</b>–<b>j</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">HDAC inhibitors generally consist of three domains: a zinc-binding group (ZBG) that chelates with the zinc ion to form a complex; a cap group, generally a hydrophobic and aromatic group, linked to the ZBG that fits into the tubular pocket; and a saturated or unsaturated linker domain composed of linear or cyclic structures that connect the ZBG and the cap group.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> It has been demonstrated the cap group can be replaced with other moieties to generate HDACi’s with dual or multiple targets, and several of these have displayed potential in preclinical studies.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32, 33)</a> In fact, Kozikowski et al. reported a series of HDAC6 inhibitors based on a β- or γ-tetrahydrocarboline and SAHA combination that showed improved isoform selectivity.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In this study, we used β-carboline aromatic heterocyclic ring as a cap group, and designed novel hybrids by introducing the ZBG group (the hydroxamic acid fragment) into the carboxyl or uramido group of β-carboline via alkyl linkers (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). We herein report the synthesis and biological evaluation of a series of novel β-carboline/hydroxamic acid hybrids (<b>5a</b>–<b>o</b>, <b>11a</b>–<b>j</b>), as well as the investigation on their antitumor mechanisms in multiple colon cancer cell lines.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34655" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34655" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">The synthesis route to compounds <b>5a</b>–<b>o</b> is depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. The substituted β-carbolines <b>3a</b>–<b>c</b> were prepared in a two-step sequence. First, starting <span class="smallcaps smallerCapital">L</span>-tryptophan <b>1</b> was converted to 1-substituted 1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid <b>2a</b>–<b>c</b> in a Pictet–Spengler reaction with the treatment of differently substituted aldehydes. Intermediates <b>2a</b>–<b>c</b> were then oxidized by KMnO<sub>4</sub> in DMF to afford compounds <b>3a</b>–<b>c</b>, which were then reacted with NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe in the presence of ethyl chloroformate to produce esters <b>4a</b>–<b>o</b>. Finally, intermediates <b>4a</b>–<b>o</b> were treated with NH<sub>2</sub>OK to give target compounds <b>5a</b>–<b>o</b>.</div><div class="NLM_p">Compounds <b>11a</b>–<b>j</b> were obtained according to the procedures described in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Acid <b>3c</b> was esterified to give methyl ester <b>6</b>, which was then reacted with iodomethane in the presence of NaH to afford <i>N</i>-methyl compound <b>7</b>. Intermediate <b>6</b> or <b>7</b> was treated with hydrazine hydrate to form hydrazide derivatives <b>8a</b>–<b>b</b>. The hydrazide group of <b>8a</b>–<b>b</b> was converted to the acylazide group in the presence of NaNO<sub>2</sub> to provide <b>9a</b>–<b>b</b>, which were then reacted with NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe to give <b>10a</b>–<b>j</b> via Curtius rearrangement. Finally, ureas <b>10a</b>–<b>j</b> were converted to hydroxamic acids <b>11a</b>–<b>j</b> with the treatment of NH<sub>2</sub>OK in MeOH. Final products <b>5a</b>–<b>o</b> and <b>11a</b>–<b>j</b> were purified by column chromatography, and their structures were characterized by <sup>1</sup>H NMR, MS, and HRMS.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0011.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Procedure to Obtain Compounds <b>5a</b>–<b>o</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>H<sup>+</sup> or OH<sup>–</sup>, RCHO, reflux, 2–4 h, 81–86%.</p><p><span class="fn-label">Scheme b</span>KMnO<sub>4</sub>, DMF, reflux, 6 h, 60–70%.</p><p><span class="fn-label">Scheme c</span>Ethyl chloroformate, <i>N</i>-methylmorpholine, NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe, rt, 5–8 h, 71–83%.</p><p class="last"><span class="fn-label">Scheme d</span>NH<sub>2</sub>OK, MeOH, rt, 10–15 h, 68–77%.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0012.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Procedure to Obtain Compounds <b>11a</b>–<b>j</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>SOCl<sub>2</sub>, MeOH, 0 °C, 1h, and then reflux 6 h, 90%.</p><p><span class="fn-label">Scheme b</span>CH<sub>3</sub>I, NaH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2–4 h, 81–86%.</p><p><span class="fn-label">Scheme c</span>NH<sub>2</sub>–NH<sub>2</sub>·H<sub>2</sub>O, CH<sub>3</sub>OH, 0 °C, 1h, 90–95%.</p><p><span class="fn-label">Scheme d</span>NaNO<sub>2</sub>, CH<sub>3</sub>OH, 0 °C, 6 h, 73–80%.</p><p><span class="fn-label">Scheme e</span>NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe, toluene, reflux, 1 h, 77–85%.</p><p class="last"><span class="fn-label">Scheme f</span>NH<sub>2</sub>OK, MeOH, 63–75%.</p></p></figure><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of cell proliferation (%) of target compounds <b>5a</b>–<b>o</b> against HCT116, SW620, and LOVO cell lines after incubation for 48 h at a concentration of 25 μM. Data are expressed as means ± SD of each compound from three separate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> In Vitro Biological Evaluations</h3><div class="NLM_p">Compounds <b>5a</b>–<b>o</b> were preliminarily screened at 25 μM for their cancer cell growth inhibitory activity against three human CRC cell lines (HCT116, SW620, and LOVO) in the MTT assay. These compounds were designed to evaluate the substitutions–activity relationships (SARs) at the C1 position of the β-carbolines. SAHA, the FDA approved HDAC inhibitor, was used as a reference compound. As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, SAHA significantly inhibited the proliferation of the cells. Interestingly, compounds <b>5a</b>–<b>e</b> with R = H as in norhamane and <b>5f</b>–<b>j</b> with R = Me as in harmane all showed limited antiproliferative activities. β-Carbolines (<b>5k</b>–<b>o</b>) with a <i>p</i>-methoxyphenyl group at the C1 positions as present in the previously reported β-carboline–benzimidazole conjugates markedly inhibited all three CRC cells at 25 μM, showing comparable or even greater inhibition than that of SAHA on the growth of all three CRC cells. These results indicate that a <i>p</i>-methoxyphenyl group is preferred for activity at the C1 position.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Compounds <b>5a</b>–<b>o</b> and <b>11a</b>–<b>j</b> and Their HDAC Inhibition</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>n</i></th><th class="colsep0 rowsep0" align="center" char=".">ClogP</th><th class="colsep0 rowsep0" align="center" char="±">nuclear extract (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">0.86</td><td class="colsep0 rowsep0" align="char" char="±">0.56 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">harmine</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="±">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">–0.23</td><td class="colsep0 rowsep0" align="char" char="±">6.17 ± 0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">–0.06</td><td class="colsep0 rowsep0" align="char" char="±">3.23 ± 0.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">0.16</td><td class="colsep0 rowsep0" align="char" char="±">1.56 ± 0.34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">0.46</td><td class="colsep0 rowsep0" align="char" char="±">1.43 ± 0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">0.69</td><td class="colsep0 rowsep0" align="char" char="±">1.81 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5f</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td><td class="colsep0 rowsep0" align="char" char="±">5.37 ± 0.75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5g</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">0.40</td><td class="colsep0 rowsep0" align="char" char="±">2.45 ± 0.36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5h</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">0.62</td><td class="colsep0 rowsep0" align="char" char="±">1.21 ± 0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5i</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td><td class="colsep0 rowsep0" align="char" char="±">1.26 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5j</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">1.15</td><td class="colsep0 rowsep0" align="char" char="±">1.43 ± 0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">p-MeOPh</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">1.77</td><td class="colsep0 rowsep0" align="char" char="±">3.02 ± 0.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">p-MeOPh</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">1.94</td><td class="colsep0 rowsep0" align="char" char="±">1.31 ± 0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">p-MeOPh</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">2.15</td><td class="colsep0 rowsep0" align="char" char="±">0.67 ± 0.08</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">p-MeOPh</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">2.45</td><td class="colsep0 rowsep0" align="char" char="±">0.81 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">p-MeOPh</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">2.68</td><td class="colsep0 rowsep0" align="char" char="±">1.17 ± 0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">2.87</td><td class="colsep0 rowsep0" align="char" char="±">2.24 ± 0.35</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">3.03</td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">3.25</td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">3.55</td><td class="colsep0 rowsep0" align="char" char="±">0.35 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">3.78</td><td class="colsep0 rowsep0" align="char" char="±">0.82 ± 0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char=".">3.14</td><td class="colsep0 rowsep0" align="char" char="±">3.16 ± 0.37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">2</td><td class="colsep0 rowsep0" align="char" char=".">3.30</td><td class="colsep0 rowsep0" align="char" char="±">1.33 ± 0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char=".">3.52</td><td class="colsep0 rowsep0" align="char" char="±">0.51 ± 0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">4</td><td class="colsep0 rowsep0" align="char" char=".">3.82</td><td class="colsep0 rowsep0" align="char" char="±">0.86 ± 0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11j</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">5</td><td class="colsep0 rowsep0" align="char" char=".">4.05</td><td class="colsep0 rowsep0" align="char" char="±">1.05 ± 0.16</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">The data are expressed as the mean ± SD of three independent experiments data.</p></div></div></div><div class="NLM_p">Compounds <b>5a</b>–<b>o</b> were also assayed for their inhibitory activity against HeLa cell nuclear extract, which is a rich source of HDACs.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The calculated lipophilicity (ClogP) and IC<sub>50</sub> values of compounds <b>5a</b>–<b>o</b> against HDAC are listed in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Compounds with one to two methylene units as the linker showed weak enzymatic inhibition (<b>5a</b>, <b>5b</b>, <b>5f</b>, <b>5g</b>, <b>5k</b>, and <b>5l</b>). The HDAC inhibitory activities increased for compounds with linker bearing three to five methylene units. This trend is the same in all three series (<b>5a</b>–<b>e</b>, <b>5f</b>–<b>j</b>, and <b>5k</b>–<b>o</b>), independent of the C1 substitution. This clearly shows that the linker length is highly important for HDAC activity. However, the substitutions at β-carboline C1 positions also played a role in the HDAC inhibitory activities, albeit in a less pronounced manner. Compounds <b>5k</b>–<b>o</b> with the <i>p</i>-methoxyphenyl group were more potent than the corresponding compounds in the R = H (<b>5a</b>–<b>e</b>) or R = Me (<b>5f</b>–<b>j</b>) series. It should be noted that the ClogP values showed the same trend across the three series (e.g., <b>5c</b>, <b>5h</b> and <b>5m</b> are 0.16, 0.62, and 2.15, respectively). Among all the compounds, <b>5m</b>–<b>n</b> showed IC<sub>50</sub> values similar to those of SAHA in the nuclear extract. These results suggest that a three- or four-carbon (<i>n</i> = 3 or 4) linker is preferred for HDAC activity, similar to the antiproliferation activities of these compounds.</div><div class="NLM_p">Compounds <b>5k</b>–<b>o</b> were then further tested, and the dose–response curves against four colon cancer cell lines (HCT116, SW620, SW480, and LOVO) were obtained. In these cell lines, these compounds all inhibited cell proliferation at significantly greater potency than did the β-carboline compound harmine and were comparable to SAHA (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Similarly, a clear dependency of the potency on the linker length is present during this series, where the antiproliferative potency initially increased and then deceased with the elongation of the linker. Compounds <b>5m</b>–<b>n</b> with three- or four-carbon linkers (<i>n</i> = 3 or 4) were the more potent compounds in the series.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. IC<sub>50</sub> Values of Compounds <b>5k</b>–<b>o</b> and <b>11a</b>–<b>j</b> against Four CRC Cell Lines<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="4" align="center">in vitro antiproliferative activity (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">HCT116</th><th class="colsep0 rowsep0" align="center" char="±">SW620</th><th class="colsep0 rowsep0" align="center">LOVO</th><th class="colsep0 rowsep0" align="center">SW480</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="left">5.53 ± 0.68</td><td class="colsep0 rowsep0" align="char" char="±">4.32 ± 0.45</td><td class="colsep0 rowsep0" align="left">6.75 ± 0.58</td><td class="colsep0 rowsep0" align="left">3.97 ± 0.52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">harmine</td><td class="colsep0 rowsep0" align="left">46.7 ± 3.92</td><td class="colsep0 rowsep0" align="char" char="±">42.8 ± 4.31</td><td class="colsep0 rowsep0" align="left">53.2 ± 4.35</td><td class="colsep0 rowsep0" align="left">ND<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">63.4 ± 6.75</td><td class="colsep0 rowsep0" align="char" char="±">71.7 ± 6.82</td><td class="colsep0 rowsep0" align="left">76.5 ± 8.16</td><td class="colsep0 rowsep0" align="left">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5k</b></td><td class="colsep0 rowsep0" align="left">>12.5</td><td class="colsep0 rowsep0" align="char" char="±">6.92 ± 0.59</td><td class="colsep0 rowsep0" align="left">>12.5</td><td class="colsep0 rowsep0" align="left">10.5 ± 0.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5l</b></td><td class="colsep0 rowsep0" align="left">8.64 ± 0.77</td><td class="colsep0 rowsep0" align="char" char="±">6.73 ± 0.71</td><td class="colsep0 rowsep0" align="left">9.01 ± 0.84</td><td class="colsep0 rowsep0" align="left">11.2 ± 0.85</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="left">2.72 ± 0.36</td><td class="colsep0 rowsep0" align="char" char="±">4.46 ± 0.52</td><td class="colsep0 rowsep0" align="left">3.77 ± 0.39</td><td class="colsep0 rowsep0" align="left">4.65 ± 0.56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5n</b></td><td class="colsep0 rowsep0" align="left">3.35 ± 0.42</td><td class="colsep0 rowsep0" align="char" char="±">2.53 ± 0.35</td><td class="colsep0 rowsep0" align="left">5.28 ± 0.48</td><td class="colsep0 rowsep0" align="left">4.43 ± 0.40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5o</b></td><td class="colsep0 rowsep0" align="left">7.16 ± 0.73</td><td class="colsep0 rowsep0" align="char" char="±">8.06 ± 0.68</td><td class="colsep0 rowsep0" align="left">7.90 ± 0.65</td><td class="colsep0 rowsep0" align="left">9.83 ± 0.86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11a</b></td><td class="colsep0 rowsep0" align="left">8.52 ± 0.90</td><td class="colsep0 rowsep0" align="char" char="±">7.12 ± 0.63</td><td class="colsep0 rowsep0" align="left">9.36 ± 1.02</td><td class="colsep0 rowsep0" align="left">10.1 ± 0.94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="left">3.08 ± 0.41</td><td class="colsep0 rowsep0" align="char" char="±">2.69 ± 0.30</td><td class="colsep0 rowsep0" align="left">3.61 ± 0.45</td><td class="colsep0 rowsep0" align="left">3.11 ± 0.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="left">0.83 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">0.94 ± 0.15</td><td class="colsep0 rowsep0" align="left">1.63 ± 0.31</td><td class="colsep0 rowsep0" align="left">1.16 ± 0.28</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="left">0.99 ± 0.26</td><td class="colsep0 rowsep0" align="char" char="±">2.02 ± 0.29</td><td class="colsep0 rowsep0" align="left">2.17 ± 0.26</td><td class="colsep0 rowsep0" align="left">1.73 ± 0.30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11e</b></td><td class="colsep0 rowsep0" align="left">4.84 ± 0.45</td><td class="colsep0 rowsep0" align="char" char="±">6.25 ± 0.70</td><td class="colsep0 rowsep0" align="left">7.34 ± 0.65</td><td class="colsep0 rowsep0" align="left">5.09 ± 0.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11f</b></td><td class="colsep0 rowsep0" align="left">9.30 ± 0.73</td><td class="colsep0 rowsep0" align="char" char="±">8.36 ± 0.75</td><td class="colsep0 rowsep0" align="left">>12.5</td><td class="colsep0 rowsep0" align="left">9.81 ± 1.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11g</b></td><td class="colsep0 rowsep0" align="left">4.27 ± 0.50</td><td class="colsep0 rowsep0" align="char" char="±">5.02 ± 0.49</td><td class="colsep0 rowsep0" align="left">5.66 ± 0.60</td><td class="colsep0 rowsep0" align="left">4.40 ± 0.38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="left">1.33 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±">1.93 ± 0.22</td><td class="colsep0 rowsep0" align="left">3.02 ± 0.35</td><td class="colsep0 rowsep0" align="left">3.15 ± 0.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11i</b></td><td class="colsep0 rowsep0" align="left">3.87 ± 0.43</td><td class="colsep0 rowsep0" align="char" char="±">5.09 ± 0.48</td><td class="colsep0 rowsep0" align="left">6.24 ± 0.66</td><td class="colsep0 rowsep0" align="left">5.80 ± 0.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11j</b></td><td class="colsep0 rowsep0" align="left">8.76 ± 0.91</td><td class="colsep0 rowsep0" align="char" char="±">9.53 ± 0.80</td><td class="colsep0 rowsep0" align="left">>12.5</td><td class="colsep0 rowsep0" align="left">>12.5</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">The inhibitory effects of individual compounds on the proliferation of cancer cell lines were determined by the MTT assay. The data are expressed as the mean ± SD of three independent experiments data.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">ND: not detected.</p></div></div></div><div class="NLM_p">We next introduced structural modifications at other positions of the β-carboline ring to investigate the SAR further. Given the importance of the <i>p</i>-methoxyphenyl group at the C1 position, it was retained in these new analogs, <b>11a</b>–<b>j</b>. The SAR studies focused on the C3 and N9 positions. First, the amide group at the C3 position was replaced with a urea group to afford hybrids <b>11a</b>–<b>e</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The corresponding N9-methylated compounds (<b>11f</b>–<b>j</b>) were also prepared. The results were shown in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Similar to the <b>5</b> series, most of compounds <b>11a</b>–<b>j</b> exhibited good antitumor activities that were significantly greater than that of parent compound <b>6</b> and harmine. The antiproliferation activities of <b>11a</b>–<b>e</b> containing a urea group were slightly higher than those of <b>5k</b>–<b>o</b> with an amide group at the C3 positions of β-carboline in four CRC cell strains, suggesting the urea group can be tolerated for antiproliferation activity. Compounds <b>11c</b>–<b>d</b> and <b>11h</b> (IC<sub>50</sub> = 0.83–3.15 μM), which have linkers comprised of three to four carbon units, showed antiproliferative activity greater than that of SAHA against all cancer cells in the series, confirming the linker length effect observed in the <b>5</b> series. In particular, compound <b>11c</b> (IC<sub>50</sub> = 0.83 μM) displayed the highest antiproliferative activity in all compounds, with an IC<sub>50</sub> value nearly sevenfold lower than that of SAHA (IC<sub>50</sub> = 5.53 μM) in HCT116 cells. The methylation of the N9 position seems to have little impact on the potency because the two series (<b>11a</b>–<b>e</b> vs <b>11f</b>–<b>j</b>) showed similar potency against both the CRC cells and nuclear extract.</div><div class="NLM_p">The IC<sub>50</sub> values of compounds <b>11a</b>–<b>j</b> against HDAC in HeLa cell nuclear extract are listed in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Similar to the antiproliferative activity, active compounds <b>11b</b>–<b>e</b> and <b>11h</b> displayed significant HDAC inhibitory activities with IC<sub>50</sub> values of 0.27–0.51 μM in HeLa nuclear extract, comparable or lower than that of SAHA (IC<sub>50</sub> = 0.56 μM). Interestingly, although <b>5m</b> (IC<sub>50</sub> = 0.67 μM) and <b>11h</b> (IC<sub>50</sub> = 0.51 μM) showed HDAC inhibition potencies similar to that of SAHA, the cell growth inhibitions induced by these two compounds are 2–4 times stronger than that of SAHA in HCT116 cells. Furthermore, the HDAC inhibition induced by <b>11c</b> (IC<sub>50</sub> = 0.27 μM) was only 2 times higher than the HDAC inhibition induced by SAHA (IC<sub>50</sub> = 0.56 μM), but the growth inhibition of <b>11c</b> was nearly 7 times greater than that induced by SAHA in HCT116 cells. These results suggest that the cytotoxicity induced by these β-carboline/hydroxamic acid hybrids may be the result of both the active β-carboline ring and HDAC inhibition.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. HDAC Inhibitory Activities of Compounds <b>5m</b>, <b>11b</b>–<b>d</b>, and <b>11h</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char="±">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char="±">HDAC1</th><th class="colsep0 rowsep0" align="center" char="±">HDAC6</th><th class="colsep0 rowsep0" align="center" char="±">HDAC8</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SAHA</td><td class="colsep0 rowsep0" align="char" char="±">0.19 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.076 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.33 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5m</b></td><td class="colsep0 rowsep0" align="char" char="±">0.13 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.061 ± 0.008</td><td class="colsep0 rowsep0" align="char" char="±">0.39 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11b</b></td><td class="colsep0 rowsep0" align="char" char="±">0.11 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.36 ± 0.05</td><td class="colsep0 rowsep0" align="char" char="±">0.43 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11c</b></td><td class="colsep0 rowsep0" align="char" char="±">0.026 ± 0.004</td><td class="colsep0 rowsep0" align="char" char="±">0.034 ± 0.005</td><td class="colsep0 rowsep0" align="char" char="±">0.16 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11d</b></td><td class="colsep0 rowsep0" align="char" char="±">0.079 ± 0.008</td><td class="colsep0 rowsep0" align="char" char="±">0.093 ± 0.01</td><td class="colsep0 rowsep0" align="char" char="±">0.20 ± 0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11h</b></td><td class="colsep0 rowsep0" align="char" char="±">0.24 ± 0.03</td><td class="colsep0 rowsep0" align="char" char="±">0.15 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±">0.57 ± 0.07</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Data are expressed as mean ± SD of three independent experiments.</p></div></div></div><div class="NLM_p last">Encouraged by the inhibitory activity of this series of compounds against the HeLa cell nuclear extract that mainly contains HDAC1 and HDAC2, we further tested a selected group of compounds (<b>5m</b>, <b>11b</b>–<b>d</b>, and <b>11h</b>) for their in vitro inhibitory activities against several HDAC enzymes. SAHA was used as the positive control. The potencies of these compounds were obtained by measuring the fluorescent-based HDAC biochemical activity using recombinant human HDAC1, HDAC6, and HDAC8 enzymes, and the IC<sub>50</sub> values are summarized in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Most of the compounds had high inhibitory potencies against all three enzymes. In particular, compound <b>11c</b> showed IC<sub>50</sub> values against HDAC1 and HDAC6 of 0.026 and 0.034 μM respectively, which were five- to sixfold lower than that against HDAC8. The potency of <b>11c</b> against HDAC1 was sevenfold higher than that of SAHA. Because compound <b>11c</b> showed the highest potency in inhibition of both cell growth and HDAC, it was advanced for further evaluation.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Acetylation of Histone H3 and α-Tubulin</h3><div class="NLM_p">Given that the inhibition of HDACs by hybrid <b>11c</b> enhanced the tumor cell antiproliferative activity, the HDAC inhibitory effects of <b>11c</b> on the levels of acetylation of histone H3 and α-tubulin were determined by immunoblotting assays using β-actin as a negative control (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). HCT116 cells were incubated with the vehicle alone, SAHA, or <b>11c</b> (0.3, 0.8, and 2.4 μM). Compared with the control group, compound <b>11c</b> demonstrated the ability to increase the expression of acetyl-histone H3 and acetyl-α-tubulin in a dose-dependent manner. Levels of acetyl-histone H3 in all <b>11c</b> treated groups (0.3, 0.8, and 2.4 uM) were higher than the values from the 5.0 μM SAHA treated group, which was consistent with the results from the HDAC fluorimetric activity assay.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Immunoblot analysis of the expression of the acetylation for histone H3 and α-tubulin in vitro. (A) HCT116 cells were treated with <b>11c</b> and SAHA for 48 h at the indicated concentrations. Cell lysates were prepared and subjected to SDS-PAGE and immunoblot analysis using anti-acetyl-histone H3 (Ac-H3), anti-acetyl-α-tubulin (Ac-α-tubulin), and anti-β-actin antibodies, respectively. β-Actin was used as the loading control. (B) Quantitative analysis. The relative levels of Ac-H3 and Ac-α-tubulin used to control β-actin were determined by densimetric scanning. The data are expressed as means ± SD of three separate experiments. *, <i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Further analysis revealed that treatment with an increased dose of <b>11c</b> had no significant effect on the survival of nontumor IEC-18 cells under 5.0 μM, whereas the same treatment induced cell death in the majority of HCT116 cells (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Moreover, <b>11c</b> displayed significant growth inhibitory activities with GI<sub>50</sub> values of 1.17 μM in HCT116 cells, nearly fivefold lower than that of <b>11c</b> in IEC-18 cells (GI<sub>50</sub> = 5.46 μM). These results suggest that <b>11c</b> has selective antiproliferation activity against tumor cells. This effect was more significant than that of SAHA (GI<sub>50</sub> = 4.64 μM in HCT116 and GI<sub>50</sub> = 9.95 μM in IEC-18) under the same treatment conditions.</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitory effects of <b>11c</b> and SAHA on the proliferation of HCT116 and IEC-18 cells. Cells were incubated with the indicated concentrations of tested compounds for 48 h. Cell proliferation was assessed using the MTT assay. Data are means + SD of the inhibition (%) from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Compound <b>11c</b> Induces Apoptosis in HCT116 Cells</h3><div class="NLM_p">To determine whether the inhibitory effects of <b>11c</b> on colon cancer cellular proliferation are accompanied by enhanced cancer cell apoptosis, FITC-Annexin V/propidium iodide (PI) staining and flow cytometry assay were carried out, and the percentages of apoptotic cells were determined. HCT116 cells were incubated with different concentrations of <b>11c</b> or SAHA for 48 h. As shown in <a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>, <b>11c</b>-treated HCT116 cells exhibited a dose-dependent increase (<i>P</i> < 0.01) of apoptosis by 21.6, 41.3, and 73.9% at 0.1, 1.0, and 5.0 μM, respectively. The 73.9% induction of HCT116 cell apoptosis with incubation with 5.0 μM of <b>11c</b> was significantly higher than that of SAHA (34.3% apoptotic cells at the same concentration).</div><div class="NLM_p">To investigate further the apoptosis induction of <b>11c</b>, we examined the expression of apoptotic proteins Bax, Bcl-2, and the cleavage states of caspase 3 and PARP in response to <b>11c</b> treatment (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Subconfluent HCT116 colon cancer cells were treated with or without <b>11c</b> for 48 h and then lysed and analyzed by Western blot. β-Actin expression was used as an internal control. It was revealed that treatment with <b>11c</b> dramatically increased the relative levels of pro-apoptotic Bax expression but reduced the levels of antiapoptotic Bcl-2 expression (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>A,B) in a dose-dependent manner. Furthermore, compound <b>11c</b> resulted in more significant cleavage of both PARP and caspase 3 than the control group in <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>C. Importantly, <b>11c</b> treatment also induced more cleavage of PARP and caspase 3 than that in the SAHA-treated group. Taken together, these results confirm that <b>11c</b> treatment induced apoptosis in HCT116 cells.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>11c</b> induces HCT116 cell apoptosis in vitro. HCT116 cells were incubated with the indicated concentrations of <b>11c</b> or SAHA (5.0 μM) for 48 h, and the cells were stained with FITC-Annexin V/PI, followed by flow cytometry analysis. (A) Flow cytometry analysis. (B) Quantitative analysis of apoptotic cells. Data are expressed as means ± SD of the percentages of apoptotic cells from three independent experiments. *, <i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Expression of (A) Bax, Bcl-2, (C) cleaved caspase 3, PARP, and (A and C) β-actin was examined by Western blot analysis. HCT116 cells were incubated with or without <b>11c</b> and SAHA at the indicated concentrations for 48 h, and the levels of protein expression were detected using specific antibodies. Data shown are representative images of each protein for three separate experiments. Quantitative analysis of (B) Bax and Bcl-2 and (D) cleaved caspase 3 and PARP. The relative levels of each protein compared to that of control β-actin were determined by densimetric scanning. Data are expressed as means ± SD from three separate experiments. *, <i>P</i> < 0.01 vs respective control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Immunoblot analysis of the expression of DNA damage and DNA-damage response p53 signaling pathway events in vitro. (A and C) HCT116 cells were treated with vehicle (control), different doses of <b>11c</b>, <b>11h</b>, harmine, or SAHA and then were homogenized; their lysates were subjected to immunoblot analysis using anti-H2AXS139ph, anti-phospho-p53 (ser15), anti-p53, anti-p21, and anti-β-actin antibodies. β-Actin was used as the control. (B and D) Quantitative analysis. The levels of each signaling event relative to those of control β-actin were determined by densimetric scanning. The data are expressed as means ± SD from three separate experiments. *, <i>P</i> < 0.01 vs respective control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Compound <b>11c</b> Induces DNA Damage and Activates the p53 Signaling Pathway</h3><div class="NLM_p">It is known that the planar-structured β-carbolines can bind to DNA and induce DNA damage.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a> To verify whether the anticancer activities of these β-carboline/hydroxamic acid hybrids were partly from DNA damage, we examined the DNA damage extent and the change of the DNA damage response p53 signaling pathway caused by <b>11c</b> in CRC cells. In the present study, we used histone H2AX phosphorylation (H2AXS139ph) and phosphor-p53, or p-p53 (Ser15) as DNA damage markers. HCT116 cells were treated with vehicle, <b>11c</b>, or <b>11h</b> for 12 h, using harmine and SAHA as positive controls. H2AXS139ph and p-p53 (ser15) were then detected using Western blot analysis. As shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A,C, treatment with <b>11c</b> or <b>11h</b> dose-dependently increased the levels of H2AX phosphorylation in HCT116 cells. Importantly, H2AXS139ph level in both 1.0 and 5.0 μM <b>11c</b> or <b>11h</b> treatment groups was significantly higher than that of the SAHA group treated at the same concentrations. Because <b>11h</b> and SAHA showed similar potency in HDAC inhibition, these results clearly indicate that the increased level likely resulted from greater DNA damage induced in the <b>11h</b>-treated cells. Phospho-H2AX level in the 20 μM harmine treatment group was similar to that of the 1.0 μM <b>11h</b> group and was significantly lower than that of the 5.0 μM <b>11h</b> group.</div><div class="NLM_p">Phosphorylation of p53 (Ser15) has been known to be the result of DNA damage induced by treatment with cisplatin or isomerase I or II inhibitors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Ser 15, a common site for a variety of kinases such as ATM/ATR/DNA-PK, is activated during the DNA repair pathway. It has been well-documented that HDACi-induced DNA damage is associated with p53 phosphorylation at threonine 18 but not p-p53 (Ser15).<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Interestingly, p-p53 (Ser15) can only be detected in the <b>11c</b> treatment group but not in the SAHA treatment group (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A). Because β-carboline complex induced DNA damage was accompanied significantly with p53 activation and p-p53 (Ser15), these results clearly indicated that the key structural elements of both HDACi and β-carboline alkaloids are involved in DNA damage induced by <b>11c</b> and <b>11h</b> treatment.</div><div class="NLM_p">p21 is a tumor-suppressor gene activated by the p53 gene. As shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>A,C, after both drug treatments, the p21 expression level was significantly upregulated compared to vehicle control group. Moreover, both <b>11c</b> and <b>11h</b> dramatically activated the expression of p21 in HCT116 cells at increased concentrations, and the p21 expression level was much higher in the <b>11c</b> or <b>11h</b> treatment groups than in the SAHA treatment group, consistent with the hypothesis that p21 induction by hybrids <b>11c</b> or <b>11h</b> treatment involves in both HDAC inhibition and β-carboline alkaloids DNA binding.</div><figure id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0009.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Expression profile of p53 in shRNA control and shRNA p53 HCT116 cell lines by Western blot in vitro. β-Actin was used as control. (B) Quantitative analysis. (C and D) Effects of SAHA or <b>11c</b> treatment on the shRNA control and shRNA p53 HCT116 colorectal cancer cell growth for 48 h at a wide range of concentrations. The data are expressed as means ± SD of three duplicate experiments. *, <i>P</i> < 0.01 vs respective control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Antitumor Activity of Compound <b>11c</b> Involves the p53 Pathway</h3><div class="NLM_p last">To determine whether the p53 pathway is involved in the antitumor activity of compound <b>11c</b>, we examined the effects of <b>11c</b> on cell growth and cell death with shRNA control and shRNA p53 HCT116 CRC cells in parallel. It has been reported that HDACi not only increased p53 activation but also increased p53 acetylation to inhibit cancer cell growth. As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>A, shRNA significantly inhibited HCT116 p53 expression. Compared with the shRNA control group, <b>11c</b> induced 10–40% less growth inhibition across a wide range of concentrations in the shRNA p53 group (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>C), which was more sensitive than that of SAHA treatments (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>B). This is consistent with a previous report that p53 activation contributed to HDACi drug response.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Anticancer Activity of <b>11c</b></h3><div class="NLM_p">To evaluate the safety of <b>11c</b> in vivo, groups of ICR mice were injected intraperitoneally with different doses of <b>11c</b> or vehicle control, respectively. The survival of mice was monitored up to 14 days after injection. Only three mice that had been treated with <b>11c</b> at the highest dose (585.9 mg/kg) survived (shown in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). In contrast, injection with <b>11c</b> at the lowest dose (240 mg/kg) did not cause any death and abnormality in eating, drinking, body weight, and activity throughout the observation period. As a result, the median lethal dose (LD<sub>50</sub>) value of <b>11c</b> was calculated to be 471.7 mg/kg for this strain of mice.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Acute Toxicity of <b>11c</b> in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="rowsep1 colsep0" colspan="7" align="center" char=".">no. of dead mice</th><th class="colsep0 rowsep0" align="center" char="."> </th><th class="colsep0 rowsep0" align="center" char="."> </th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">no. of mice</th><th class="colsep0 rowsep0" align="center" char=".">1 h</th><th class="colsep0 rowsep0" align="center" char=".">4 h</th><th class="colsep0 rowsep0" align="center" char=".">1 d</th><th class="colsep0 rowsep0" align="center" char=".">2 days</th><th class="colsep0 rowsep0" align="center" char=".">3 days</th><th class="colsep0 rowsep0" align="center" char=".">4 days</th><th class="colsep0 rowsep0" align="center" char=".">5–14 days</th><th class="colsep0 rowsep0" align="center" char=".">total deaths</th><th class="colsep0 rowsep0" align="center" char=".">survival (%) on day 14</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">585.9</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">468.8</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">375.0</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">300.0</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char=".">240.0</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div></div><figure id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Inhibitory effects of <b>11c</b> on the growth of an implanted HCT116 xenograft in nude mice. BALB/c nude mice were subcutaneously inoculated with HCT116 cells. After establishment of solid tumor, the mice were randomized and treated with solvent control, SAHA, or <b>11c</b> at the indicated doses, respectively. The growth of tumors was measured longitudinally. Data are expressed as means (SD of tumor volumes at each time point for each group of mice; <i>n</i> = 6 per group). *, <i>P</i> < 0.01 vs control group; #, <i>P</i> < 0.05 vs SAHA group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Next, to evaluate the in vivo antitumor activity of <b>11c</b>, we established a BALB/c nude mice model that was inoculated subcutaneously with HCT116 cells. After the establishment of solid tumor, BALB/c nude mice were randomly intraperitoneally or orally administered with vehicle, <b>11c</b>, or SAHA, respectively. The changes in tumor size and body weight were monitored twice per week over 22 days. There was no statistical difference in body weight change among the three groups of mice. A steady tumor growth was observed with the vehicle-treated group. In contrast, both intravenous and oral <b>11c</b> treatment significantly reduced the volumes of implanted colon tumors. As shown in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>, although oral treatment with the same dose of <b>11c</b> initially exhibited almost identical antitumor activity as that of the SAHA treatment, <b>11c</b> produced greater tumor reduction at the end of the treatment (days 19 and 22). The tumor weight (0.53 ± 0.12 g) in mice treated with oral <b>11c</b> at 90 mg/kg was reduced by 61.6% compared to that of the vehicle-treated controls (1.38 ± 0.35 g), and the tumor weight was 0.62 ± 0.13 g in SAHA-treated group at the same dosing. According to the preliminary pharmacokinetic profiling of <b>11c</b> in SD rats (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_001.pdf" class="ext-link">Table S1</a>), there were no significant differences in the pharmacokinetics between intraperitoneal and oral administration. Together, our data clearly demonstrated that <b>11c</b> had potent antitumor activity against the growth of implanted human colon tumors in vivo.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_44465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_44465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Our group has successfully designed, synthesized, and evaluated a series of novel β-carboline/hydroxamic acid hybrids that have the key structures of β-carbolines and HDACi. Our in vitro and in vivo studies of these compounds have resulted in several significant findings. First, β-carboline/hydroxamic acid hybrids (<b>5m</b>, <b>11b</b>–<b>d</b>, and <b>11h</b>) with three- or four-carbon alkyl linkers exhibited greater potency in antiproliferative activity than did their analogs and the FDA-approved clinical chemotherapeutic agent SAHA. Cytotoxicity experiments in vitro demonstrated that hybrids with <i>p</i>-methoxyphenyl-substituted β-carboline exhibited higher cytotoxic potency than did other hybrids with methyl- or hydrogen-substituted β-carboline. Second, treatment of CRC cells with <b>11c</b> demonstrated a significant induction of cell apoptosis and significant cleavage of both PARP and caspase 3 in vitro. Third, our study demonstrated that the potent anticancer activity of <b>11c</b> is related to HDAC inhibition, DNA damage, and activation of the p53 signaling pathway. Finally, the most potent compound <b>11c</b> displayed low acute toxicity and significant growth inhibition of cancer cells in vivo. These results demonstrated the great promise of β-carboline/hydroxamic acid hybrids with multiple anticancer activity. Our findings may assist the design and development of more hybrids as novel anticancer agents. Additional structural refinement and biological evaluations are ongoing in our lab and the results will be reported in due course.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> General Procedures</h3><div class="NLM_p"><sup>1</sup>H NMR spectra were recorded with a Bruker Avance 300 MHz spectrometer at 300 K, using TMS as an internal standard. MS spectra were recorded on a Mariner Mass Spectrum (ESI). High-resolution mass spectra (HRMS) were recorded using an Agilent Technologies LC/MSD TOF. All compounds were routinely checked by thin-layer chromatography (TLC) and <sup>1</sup>H NMR. TLCs and preparative TLC were carried out on silica gel GF/UV 254, and the chromatograms were conducted on silica gel (200–300 mesh, Merck) and visualized under UV light at 254 and 365 nm. All solvents were reagent-grade and when necessary were purified and dried by standard methods. <span class="smallcaps smallerCapital">L</span>-Tryptophan <b>1</b> and different substituted aldehydes were commercially available. Compounds <b>3a</b>–<b>c</b>, <b>4a</b>–<b>c</b>, and <b>6</b> were synthesized according the literature.<a onclick="showRef(event, 'ref7 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref7 ref11 ref12">(7, 11, 12)</a> Solutions after reactions and extractions were concentrated using a rotary evaporator operating at a reduced pressure of ca. 20 Torr. Organic solutions were dried over anhydrous sodium sulfate. The high-performance liquid chromatography (HPLC) analysis conditions were as follows: column: Shimadzu C18 (150 mm × 4.6 mm × 5 μm); mobile phase: methanol/aqueous solution = 65:35; wavelength: 254 nm; rate: 1 mL/min; temperature: 30 °C; pressure: 85–142 kgf. All compounds were of >95% purity as determined by HPLC.</div><div id="sec4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Procedure for the Preparation of <b>4a</b>–<b>o</b></h4><div class="NLM_p">To a solution of <b>3a</b>–<b>c</b> (1.0 mmol) in 5 mL anhydrous THF at 0 °C were added <i>N</i>-methylmorpholine (0.1 g, 1.0 mmol) and ethyl carbonochloridate (0.11 g, 1.0 mmol). After 0.5 h, the mixture was added dropwise to a solution of NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe(1.0 mmol) and Et<sub>3</sub>N (1.0 mmol) in 5 mL of anhydrous THF, and the reaction was then stirred at room temperature for 5–8h. After the reaction, the resulting mixture was poured into ice water and extracted with ethyl acetate (30 mL × 3). The organic phase was combined and washed with water and brine and then dried with anhydrous sodium sulfate. After filtration, the filtrate was collected and concentrated in vacuo. The resulting residue was purified by column chromatography (EtOAc-PE = 1:1–4:1, v/v as the eluate) to afford compound <b>4a</b>–<b>o</b>.</div><div id="sec4_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20"> Methyl 2-(9<i>H</i>-Pyrido[3,4-<i>b</i>]indole-3-carboxamido)acetate (<b>4a</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3a</b>, ethyl carbonochloridate, and NH<sub>2</sub>CH<sub>2</sub>COOMe to afford an off-white solid, yield: 81%. MS (ESI) <i>m</i>/<i>z</i> 284 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21"> Methyl 3-(9<i>H</i>-Pyrido[3,4-<i>b</i>]indole-3-carboxamido)propanoate (<b>4b</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3a</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>COOMe to afford an off-white solid, yield: 78%. MS (ESI) <i>m</i>/<i>z</i> 298 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22"> Methyl 4-(9<i>H</i>-Pyrido[3,4-<i>b</i>]indole-3-carboxamido)butanoate (<b>4c</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3a</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>COOMe to afford an off-white solid, yield: 77%. MS (ESI) <i>m</i>/<i>z</i> 312 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i23" class="anchor-spacer"></div><h5 class="article-section__title" id="_i23"> Methyl 5-(9<i>H</i>-Pyrido[3,4-<i>b</i>]indole-3-carboxamido)pentanoate (<b>4d</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3a</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>COOMe to afford an off-white solid, yield: 73%. MS (ESI) <i>m</i>/<i>z</i> 326 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i24" class="anchor-spacer"></div><h5 class="article-section__title" id="_i24"> Methyl 6-(9<i>H</i>-Pyrido[3,4-<i>b</i>]indole-3-carboxamido)hexanoate (<b>4e</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3a</b>, ethyl carbonochloridate, andNH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>COOMe to afford an off-white solid, yield: 71%. MS (ESI) <i>m</i>/<i>z</i> 340 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Methyl 2-(1-Methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)acetate (<b>4f</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3b</b>, ethyl carbonochloridate, and NH<sub>2</sub>CH<sub>2</sub>COOMe to afford an off-white solid, yield: 80%. MS (ESI) <i>m</i>/<i>z</i> 298 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> Methyl 3-(1-Methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)propanoate (<b>4g</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3b</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>COOMe to afford an off-white solid, yield: 79%. MS (ESI) <i>m</i>/<i>z</i> 312 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Methyl 4-(1-Methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)butanoate (<b>4h</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3b</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>COOMe to afford an off-white solid, yield: 77%. MS (ESI) <i>m</i>/<i>z</i> 326 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Methyl 5-(1-Methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)pentanoate (<b>4i</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3b</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>COOMe to afford an off-white solid, yield: 73%. MS (ESI) <i>m</i>/<i>z</i> 340 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Methyl 6-(1-Methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)hexanoate (<b>4j</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3b</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>COOMe to afford an off-white solid, yield: 75%. MS (ESI) <i>m</i>/<i>z</i> 354 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Methyl 2-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)acetate (<b>4k</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3c</b>, ethyl carbonochloridate, and NH<sub>2</sub>CH<sub>2</sub>COOMe to afford an off-white solid, yield: 83%. MS (ESI) <i>m</i>/<i>z</i> 390 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i31" class="anchor-spacer"></div><h5 class="article-section__title" id="_i31"> Methyl 3-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)propanoate (<b>4l</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3c</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>–COOMe to afford an off-white solid, yield: 80%. MS (ESI) <i>m</i>/<i>z</i> 404 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> Methyl 4-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)butanoate (<b>4m</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3c</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>COOMe to afford an off-white solid, yield: 77%. MS (ESI) <i>m</i>/<i>z</i> 418 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> Methyl 5-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)pentanoate (<b>4n</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3c</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>COOMe to afford an off-white solid, yield: 74%. MS (ESI) <i>m</i>/<i>z</i> 432 [M + H]<sup>+</sup>.</div></div><div id="sec4_2_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> Methyl 6-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamido)hexanoate (<b>4o</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>3c</b>, ethyl carbonochloridate, and NH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>COOMe to afford an off-white solid, yield: 75%. MS (ESI) <i>m</i>/<i>z</i> 446 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> General Procedure for the Preparation of <b>5a</b>–<b>o</b></h4><div class="NLM_p">To a solution of <b>4a</b>–<b>o</b> (0.4 mmol) in 5 mL of anhydrous methanol was added a solution of NH<sub>2</sub>OK (0.09 g, 4 mmol) in 3 mL of anhydrous methanol. The mixture was stirred for 10–15 h and the solvent was evaporated under vacuum. The residue was diluted with saturated NH<sub>4</sub>Cl aqueous solution and then extracted with ethyl acetate (8 mL × 5). The organic layers were combined, washed with brine (10 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and evaporated, with the residue being purified by column chromatography (eluting with EA followed by 20:1 CHCl<sub>3</sub>/MeOH followed by 10:1 CHCl<sub>3</sub>/MeOH) on silica gel to yield <b>5a</b>–<b>o</b> as an off-white solid (68–77%).</div><div id="sec4_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> <i>N</i>-(2-(Hydroxyamino)-2-oxoethyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide(<b>5a</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4a</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 73%. Analytical data for <b>5a</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.35 (s, 1H, NH), 10.12 (s, 1H, NH), 8.88 (s, 1H, Ar–H), 8.71 (s, 1H, Ar–H), 8.23–8.29 (m, 2H, CONH, Ar–H), 7.68 (m, 1H, Ar–H), 7.33 (m, 1H, Ar–H), 4.27 (m, 2H, NCH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 285 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>14</sub>H<sub>13</sub>N<sub>4</sub>O<sub>3</sub>: 285.0988; found, 285.0997 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i37" class="anchor-spacer"></div><h5 class="article-section__title" id="_i37"> <i>N</i>-(3-(Hydroxyamino)-3-oxopropyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5b</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4b</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 77%. Analytical data for <b>5b</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.20 (s, 1H, NH), 9.03 (s, 1H, NH), 8.85 (s, 1H, Ar–H), 8.73 (s, 1H, Ar–H), 8.27 (m, 1H, CONH), 8.16 (m, 1H, Ar–H), 7.70 (m, 1H, Ar–H), 7.56 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 3.65 (m, 2H, NCH<sub>2</sub>), 2.71 (m, 2H, CH<sub>2</sub>C═O). MS (ESI) <i>m</i>/<i>z</i> 299 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>15</sub>N<sub>4</sub>O<sub>3</sub>, 299.1144; found, 299.1152 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> <i>N</i>-(4-(Hydroxyamino)-4-oxobutyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5c</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4c</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 72%. Analytical data for <b>5c</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.08 (s, 1H, NH), 9.16 (s, 1H, NH), 8.89 (s, 1H, Ar–H), 8.70 (s, 1H, Ar–H), 8.28 (m, 1H, CONH), 8.20 (m, 1H, Ar–H), 7.71 (m, 1H, Ar–H), 7.60 (m, 1H, Ar–H), 7.36 (m, 1H, Ar–H), 3.48 (m, 2H, NCH<sub>2</sub>), 2.63 (m, 2H, CH<sub>2</sub>CO), 1.91 (m, 2H, CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 313 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub>, 313.1301; found, 313.1310 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> <i>N</i>-(5-(Hydroxyamino)-5-oxopentyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5d</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4d</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 73%. Analytical data for <b>5d</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 10.15 (s, 1H, NH), 8.87 (s, 1H, Ar–H), 8.70 (s, 1H, Ar–H), 8.27 (m, 1H, CONH), 8.20 (m, 1H, Ar–H), 7.58 (m, 1H, Ar–H), 7.38 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 3.45 (m, 2H, NCH<sub>2</sub>), 2.36 (m, 2H, CH<sub>2</sub>C═O), 1.81–1.85 (m, 4H, CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 327 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>, 327.1457; found, 327.1446 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> <i>N</i>-(6-(Hydroxyamino)-6-oxohexyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5e</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4e</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 68%. Analytical data for <b>5e</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.41 (s, 1H, NH), 8.89 (s, 1H, Ar–H), 8.71 (s, 1H, Ar–H), 8.21–8.27 (m, 1H, CONH, Ar–H), 7.61 (m, 1H, Ar–H), 7.39 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 3.41 (m, 2H, NCH<sub>2</sub>), 2.35 (m, 2H, CH<sub>2</sub>C═O), 1.72–1.77 (m, 4H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>), 1.50 (m, 2H, NCH<sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 341 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>, 341.1614; found, 341.1622 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> <i>N</i>-(2-(Hydroxyamino)-2-oxoethyl)-1-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5f</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4f</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 71%. Analytical data for <b>5f</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.12 (s, 1H, NH), 8.75 (m, 2H, Ar–H, CONH), 8.28 (m, 1H, Ar–H), 8.10 (m, 1H, Ar–H), 7.56 (m, 1H, Ar–H), 7.30 (m, 1H, Ar–H), 4.24 (m, 2H, CH<sub>2</sub>), 2.91 (s, 3H, CH<sub>3</sub>). MS (ESI) <i>m</i>/<i>z</i> 299 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>, 299.1144; found, 299.1156 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> <i>N</i>-(3-(Hydroxyamino)-3-oxopropyl)-1-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5g</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4g</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 69%. Analytical data for <b>5g</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.01 (s, 1H, NH), 8.72 (s, 1H, Ar–H), 8.29–8.41 (m, 2H, CONH, Ar–H), 8.07 (m, 1H, Ar–H), 7.59 (m, H, Ar–H), 7.28 (m, 1H, Ar–H), 3.62 (m, 2H, NCH<sub>2</sub>), 2.89 (s, 3H, CH<sub>3</sub>), 2.73 (m, 2H, CH<sub>2</sub>CO). MS (ESI) <i>m</i>/<i>z</i> 313 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>N<sub>4</sub>O<sub>3</sub>, 313.1301; found, 313.1311 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> <i>N</i>-(4-(Hydroxyamino)-4-oxobutyl)-1-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5h</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4h</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 75%. Analytical data for <b>5h</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.68 (m, 1H, NH), 8.76 (s, 1H, Ar–H), 8.69 (m, 1H, CONH), 8.27 (m, 1H, Ar–H), 8.08 (m, 1H, Ar–H), 7.60 (m, H, Ar–H), 7.28 (m, 1H, Ar–H), 3.77 (m, 2H, NCH<sub>2</sub>), 2.92 (s, 3H, CH<sub>3</sub>), 2.67 (m, 2H, CH<sub>2</sub>CO), 2.01 (s, 1H, OH), 1.91 (m, 2H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 327 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>17</sub>H<sub>19</sub>N<sub>4</sub>O<sub>3</sub>, 327.1457; found, 327.1465 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> <i>N</i>-(5-(Hydroxyamino)-5-oxopentyl)-1-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5i</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4i</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 72%. Analytical data for <b>5i</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.56 (s, 1H, NH), 8.70 (s, 1H, Ar–H), 8.65 (m, 1H, CONH), 8.30 (m, 1H, Ar–H), 8.09 (m, 1H, Ar–H), 7.61 (m, H, Ar–H), 7.28 (m, 1H, Ar–H), 3.55 (m, 2H, NCH<sub>2</sub>), 2.89 (s, 3H, CH<sub>3</sub>), 2.29 (m, 2H, CH<sub>2</sub>CO), 1.80–1.84 (m, 4H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 341 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>18</sub>H<sub>21</sub>N<sub>4</sub>O<sub>3</sub>, 341.1614; found, 341.1623 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> <i>N</i>-(6-(Hydroxyamino)-6-oxohexyl)-1-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5j</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4j</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 75%. Analytical data for <b>5j</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 10.30 (s, 1H, NH), 8.75 (s, 1H, Ar–H), 8.37–8.43 (m, 2H, CONH, Ar–H), 8.11 (m, 1H, Ar–H), 7.62 (m, H, Ar–H), 7.30 (m, 1H, Ar–H), 3.51 (m, 2H, NCH<sub>2</sub>), 2.89 (s, 3H, CH<sub>3</sub>), 2.30 (m, 2H, CH<sub>2</sub>CO), 1.71–1.76 (m, 4H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>), 1.48 (m, 4H, NCH<sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 355 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>19</sub>H<sub>23</sub>N<sub>4</sub>O<sub>3</sub>, 355.1770; found, 355.1759 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> <i>N</i>-(2-(Hydroxyamino)-2-oxoethyl)-1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5k</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4k</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 77%. Analytical data for <b>5k</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.91 (s, 1H, NH), 8.71 (m, 2H, Ar–H, CONH), 8.59 (m, 1H, Ar–H), 8.15 (d, 1H, <i>J</i> = 7.5 Hz, Ar–H), 7.75 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.63 (m, 1H, Ar–H), 7.41 (m, 1H, Ar–H), 7.02 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 4.21 (m, 2H, NCH<sub>2</sub>), 3.85 (s, 3H, OCH<sub>3</sub>). MS (ESI) <i>m</i>/<i>z</i> 391 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>19</sub>N<sub>4</sub>O<sub>4</sub>, 391.1406; found, 391.1415 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> <i>N</i>-(3-(Hydroxyamino)-3-oxopropyl)-1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5l</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4l</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 71%. Analytical data for <b>5l</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 10.13 (s, 1H, NH), 8.71 (s, 1H, Ar–H), 8.42 (m, 2H, Ar–H, CONH), 8.18 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.74 (m, 1H, Ar–H), 7.61 (m, 1H, Ar–H), 7.48 (m, 1H, Ar–H), 7.09 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.67 (m, 2H, NCH<sub>2</sub>), 2.74 (m, 2H, CH<sub>2</sub>CO). MS (ESI) <i>m</i>/<i>z</i> 405 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>21</sub>N<sub>4</sub>O<sub>4</sub>, 405.1563; found, 405.1575 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> <i>N</i>-(4-(Hydroxyamino)-4-oxobutyl)-1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5m</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4m</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 72%. Analytical data for <b>5m</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.02 (s, 1H, NH), 9.46 (s, 1H, NH), 8.75 (s, 1H, Ar–H), 8.46 (m, 2H, Ar–H, CONH), 8.19 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.84 (m, 1H, Ar–H), 7.65 (m, 1H, Ar–H), 7.47 (m, 1H, Ar–H), 7.06 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.48 (m, 2H, NCH<sub>2</sub>), 2.32 (m, 2H, CH<sub>2</sub>CO), 1.89 (m, 2H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 419 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>23</sub>N<sub>4</sub>O<sub>4</sub>, 419.1719; found, 419.1731 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> <i>N</i>-(5-(Hydroxyamino)-5-oxopentyl)-1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5n</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4n</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 69%. Analytical data for <b>5n</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.45 (s, 1H, NH), 10.26 (s, 1H, NH), 8.70 (s, 1H, Ar–H), 8.25 (m, 1H, CONH), 8.13–8.17 (m, 2H, Ar–H), 7.86 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.66 (m, 1H, Ar–H), 7.46 (m, 1H, Ar–H), 7.07 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.55 (m, 2H, NCH<sub>2</sub>), 2.29 (m, 2H, CH<sub>2</sub>CO), 1.98 (m, 1H, OH), 1.72–1.77 (m, 4H, CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 433 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>4</sub>O<sub>4</sub>, 433.1876; found, 433.1887 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> <i>N</i>-(6-(Hydroxyamino)-6-oxohexyl)-1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carboxamide (<b>5o</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>4o</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 70%. Analytical data for <b>5o</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.20 (s, 1H, NH), 8.72 (s, 1H, Ar–H), 8.14–8.25 (m, 3H, Ar–H,CONH), 7.86 (d, 2H, <i>J</i> = 8.76 Hz, Ar–H), 7.66 (m, 1H, Ar–H), 7.48 (m, 1H, Ar–H), 7.07 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.53 (m, 2H, NCH<sub>2</sub>), 2.39 (m, 2H, CH<sub>2</sub>CO), 1.70 (m, 4H, 2 × NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>), 1.49 (m, 2H, C<u class="uu">H</u><sub>2</sub>(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>); MS (ESI) <i>m</i>/<i>z</i> 447 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>27</sub>N<sub>4</sub>O<sub>4</sub>, 447.2032; found, 447.2043 [M + H]<sup>+</sup>.</div></div><div id="sec4_3_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> Methyl 1-(4-Methoxyphenyl)-9-methyl-9H-pyrido[3,4-<i>b</i>]indole-3-carboxylate (<b>7</b>)</h5><div class="NLM_p last">To <b>3c</b> (1.82 g, 10 mmol) in anhydrous DMF (25 mL) was slowly added 60% NaH (0.6 g, 15 mmol). The mixture was stirred for 0.5 h, and then iodomethane (1 mL, 15 mmol) was slowly added into the mixture. The mixture was stirred at rt for 1 h. The resulting mixture was poured into water (50 mL) and extracted with ethyl acetate (30 mL × 2). The organic phase was washed with water and brine, then dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue (<b>7</b>) was directly used in the next reaction without further purification.</div></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure for the Preparation of <b>9a</b>–<b>b</b></h4><div class="NLM_p">A solution of <b>6</b> or <b>7</b> (3 mmol) and 85% hydrazine hydrate (5 mL) in 30 mL of methanol was refluxed for 8 h. The resulting mixture was cooled, and the precipitate was collected by filtration, washed with methanol, and then dried in vacuum to obtain <b>8a</b>–<b>b</b>, which was poured into 50 mL of water and dissolved by concentrated hydrochloric acid (6.5 mL). The yellow solution was cooled to 0 °C before the addition of a solution of NaNO<sub>2</sub> (0.7 g, 10 mmol) in 10 mL of water and continually stirred for 40 min at 0 °C. After the reaction, the mixture was basified with saturated aqueous sodium hydrogen carbonate, and the precipitate was collected by filtration, washed with water, and dried under vacuum to yield an off-white solid <b>9a</b> or <b>9b</b>. These compounds were easy to decompose in the air and were used without further purification in the following steps.</div><div id="sec4_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> 1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carbonyl Azide (<b>9a</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>6</b>, hydrazine hydrate, and NaNO<sub>2</sub> to afford an off-white solid, yield: 73%. MS (ESI) <i>m</i>/<i>z</i> 344 [M + H]<sup>+</sup>.</div></div><div id="sec4_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> 1-(4-Methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indole-3-carbonyl Azide (<b>9b</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>7</b>, hydrazine hydrate, and NaNO<sub>2</sub> to afford an off-white solid, yield: 80%. MS (ESI) <i>m</i>/<i>z</i> 358 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> General Procedure for the Preparation of <b>10a</b>–<b>j</b></h4><div class="NLM_p">A solution of <b>9a</b> or <b>9b</b> (0.5 mmol) and NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe (0.75 mmol) in anhydrous toluene (20 mL) was refluxed for 2 h. After the reaction, the mixture was concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography on silica gel to afford <b>10a</b>–<b>j</b> as a yellowish solid.</div><div id="sec4_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> Methyl 2-(3-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)acetate (<b>10a</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9a</b> and NH<sub>2</sub>CH<sub>2</sub>COOMe to afford an off-white solid, yield: 82%. MS (ESI) <i>m</i>/<i>z</i> 405 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> Methyl 3-(3-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)propanoate (<b>10b</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9a</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>COOMe to afford an off-white solid, yield: 83%. MS (ESI) <i>m</i>/<i>z</i> 419 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> Methyl 4-(3-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)butanoate (<b>10c</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9a</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>COOMe to afford an off-white solid, yield: 79%. MS (ESI) <i>m</i>/<i>z</i> 433 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> Methyl 5-(3-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)pentanoate (<b>10d</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9a</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>COOMe to afford an off-white solid, yield: 77%. MS (ESI) <i>m</i>/<i>z</i> 447 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> Methyl 6-(3-(1-(4-Methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)hexanoate (<b>10e</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9a</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>COOMe to afford an off-white solid, yield: 77%. MS (ESI) <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> Methyl 2-(3-(1-(4-Methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)acetate (<b>10f</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9b</b> and NH<sub>2</sub>CH<sub>2</sub>COOMe to afford an off-white solid, yield: 85%. MS (ESI) <i>m</i>/<i>z</i> 419 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> Methyl 3-(3-(1-(4-Methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido) propanoate (<b>10g</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9b</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>COOMe to afford an off-white solid, yield: 82%. MS (ESI) <i>m</i>/<i>z</i> 433 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> Methyl 4-(3-(1-(4-Methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)butanoate (<b>10h</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9b</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>3</sub>COOMe to afford an off-white solid, yield: 81%. MS (ESI) <i>m</i>/<i>z</i> 447 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> Methyl 5-(3-(1-(4-Methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido) pentanoate (<b>10i</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9b</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>COOMe to afford an off-white solid, yield: 78%. MS (ESI) <i>m</i>/<i>z</i> 461 [M + H]<sup>+</sup>.</div></div><div id="sec4_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> Methyl 6-(3-(1-(4-Methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)hexanoate (<b>10j</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>9b</b> and NH<sub>2</sub>(CH<sub>2</sub>)<sub>5</sub>COOMe to afford an off-white solid, yield: 79%. MS (ESI) <i>m</i>/<i>z</i> 475 [M + H]<sup>+</sup>.</div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> General Procedure for the Preparation of <b>11a</b>–<b>j</b></h4><div class="NLM_p">To a solution of <b>10a</b>–<b>j</b> (0.2 mmol) in 3 mL of anhydrous methanol was added a solution of NH<sub>2</sub>OK (0.05 g, 2 mmol) in 3 mL of anhydrous methanol. The mixture was stirred for 10–15 h, and the solvent was evaporated under vacuum. The residue was acidified with 2 mol/L HCl to pH 7 and then extracted with ethyl acetate (10 mL × 3). The organic layers were combined, washed with brine (10 mL × 3), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and evaporated, with the residue being purified by column chromatography on silica gel to yield <b>11a</b>–<b>j</b> as an off-white solid (42–55%).</div><div id="sec4_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>N</i>-Hydroxy-2-(3-(1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)acetamide (<b>11a</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10a</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 68%. Analytical data for <b>11a</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.28 (s, 1H, NH), 8.73 (m, 1H, Ar–H), 8.40–8.47 (m, 3H, Ar–H, CONH), 8.16 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.68 (m, 1H, Ar–H), 7.60 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 7.13 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.88 (s, 3H, OCH<sub>3</sub>), 4.33 (m, 2H, NCH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 406 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>21</sub>H<sub>20</sub>N<sub>5</sub>O<sub>4</sub>, 406.1515; found, 403.1528 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <i>N</i>-Hydroxy-3-(3-(1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)propanamide (<b>11b</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10b</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 75%. Analytical data for <b>11b</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.40 (s, 1H, NH), 8.75 (m, 1H, Ar–H), 8.39–8.47 (m, 3H, Ar–H, CONH), 8.16 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.68 (m, 1H, Ar–H), 7.59 (m, 1H, Ar–H), 7.30 (m, 1H, Ar–H), 7.15 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.66 (m, 2H, NCH<sub>2</sub>), 2.72 (m, 2H, CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 420 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub>, 420.1672; found, 420.1685 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> <i>N</i>-Hydroxy-4-(3-(1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)butanamide (<b>11c</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10c</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 73%. Analytical data for <b>11c</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.81 (s, 1H, NH), 10.43 (s, 1H, NH), 8.77 (m, 3H, Ar–H, 2 × CONH), 8.41 (d, 1H, <i>J</i> = 7.5 Hz, Ar–H), 8.17 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.71 (m, 1H, Ar–H), 7.61 (m, 1H, Ar–H), 7.33 (m, 1H, Ar–H), 7.19 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.90 (s, 3H, OCH<sub>3</sub>), 3.40 (m, 2H, NCH<sub>2</sub>), 2.07 (m, 2H, CH<sub>2</sub>), 1.84 (m, 2H, CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 434 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub>, 434.1828; found, 434.1841 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> <i>N</i>-Hydroxy-5-(3-(1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)pentanamide (<b>11d</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10d</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 66%. Analytical data for <b>11d</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.63 (s, 1H, NH), 10.52 (s, 1H, NH), 8.72 (m, 1H, Ar–H), 8.42 (m, 1H, Ar–H), 8.27 (m, 2H, CONH), 8.16 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.69 (m, 1H, Ar–H), 7.60 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 7.17 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.41 (m, 2H, NCH<sub>2</sub>), 2.27 (m, 2H, CH<sub>2</sub>), 1.73–1.78 (m, 4H, CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 448 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub>, 448.1985; found, 448.1996 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> <i>N</i>-Hydroxy-6-(3-(1-(4-methoxyphenyl)-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)hexanamide (<b>11e</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10e</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 63%. Analytical data for <b>11e</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 11.20 (s, 1H, NH), 10.36 (s, 1H, NH), 8.79 (m, 1H, Ar–H), 8.40–8.45 (m, 3H, Ar–H, 2 × CONH), 8.17 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.73 (m, 1H, Ar–H), 7.58 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 7.18 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.89 (s, 3H, OCH<sub>3</sub>), 3.43 (m, 2H, NCH<sub>2</sub>), 2.28 (m, 2H, CH<sub>2</sub>), 1.70–1.73 (m, 4H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>), 1.49 (m, 2H, NCH<sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 462 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>4</sub>, 462.2141; found, 462.2156 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> <i>N</i>-Hydroxy-2-(3-(1-(4-methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)acetamide (<b>11f</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10f</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 75%. Analytical data for <b>11f</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 8.71 (m, 1H, Ar–H), 8.42–8.48 (m, 3H, Ar–H, CONH), 8.15 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.67 (m, 1H, Ar–H), 7.58 (m, 1H, Ar–H), 7.31 (m, 1H, Ar–H), 7.13 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.87 (s, 3H, OCH<sub>3</sub>), 4.30 (m, 2H, NCH<sub>2</sub>), 3.56 (s, 3H, NCH<sub>3</sub>). MS (ESI) <i>m</i>/<i>z</i> 420 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>22</sub>H<sub>22</sub>N<sub>5</sub>O<sub>4</sub>, 420.1672; found, 420.1689 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> <i>N</i>-Hydroxy-3-(3-(1-(4-methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)propanamide (<b>11g</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10g</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 71%. Analytical data for <b>11g</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.07 (s, 1H, NH), 8.70 (s, 1H, Ar–H), 8.39–8.45 (m, 3H, Ar–H, CONH), 8.14 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.68 (m, 1H, Ar–H), 7.59 (m, 1H, Ar–H), 7.47 (m, 1H, Ar–H), 7.12 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.87 (s, 3H, OCH<sub>3</sub>), 3.55–3.63 (m, 5H, NCH<sub>3</sub>, NCH<sub>2</sub>), 2.69 (m, 2H, CH<sub>2</sub>CO). MS (ESI) <i>m</i>/<i>z</i> 434 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub>, 434.1828; found, 434.1844 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> <i>N</i>-Hydroxy-4-(3-(1-(4-methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)butanamide (<b>11h</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10h</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 72%. Analytical data for <b>11h</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 10.36 (s, 1H, NH), 8.76 (m, 1H, Ar–H), 8.43–8.51 (m, 3H, Ar–H, 2 × CONH), 8.17 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.70 (m, 1H, Ar–H), 7.58 (m, 1H, Ar–H), 7.31 (m, 1H, Ar–H), 7.18 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.90 (s, 3H, OCH<sub>3</sub>), 3.59 (s, 3H, NCH<sub>3</sub>), 3.43 (m, 2H, NCH<sub>2</sub>), 2.26 (m, 2H, CH<sub>2</sub>), 1.83 (m, 2H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 448 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>26</sub>N<sub>5</sub>O<sub>4</sub>, 448.1985; found, 448.2002 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> <i>N</i>-Hydroxy-5-(3-(1-(4-methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)pentanamide (<b>11i</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10i</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 66%. Analytical data for 11i: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.61 (s, 1H, NH), 8.78 (m, 1H, Ar–H), 8.42–8.48 (m, 3H, Ar–H, CONH), 8.18 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.67 (m, 1H, Ar–H), 7.60 (m, 1H, Ar–H), 7.33 (m, 1H, Ar–H), 7.17 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.90 (s, 3H, OCH<sub>3</sub>), 3.58 (s, 3H, NCH<sub>3</sub>), 3.46 (m, 2H, NCH<sub>2</sub>), 2.27 (m, 2H, CH<sub>2</sub>), 1.72–1.76 (m, 4H, NCH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 462 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>25</sub>H<sub>28</sub>N<sub>5</sub>O<sub>4</sub>, 462.2141; found, 462.2128 [M + H]<sup>+</sup>.</div></div><div id="sec4_6_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> <i>N</i>-Hydroxy-6-(3-(1-(4-methoxyphenyl)-9-methyl-9<i>H</i>-pyrido[3,4-<i>b</i>]indol-3-yl)ureido)hexanamide (<b>11j</b>)</h5><div class="NLM_p last">The title compound was obtained starting from <b>10j</b> and NH<sub>2</sub>OK to afford an off-white solid, yield: 70%. Analytical data for <b>11j</b>: <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz, δ) 9.07 (s, 1H, NH), 8.73 (m, 1H, Ar–H), 8.41–8.46 (m, 3H, Ar–H, CONH), 8.16 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 7.67 (m, 1H, Ar–H), 7.58 (m, 1H, Ar–H), 7.32 (m, 1H, Ar–H), 7.15 (d, 2H, <i>J</i> = 7.5 Hz, Ar–H), 3.88 (s, 3H, OCH<sub>3</sub>), 3.55 (s, 3H, NCH<sub>3</sub>), 3.40 (m, 2H, NCH<sub>2</sub>), 2.26 (m, 2H, CH<sub>2</sub>), 1.70–1.75 (m, 4H, CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>C<u class="uu">H</u><sub>2</sub>CH<sub>2</sub>), 1.47 (m, 2H, NCH<sub>2</sub>CH<sub>2</sub>C<u class="uu">H</u><sub>2</sub>). MS (ESI) <i>m</i>/<i>z</i> 476 [M + H]<sup>+</sup>. HRMS (ESI) <i>m</i>/<i>z</i> calcd for C<sub>26</sub>H<sub>30</sub>N<sub>5</sub>O<sub>4</sub>, 476.2298; found, 476.2312 [M + H]<sup>+</sup>.</div></div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Cell Culture and Reagents</h3><div class="NLM_p last">Human colon cancer cells (HCT116, SW620, Lovo, and SW480) and HeLa cells were maintained in DMEM supplemented with 10% fetal bovine serum (Invitrogen), 100 units/mL penicillin, and 0.1 μg/mL streptomycin in a humid atmosphere incubator with 5% CO<sub>2</sub> at 37 °C. All cell lines were originally from the Shanghai Institute of Cell Biology (Shanghai, China). Cells were routinely subcultured twice weekly. Antibodies against p53, p21, and PARP were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), monoclonal anti-actin antibody, and goat peroxidase-conjugated anti-rabbit IgG antibody, and goat peroxidase-conjugated anti-mouse IgG antibody were purchased from Sigma-Aldrich (St. Louis, MO, USA). FITC-Annexin V and PI are from (BioVision). The chemiluminescence (ECL) kit was purchased from Thermo Fisher Scientific (Rockford, IL, USA). Antibodies against acetyl-H3, acetyl-tubulin, Bax, Bcl-2, p-H2AX cleaved-caspase 3, and p-p53 (S15) are from Cell Signaling Technology (Danvers, MA, USA).</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Cell Viability Assay</h3><div class="NLM_p last">Antiproliferative activities of synthesized compounds were evaluated in vitro against four human colon cancer cell lines (HCT116, SW620, LOVO, and SW480). Briefly, 100 μL of different colon cancer cells were plated in a 96-well flat-bottomed tissue culture plate at a density of 10<sup>4</sup> cells/mL in DMEM medium and 10% fetal bovine serum and allowed to adhere overnight at 37 °C in 5% CO<sub>2</sub>. The cells were treated by adding 100 μL of different compounds at various concentrations into the respective well. The reagent DMSO (0.1%) was used as a negative control. The cell viability assay (MTT assay) was carried out at 48 h after drug treatment. The concentration that inhibited 50% of cellular growth (IC<sub>50</sub> value) was calculated by the following formula: Cell inhibition rate (%) = (1 – OD of treatment group/OD of control group) × 100%. The cytotoxicity potency of tested compounds on colon cancer cells was expressed as IC<sub>50</sub> values or by a histogram. (The bars are the mean ± SD.) All the data were derived from three independent measurements.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> HDAC Activity Assay</h3><div class="NLM_p last">HDAC activity assays were carried out as previously reported.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> HeLa cell nuclear extract, which is a rich source of HDACs, was prepared using the EpiQuik nuclear extraction kit (OP-0002, Epigentek Group, Inc.). HDAC activity was determined using the HDAC fluorimetric activity assay kit (Enzo Life Sciences, Inc.) according to the manufacturer’s instructions. Briefly, HDAC enzyme solution (HeLa nuclear extract, HDAC1, HDAC6, or HDAC8) was incubated with test compounds at different concentrations in the presence of HDAC substrate (Boc-Lys (Ac)-AMC) at 37 °C for 60 min. Then, the lysine developer was added to stop the reaction. After 30 min, the data was recorded in a fluorescence plate reader with excitation at 355 nm and emission at 460 nm. The HDAC activity was calculated as a percentage of activity compared with the control group. The concentration required for 50% inhibition (IC<sub>50</sub>) was calculated using the software GraphPad Prism (version 4.03).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> Flow Cytometry Assay of Cell Apoptosis</h3><div class="NLM_p last">HCT116 cells cells were cultured overnight and incubated in triplicate with different concentrations of <b>11c</b> (0.1, 1.0, and 5.0 μM), SAHA (5.0 μM), or vehicle for 48 h. The cells were harvested and stained with FITC-Annexin V and PI at room temperature for 15 min. The percentage of apoptotic cells was determined by flow cytometry (Epics XL-MCL, Beckman Coulter, Indianapolis, IN, USA) analysis. The FITC signal detector (FL1) and PI staining signal detector (FL3) were used to detect the cells with the flow cytometer (Ex = 488 nm; Em = 530 nm). A total of 10 000 cells were counted for three independent experiments. The data were analyzed using WinList 3D (version 7.1), and the histogram was plotted using Excel 2010.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Western Blot Analysis</h3><div class="NLM_p last">HCT116 cells with or without harmine, <b>11c</b>, or <b>11h</b> treatment at indicated times and doses were washed with PBS and lysed on ice for 30 min in PBS containing 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 mg/mL PMSF, and 20 mM leupeptin. The protein concentrations were determined using a Bio-Rad protein assay kit (Bio-Rad Laboratories Inc., Hercules, CA, USA). Up to 50 μg of total protein was separated via SDS-PAGE and transferred to polyvinylidenedifluoride membranes. After blocking with 5% fat free milk for 2 h, membranes were incubated overnight at 4 °C with a primary antibody in TBS-T and then reacted with a peroxidase-conjugated secondary antibody for 1 h. Immunoreactive proteins were detected with the ECL Western blotting Detection System.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> shRNA Knockdown</h3><div class="NLM_p last">For p53 knockdown, lentiviruses encoding p53 shRNA or control shRNA were purchased from Open Biosystem. HCT116 cells were infected with p53 shRNA lentivirus or control shRNA lentivirus for 12 h. They were then cultured for 2 days. Positive clones expressing shRNAs were selected by puromycin (2 μg/mL). Immunoblot analysis was used to determine the expression levels of p53 in these cells.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Maximum Tolerated Dose Determination</h3><div class="NLM_p last">All in vivo studies were approved by the Nantong University Animal Care and Use Committee. The maximum tolerated dose (MTD) of compound <b>11c</b> in female ICR mice was determined by intraperitoneal injection of a single dose of <b>11c</b> (585.9, 468.8, 374.0, 300, and 240 mg/kg) or vehicle control (<i>n</i> = 10 per group), respectively. The MTD was set below the dose that caused severe loss of body weight (>20% of original weight), or death of one or more animals of a dose group. MTD was defined as the highest dose that could be given resulting in non-drug-related moribund state or death, whereas temporary body weight loss was within 20%.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> In Vivo Tumor Growth Inhibition</h3><div class="NLM_p last">Female BALB/c nude mice at the age of 5–6 weeks old were inoculated subcutaneously with 10<sup>6</sup> HCT116 cells. When tumor volumes reached 100–200 mm<sup>3</sup>, the mice were randomly administered with <b>11c</b>, SAHA, or vehicle, respectively. The body weight of all animals was monitored throughout the study, and animals were euthanized if they incurred 20% weight loss between observations. Two axes (mm) of a tumor (<i>L</i>, longest axis; <i>W</i>, shortest axis) were measured with a Vernier caliper. Tumor volume (mm<sup>3</sup>) was calculated using the following formula: tumor volume = 1/2(<i>L</i> × <i>W</i><sup>2</sup>). Progression of tumors was monitored every 3 days up to 22 days posttreatment. At the end of the experiment, the mice were sacrificed, and their tumors were dissected out and weighed.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="NOTES-d2022e6467-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i85"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01052">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36332" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36332" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01052" class="ext-link">10.1021/acs.jmedchem.5b01052</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental details pertaining to pharmacokinetic studies. (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Structures for compounds <b>5a</b>–<b>o</b> and <b>11a</b>–<b>j</b>. (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_001.pdf">jm5b01052_si_001.pdf (57.42 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_002.csv">jm5b01052_si_002.csv (1.47 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01052" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74543" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74543" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yanan Zhang</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b4cedcd5dad3cdd5dad5daf4d3d9d5ddd89ad7dbd9"><span class="__cf_email__" data-cfemail="f3899b929d948a929d929db3949e929a9fdd909c9e">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xiang Ling</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#2b53424a454c05454a455f44454c6b4c464a424705484446"><span class="__cf_email__" data-cfemail="b4ccddd5dad39adad5dac0dbdad3f4d3d9d5ddd89ad7dbd9">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yong Ling</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chenjun Xu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lin Luo</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jingyi Cao</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiao Feng</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yu Xue</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qing Zhu</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Caoyun Ju</span> - <span class="hlFld-Affiliation affiliation">†School of Pharmacy and Jiangsu Province
Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong 226001, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengzhi Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology and Therapeutics, Roswell
Park Cancer Institute, Buffalo, New York, USA</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yihua Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Natural Medicines, China
Pharmaceutical University, Nanjing 210009, P.R. China</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d2022e6504-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64317" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64317" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We gratefully acknowledge the financial support by the Natural Science Foundation of China (grant nos. 81302628 and 81473089), the Project of “Jiangsu Six Peaks of Talent” (2014-SWYY-044), China Pharmaceutical University for the Open Project Program of State Key Laboratory of Natural Medicines (SKLNMKF201415), Jiangsu Government Scholarship for Overseas Studies (JS-2014-212), and we also thank a project funded by the Priority Academic Programs Development of Jiangsu Higher Education Institutions (PAPD).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i87" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i87"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i88" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i88"> Abbreviations</h2><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">ESI</td><td class="NLM_def"><p class="first last">electrospray ionization</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">PE</td><td class="NLM_def"><p class="first last">petroleum ether</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">propidium iodide</p></td></tr><tr><td class="NLM_term">SAHA</td><td class="NLM_def"><p class="first last">Vorinostat</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i89">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78821" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78821" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 37 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Kim, J. H.</span><span> </span><span class="NLM_article-title">Chemotherapy for colorectal cancer in the elderly</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5158</span><span class="NLM_x">–</span> <span class="NLM_lpage">5166</span><span class="refDoi"> DOI: 10.3748/wjg.v21.i17.5158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.3748%2Fwjg.v21.i17.5158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=25954089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFaktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5158-5166&author=J.+H.+Kim&title=Chemotherapy+for+colorectal+cancer+in+the+elderly&doi=10.3748%2Fwjg.v21.i17.5158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy for colorectal cancer in the elderly</span></div><div class="casAuthors">Kim, Jung Han</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5158-5166</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">2219-2840</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the elderly.  However, elderly patients with CRC tend to be under-presented in clin. trials and undertreated in clin. practice.  Advanced age alone should not be the only criteria to preclude effective therapy in elderly patients with CRC.  The best guide about optimal cancer treatment can be provided by comprehensive geriatric assessment.  Elderly patients with stage  colon cancer can enjoy the same benefit from adjuvant chemotherapy with 5-fluorouracil/leucovorin or capecitabine as younger patients, without a substantial increase in toxicity.  With conflicting results of retrospective studies and a lack of data available from randomized studies, combined modality treatment should be used with great caution in elderly patients with locally advanced rectal cancer.  Combination chemotherapy can be considered for older patients with metastatic CRC.  For elderly patients who are frail or vulnerable, however, monotherapy or a stopand- go strategy may be desirable.  The use of targeted therapies in older patients with metastatic CRC appears to be promising in view of their better efficacy and toxicity.  Treatment should be individualized based on the nature of the disease, the physiol. or functional status, and the patient's preference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd3RvF6ygpALVg90H21EOLACvtfcHk0ljpm4frHf28bQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFaktrrI&md5=e89c264b4fe5633ef1a406d8402e7491</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v21.i17.5158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v21.i17.5158%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26atitle%3DChemotherapy%2520for%2520colorectal%2520cancer%2520in%2520the%2520elderly%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2015%26volume%3D21%26spage%3D5158%26epage%3D5166%26doi%3D10.3748%2Fwjg.v21.i17.5158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Fakih, M. G.</span><span> </span><span class="NLM_article-title">Metastatic colorectal cancer: current state and future directions</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1809</span><span class="NLM_x">–</span> <span class="NLM_lpage">1824</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.7633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1200%2FJCO.2014.59.7633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=25918280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eisb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1809-1824&author=M.+G.+Fakih&title=Metastatic+colorectal+cancer%3A+current+state+and+future+directions&doi=10.1200%2FJCO.2014.59.7633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic colorectal cancer: current state and future direction</span></div><div class="casAuthors">Fakih, Marwan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1809-1824</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Substantial improvements have been made in the management of metastatic colorectal cancer over the last two decades.  The overall survival of patients diagnosed with unresectable metastatic colorectal cancer has increased from approx. 1 yr during the era of fluoropyrimidine monotherapy to more than 30 mo with the integration of multiple cytotoxic agents and targeted therapies.  More effective therapeutic combinations have increased the rate of curative-intent surgical resections, resulting in median survival in this subgroup that exceed 5 years.  Here we review the landscape of systemic therapies for unresectable metastatic colorectal cancer during the current era of targeted therapies, review the effects of RAS and BRAF mutations on clin. decision making, and reflect on future directions for the treatment of metastatic colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0_vqdnGQXi7Vg90H21EOLACvtfcHk0lhzHvMlv4P5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eisb3L&md5=c9c27ec937920458df9394eaceecb345</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.7633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.7633%26sid%3Dliteratum%253Aachs%26aulast%3DFakih%26aufirst%3DM.%2BG.%26atitle%3DMetastatic%2520colorectal%2520cancer%253A%2520current%2520state%2520and%2520future%2520directions%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1809%26epage%3D1824%26doi%3D10.1200%2FJCO.2014.59.7633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Musso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallavalle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">Perspectives in the development of hybrid bifunctional antitumour agents</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="refDoi"> DOI: 10.1016/j.bcp.2015.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.bcp.2015.06.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=297&author=L.+Mussoauthor=S.+Dallavalleauthor=F.+Zunino&title=Perspectives+in+the+development+of+hybrid+bifunctional+antitumour+agents&doi=10.1016%2Fj.bcp.2015.06.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DDallavalle%26aufirst%3DS.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DPerspectives%2520in%2520the%2520development%2520of%2520hybrid%2520bifunctional%2520antitumour%2520agents%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D96%26spage%3D297%26doi%3D10.1016%2Fj.bcp.2015.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadewar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. K.</span><span> </span><span class="NLM_article-title">A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ’’Harmine’’</span> <span class="citation_source-journal">Asian Pac. J. Trop. Biomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1016/S2221-1691(12)60116-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2FS2221-1691%2812%2960116-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=23569990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ent73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=660-664&author=K.+Patelauthor=M.+Gadewarauthor=R.+Tripathiauthor=S.+K.+Prasadauthor=D.+K.+Patel&title=A+review+on+medicinal+importance%2C+pharmacological+activity+and+bioanalytical+aspects+of+beta-carboline+alkaloid+%E2%80%99%E2%80%99Harmine%E2%80%99%E2%80%99&doi=10.1016%2FS2221-1691%2812%2960116-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid "Harmine"</span></div><div class="casAuthors">Patel, K.; Gadewar, M.; Tripathi, R.; Prasad, S. K.; Patel, Dinesh Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Asian Pacific Journal of Tropical Biomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">660-664</span>CODEN:
                <span class="NLM_cas:coden">APJTC7</span>;
        ISSN:<span class="NLM_cas:issn">2221-1691</span>.
    
            (<span class="NLM_cas:orgname">Asian Pacific Tropical Medicine Press</span>)
        </div><div class="casAbstract">A review.  Harmine, a beta-carboline alkaloid, is widely distributed in the plants, marine creatures, insects, mammalians as well as in human tissues and body fluids.  Harmine was originally isolated from seeds of Peganum harmal in 1847 having a core indole structure and a pyridine ring.  Harmine has various types of pharmacol. activities such as antimicrobial, antifungal, antitumor, cytotoxic, antiplasmodial, antioxidant, antimutagenic, antigenotoxic and hallucinogenic properties.  It acts on gamma-aminobutyric acid type A and monoamine oxidase A or B receptor, enhances insulin sensitivity and also produces vasorelaxant effect.  Harmine prevents bone loss by suppressing osteoclastogenesis.  The current review gives an overview on pharmacol. activity and anal. techniques of harmine, which may be useful for researchers to explore the hidden potential of harmine and will also help in developing new drugs for the treatment of various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphYIg7jC3SRrVg90H21EOLACvtfcHk0lhzHvMlv4P5_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ent73E&md5=0faccc657b181ef34db4d839fa2487ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS2221-1691%2812%2960116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2221-1691%252812%252960116-6%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DGadewar%26aufirst%3DM.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%2BK.%26aulast%3DPatel%26aufirst%3DD.%2BK.%26atitle%3DA%2520review%2520on%2520medicinal%2520importance%252C%2520pharmacological%2520activity%2520and%2520bioanalytical%2520aspects%2520of%2520beta-carboline%2520alkaloid%2520%25E2%2580%2599%25E2%2580%2599Harmine%25E2%2580%2599%25E2%2580%2599%26jtitle%3DAsian%2520Pac.%2520J.%2520Trop.%2520Biomed.%26date%3D2012%26volume%3D2%26spage%3D660%26epage%3D664%26doi%3D10.1016%2FS2221-1691%2812%2960116-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesuma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, R. Z.</span><span> </span><span class="NLM_article-title">Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">317</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2004.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.bbrc.2004.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=15047157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVKmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2004&pages=128-132&author=Y.+Songauthor=D.+Kesumaauthor=J.+Wangauthor=Y.+Dengauthor=J.+Duanauthor=J.+H.+Wangauthor=R.+Z.+Qi&title=Specific+inhibition+of+cyclin-dependent+kinases+and+cell+proliferation+by+harmine&doi=10.1016%2Fj.bbrc.2004.03.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine</span></div><div class="casAuthors">Song, Yongcheng; Kesuma, Djohan; Wang, Jian; Deng, Yu; Duan, Jinao; Wang, Jerry H.; Qi, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-132</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">As key regulators of the cell proliferation cycle, cyclin-dependent kinases (CDKs) are attractive targets for the development of anti-tumor drugs.  In the present study, harmine was identified from a collection of herbal compds. to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.  It displayed little effect on other serine/threonine and tyrosine kinases tested.  The CDK inhibition by harmine is competitive with ATP-Mg2+, suggesting that it binds to the ATP-Mg2+-binding pocket of CDKs.  In cytotoxicity assays, harmine exhibited a strong inhibitory effect on the growth and proliferation of carcinoma cells whereas it had no significant effect on quiescent fibroblasts.  Further, harmine was found to block DNA replication in the carcinoma cells.  Taken together, harmine is a selective inhibitor of CDKs and cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9drfO7NpUHrVg90H21EOLACvtfcHk0ljCFkE4JzgWkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVKmt74%253D&md5=1a88a183ab790612a3e4c3d7c147eca6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2004.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2004.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKesuma%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DQi%26aufirst%3DR.%2BZ.%26atitle%3DSpecific%2520inhibition%2520of%2520cyclin-dependent%2520kinases%2520and%2520cell%2520proliferation%2520by%2520harmine%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D317%26spage%3D128%26epage%3D132%26doi%3D10.1016%2Fj.bbrc.2004.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Frédérick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruyère, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vancraeynest, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reniers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pochet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backlund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masereel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wouters, J.</span><span> </span><span class="NLM_article-title">Novel trisubstituted harmine derivatives with original in vitro anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6489</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span><span class="refDoi"> DOI: 10.1021/jm300542e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300542e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6489-6501&author=R.+Fr%C3%A9d%C3%A9rickauthor=C.+Bruy%C3%A8reauthor=C.+Vancraeynestauthor=J.+Reniersauthor=C.+Meinguetauthor=L.+Pochetauthor=A.+Backlundauthor=B.+Masereelauthor=R.+Kissauthor=J.+Wouters&title=Novel+trisubstituted+harmine+derivatives+with+original+in+vitro+anticancer+activity&doi=10.1021%2Fjm300542e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm300542e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300542e%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25A9d%25C3%25A9rick%26aufirst%3DR.%26aulast%3DBruy%25C3%25A8re%26aufirst%3DC.%26aulast%3DVancraeynest%26aufirst%3DC.%26aulast%3DReniers%26aufirst%3DJ.%26aulast%3DMeinguet%26aufirst%3DC.%26aulast%3DPochet%26aufirst%3DL.%26aulast%3DBacklund%26aufirst%3DA.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DWouters%26aufirst%3DJ.%26atitle%3DNovel%2520trisubstituted%2520harmine%2520derivatives%2520with%2520original%2520in%2520vitro%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6489%26epage%3D6501%26doi%3D10.1021%2Fjm300542e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudy-Floc’h, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ju, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span> </span><span class="NLM_article-title">Synthesis and cytotoxic activities of beta-carboline amino acid ester conjugates</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6998</span><span class="NLM_x">–</span> <span class="NLM_lpage">7010</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.bmc.2006.06.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=6998-7010&author=M.+Zhaoauthor=L.+Biauthor=W.+Wangauthor=C.+Wangauthor=M.+Baudy-Floc%E2%80%99hauthor=J.+Juauthor=S.+Peng&title=Synthesis+and+cytotoxic+activities+of+beta-carboline+amino+acid+ester+conjugates&doi=10.1016%2Fj.bmc.2006.06.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DBi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DBaudy-Floc%25E2%2580%2599h%26aufirst%3DM.%26aulast%3DJu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520cytotoxic%2520activities%2520of%2520beta-carboline%2520amino%2520acid%2520ester%2520conjugates%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D6998%26epage%3D7010%26doi%3D10.1016%2Fj.bmc.2006.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Z. W.</span><span> </span><span class="NLM_article-title">Ruthenium-arene-beta-carboline complexes as potent inhibitors of cyclin-dependent kinase 1: synthesis, characterization and anticancer mechanism studies</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">12152</span><span class="NLM_x">–</span> <span class="NLM_lpage">12160</span><span class="refDoi"> DOI: 10.1002/chem.201301389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1002%2Fchem.201301389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=23878093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=12152-12160&author=L.+Heauthor=S.+Y.+Liaoauthor=C.+P.+Tanauthor=R.+R.+Yeauthor=Y.+W.+Xuauthor=M.+Zhaoauthor=L.+N.+Jiauthor=Z.+W.+Mao&title=Ruthenium-arene-beta-carboline+complexes+as+potent+inhibitors+of+cyclin-dependent+kinase+1%3A+synthesis%2C+characterization+and+anticancer+mechanism+studies&doi=10.1002%2Fchem.201301389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies</span></div><div class="casAuthors">He, Liang; Liao, Si-Yan; Tan, Cai-Ping; Ye, Rui-Rong; Xu, Yu-Wen; Zhao, Meng; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12152-12160</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ru(II)-arene complexes, [(η6-arene)Ru(L)Cl]PF6 (1-6, arene = benzene or p-cymene; L = bidentate β-carboline deriv., an indole alkaloid with potential cyclin-dependent kinases (CDKs) inhibitory activities), are prepd. from [(η6-arene)RuCl2]2 and L.  All the complexes were fully characterized by classical anal. methods, and three were characterized by x-ray crystallog.  Hydrolytic studies show that β-carboline ligands play a vital role in their aq. behavior.  These complexes are highly active in vitro, with the most active complex 6 displaying a 3-12-fold higher anticancer activity than cisplatin against several cancer cell lines.  The complexes are able to overcome cross-resistance to cisplatin, and show much lower cytotoxicity against normal cells.  Complexes 1-6 may directly target CDK1, because they can block cells in the G2M phase, down-regulate the expression of CDK1 and cyclin B1, and inhibit CDK1/cyclin B in vitro.  Further mechanism studies show that the complexes can effectively induce apoptosis through mitochondrial-related pathways and intracellular reactive O species (ROS) elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6h10BlYuFK7Vg90H21EOLACvtfcHk0ljCFkE4JzgWkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK&md5=fb2b63894c4f96209d60c1b4e8266e9a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fchem.201301389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201301389%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DS.%2BY.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DYe%26aufirst%3DR.%2BR.%26aulast%3DXu%26aufirst%3DY.%2BW.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.%2BW.%26atitle%3DRuthenium-arene-beta-carboline%2520complexes%2520as%2520potent%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25201%253A%2520synthesis%252C%2520characterization%2520and%2520anticancer%2520mechanism%2520studies%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2013%26volume%3D19%26spage%3D12152%26epage%3D12160%26doi%3D10.1002%2Fchem.201301389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, S.</span><span> </span><span class="NLM_article-title">A series of beta-carboline derivatives inhibit the kinase activity of PLKs</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e46546</span><span class="refDoi"> DOI: 10.1371/journal.pone.0046546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1371%2Fjournal.pone.0046546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e46546&author=X.+Hanauthor=J.+Zhangauthor=L.+Guoauthor=R.+Caoauthor=Y.+Liauthor=N.+Liauthor=Q.+Maauthor=J.+Wuauthor=Y.+Wangauthor=S.+Si&title=A+series+of+beta-carboline+derivatives+inhibit+the+kinase+activity+of+PLKs&doi=10.1371%2Fjournal.pone.0046546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0046546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0046546%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DA%2520series%2520of%2520beta-carboline%2520derivatives%2520inhibit%2520the%2520kinase%2520activity%2520of%2520PLKs%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De46546%26doi%3D10.1371%2Fjournal.pone.0046546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Herraiz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancin-Azpilicueta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aran, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen, H.</span><span> </span><span class="NLM_article-title">beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)</span> <span class="citation_source-journal">Food Chem. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">845</span><span class="refDoi"> DOI: 10.1016/j.fct.2009.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.fct.2009.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20036304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1OrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2010&pages=839-845&author=T.+Herraizauthor=D.+Gonzalezauthor=C.+Ancin-Azpilicuetaauthor=V.+J.+Aranauthor=H.+Guillen&title=beta-Carboline+alkaloids+in+Peganum+harmala+and+inhibition+of+human+monoamine+oxidase+%28MAO%29&doi=10.1016%2Fj.fct.2009.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)</span></div><div class="casAuthors">Herraiz, T.; Gonzalez, D.; Ancin-Azpilicueta, C.; Aran, V. J.; Guillen, H.</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-845</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Peganum harmala L. is a multipurpose medicinal plant increasingly used for psychoactive recreational purposes (Ayahuasca analog).  Harmaline, harmine, harmalol, harmol, and tetrahydroharmine were identified and quantified as the main β-carboline alkaloids in P. harmala exts.  Seeds and roots contained the highest levels of alkaloids with low levels in stems and leaves, and absence in flowers.  Harmine and harmaline accumulated in dry seeds at 4.3 and 5.6% (wt./wt.), resp., harmalol at 0.6%, and tetrahydroharmine at 0.1% (wt./wt.).  Roots contained harmine and harmol with 2.0 and 1.4% (wt./wt.), resp.  Seed exts. were potent reversible and competitive inhibitors of human monoamine oxidase (MAO-A) with an IC50 of 27 μg/l whereas root exts. strongly inhibited MAO-A with an IC50 of 159 μg/l.  In contrast, they were poor inhibitors of MAO-B.  Inhibition of MAO-A by seed exts. was quant. attributed to harmaline and harmine whereas inhibition by root exts. came from harmine with no addnl. interferences.  Stems and leaves exts. were poor inhibitors of MAO.  The potent inhibition of MAO-A by seed and root exts. of P. harmala contg. β-carbolines should contribute to the psychopharmacol. and toxicol. effects of this plant and could be the basis for its purported antidepressant actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj_9T1Mqk4U7Vg90H21EOLACvtfcHk0lh5lyEPgHobEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1OrtLk%253D&md5=34d13b816d538df99ff19d421ec22519</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2009.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2009.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DHerraiz%26aufirst%3DT.%26aulast%3DGonzalez%26aufirst%3DD.%26aulast%3DAncin-Azpilicueta%26aufirst%3DC.%26aulast%3DAran%26aufirst%3DV.%2BJ.%26aulast%3DGuillen%26aufirst%3DH.%26atitle%3Dbeta-Carboline%2520alkaloids%2520in%2520Peganum%2520harmala%2520and%2520inhibition%2520of%2520human%2520monoamine%2520oxidase%2520%2528MAO%2529%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2010%26volume%3D48%26spage%3D839%26epage%3D845%26doi%3D10.1016%2Fj.fct.2009.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimha Rao, M. P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swapna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasulu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullagiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovvuri, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidyasagar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagesh, N.</span><span> </span><span class="NLM_article-title">Synthesis of beta-carboline-benzimidazole conjugates using lanthanum nitrate as a catalyst and their biological evaluation</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2370</span><span class="NLM_x">–</span> <span class="NLM_lpage">2387</span><span class="refDoi"> DOI: 10.1039/c3ob42236d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1039%2Fc3ob42236d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=2370-2387&author=A.+Kamalauthor=M.+P.+N.+Narasimha+Raoauthor=P.+Swapnaauthor=V.+Srinivasuluauthor=C.+Bagulauthor=A.+B.+Shaikauthor=K.+Mullagiriauthor=J.+Kovvuriauthor=V.+S.+Reddyauthor=K.+Vidyasagarauthor=N.+Nagesh&title=Synthesis+of+beta-carboline-benzimidazole+conjugates+using+lanthanum+nitrate+as+a+catalyst+and+their+biological+evaluation&doi=10.1039%2Fc3ob42236d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1039%2Fc3ob42236d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob42236d%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DNarasimha%2BRao%26aufirst%3DM.%2BP.%2BN.%26aulast%3DSwapna%26aufirst%3DP.%26aulast%3DSrinivasulu%26aufirst%3DV.%26aulast%3DBagul%26aufirst%3DC.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DMullagiri%26aufirst%3DK.%26aulast%3DKovvuri%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DV.%2BS.%26aulast%3DVidyasagar%26aufirst%3DK.%26aulast%3DNagesh%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520beta-carboline-benzimidazole%2520conjugates%2520using%2520lanthanum%2520nitrate%2520as%2520a%2520catalyst%2520and%2520their%2520biological%2520evaluation%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D2370%26epage%3D2387%26doi%3D10.1039%2Fc3ob42236d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Wu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris-Natschke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. Q.</span><span> </span><span class="NLM_article-title">Novel N-(3-carboxyl-9-benzyl-beta-carboline-1-yl)ethylamino acids: Synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4153</span><span class="NLM_x">–</span> <span class="NLM_lpage">4161</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2009.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.ejmech.2009.05.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=4153-4161&author=J.+H.+Wuauthor=M.+Zhaoauthor=K.+D.+Qianauthor=K.+H.+Leeauthor=S.+Morris-Natschkeauthor=S.+Q.+Peng&title=Novel+N-%283-carboxyl-9-benzyl-beta-carboline-1-yl%29ethylamino+acids%3A+Synthesis%2C+anti-tumor+evaluation%2C+intercalating+determination%2C+3D+QSAR+analysis+and+docking+investigation&doi=10.1016%2Fj.ejmech.2009.05.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BH.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DK.%2BD.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DMorris-Natschke%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BQ.%26atitle%3DNovel%2520N-%25283-carboxyl-9-benzyl-beta-carboline-1-yl%2529ethylamino%2520acids%253A%2520Synthesis%252C%2520anti-tumor%2520evaluation%252C%2520intercalating%2520determination%252C%25203D%2520QSAR%2520analysis%2520and%2520docking%2520investigation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D4153%26epage%3D4161%26doi%3D10.1016%2Fj.ejmech.2009.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Sobhani, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimi, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmoudian, M.</span><span> </span><span class="NLM_article-title">An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids</span> <span class="citation_source-journal">J. Pharm. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=12042115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BD38zhs1antw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=19-23&author=A.+M.+Sobhaniauthor=S.+A.+Ebrahimiauthor=M.+Mahmoudian&title=An+in+vitro+evaluation+of+human+DNA+topoisomerase+I+inhibition+by+Peganum+harmala+L.+seeds+extract+and+its+beta-carboline+alkaloids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids</span></div><div class="casAuthors">Sobhani Armin Madadkar; Ebrahimi Sultan-Ahmad; Mahmoudian Massoud</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Peganum harmala L. (Zygophyllaceae) seeds extract is one of the main components of an ethnobotanical preparation used in the treatment of neoplasms in Iran.  Cytotoxic effects of P. harmala extract on cancerous cell-lines have been reported before. beta-carbolines like harmaline and harmine are the major alkaloids present in the seeds of the P. harmala.  Considering reports concerning DNA topoisomerase inhibition by other beta-carbolines like harmane, we have used DNA relaxation assays to investigate topoisomerase I inhibitory activity of P. harmala seeds extract and its beta-carboline alkaloids to further inspecting the mechanism of its cytotoxic activity.  METHODS:  Harmine and harmaline contents of the extract were determined using an HPTLC method.  DNA topoisomerase I enzyme needed for investigating inhibitory effect of the compounds using DNA relaxation assay, was partially purified from the human placenta.  DNA relaxation assay is based on the conversion of a supercoiled plasmid substrate to its relaxed form by the catalytic activity of the enzyme.  The supercoiled substrate and its relaxed product can be easily distinguished using agarose gel electrophoresis, since the relaxed topological isomers of DNA migrate more slowly than supercoiled species.  RESULTS:  Using HPTLC method, it was found that each gram of dried extract contained 55.5 and 79.0 mg of harmine and harmaline respectively.  In the DNA relaxation assay, order of potency was harmine > harmane > harmaline > extract.  The most active compound was harmine with IC50 value of 13.5 +/- 1.7 microg/ml.  CONCLUSIONS:  Our in vitro findings demonstrate that P. harmala seeds extract do inhibit human DNA topoisomerase I and based on the results of HPTLC analysis, it appears that the biological activity of the extract can be explained by its beta-carboline content.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTco1bQOg25AENHe_gFldTbfW6udTcc2ebn1fVNmPEqs7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zhs1antw%253D%253D&md5=9a28f3bbbc901f48c665505be4e98b2a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSobhani%26aufirst%3DA.%2BM.%26aulast%3DEbrahimi%26aufirst%3DS.%2BA.%26aulast%3DMahmoudian%26aufirst%3DM.%26atitle%3DAn%2520in%2520vitro%2520evaluation%2520of%2520human%2520DNA%2520topoisomerase%2520I%2520inhibition%2520by%2520Peganum%2520harmala%2520L.%2520seeds%2520extract%2520and%2520its%2520beta-carboline%2520alkaloids%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2002%26volume%3D5%26spage%3D19%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, E.</span><span> </span><span class="NLM_article-title">HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5310</span><span class="NLM_x">–</span> <span class="NLM_lpage">5318</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2Fsj.onc.1210599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=17694074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFekurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5310-5318&author=X.+J.+Yangauthor=E.+Seto&title=HATs+and+HDACs%3A+from+structure%2C+function+and+regulation+to+novel+strategies+for+therapy+and+prevention&doi=10.1038%2Fsj.onc.1210599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention</span></div><div class="casAuthors">Yang, X.-J.; Seto, E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5310-5318</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The acetylation of the ε-NH2 group of a Lys residue was 1st discovered with histones in 1968, but the responsible enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), were not identified until the mid-1990s.  In the past decade, knowledge about this modification has exploded, with targets rapidly expanding from histones to transcription factors and other nuclear proteins, and then to the cytoskeleton, metabolic enzymes, and signaling regulators in the cytoplasm.  Thus, protein Lys acetylation has emerged as a major post-translational modification to rival phosphorylation.  Here, various aspects of the enzymes governing Lys acetylation, esp. about their intimate links to cancer are reviewed.  For central themes are highlighted: (1) multisubunit enzymic complexes; (2) non-histone substrates in diverse cellular processes; (3) interplay of Lys acetylation with other regulatory mechanisms, such as noncoding RNA-mediated gene silencing and activation; and (4) novel therapeutic strategies and preventive measures to combat cancer and other human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuGSkc-b3umrVg90H21EOLACvtfcHk0lgVB9hCw0ytow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFekurc%253D&md5=de49d71791356a55d90fd797cbecaf4b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210599%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHATs%2520and%2520HDACs%253A%2520from%2520structure%252C%2520function%2520and%2520regulation%2520to%2520novel%2520strategies%2520for%2520therapy%2520and%2520prevention%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5310%26epage%3D5318%26doi%3D10.1038%2Fsj.onc.1210599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Gryder, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodji, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyelere, A. K.</span><span> </span><span class="NLM_article-title">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span><span class="refDoi"> DOI: 10.4155/fmc.12.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.4155%2Ffmc.12.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=22416777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=505-524&author=B.+E.+Gryderauthor=Q.+H.+Sodjiauthor=A.+K.+Oyelere&title=Targeted+cancer+therapy%3A+giving+histone+deacetylase+inhibitors+all+they+need+to+succeed&doi=10.4155%2Ffmc.12.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span></div><div class="casAuthors">Gryder, Berkley E.; Sodji, Quaovi H.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-524</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-mol. therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets.  Over 490 clin. trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis-SAHA (vorinostat, Zolinza) and FK228 (romidepsin, Istodax).  However, the current HDACis have serious limitations, including ineffectively low concns. in solid tumors and cardiac toxicity, which is hindering their progress in the clinic.  Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwrW1IVCIULVg90H21EOLACvtfcHk0lgVB9hCw0ytow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D&md5=234080d1b0862680a68062a03afee20c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.3%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DSodji%26aufirst%3DQ.%2BH.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520giving%2520histone%2520deacetylase%2520inhibitors%2520all%2520they%2520need%2520to%2520succeed%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D505%26epage%3D524%26doi%3D10.4155%2Ffmc.12.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiloh, A.</span><span> </span><span class="NLM_article-title">Deacetylation of p53 modulates its effect on cell growth and apoptosis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span><span class="refDoi"> DOI: 10.1038/35042612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2F35042612" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=377-381&author=W.+Guauthor=J.+Luoauthor=F.+Suauthor=D.+Chenauthor=A.+Shiloh&title=Deacetylation+of+p53+modulates+its+effect+on+cell+growth+and+apoptosis&doi=10.1038%2F35042612"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F35042612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35042612%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DShiloh%26aufirst%3DA.%26atitle%3DDeacetylation%2520of%2520p53%2520modulates%2520its%2520effect%2520on%2520cell%2520growth%2520and%2520apoptosis%26jtitle%3DNature%26date%3D2000%26volume%3D408%26spage%3D377%26epage%3D381%26doi%3D10.1038%2F35042612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Grant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Vorinostat</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1038/nrd2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2Fnrd2227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=17269160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=21-22&author=S.+Grantauthor=C.+Easleyauthor=P.+Kirkpatrick&title=Vorinostat&doi=10.1038%2Fnrd2227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat</span></div><div class="casAuthors">Grant, Steven; Easley, Chris; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-22</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtFgooxRrcbVg90H21EOLACvtfcHk0ljYFXu1usUkZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK&md5=4017dcf775971088e24fca37e8a369af</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2227%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DEasley%26aufirst%3DC.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVorinostat%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D21%26epage%3D22%26doi%3D10.1038%2Fnrd2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Grant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piekarz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robey, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1008</span><span class="refDoi"> DOI: 10.1586/era.10.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1586%2Fera.10.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20645688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=997-1008&author=C.+Grantauthor=F.+Rahmanauthor=R.+Piekarzauthor=C.+Peerauthor=R.+Fryeauthor=R.+W.+Robeyauthor=E.+R.+Gardnerauthor=W.+D.+Figgauthor=S.+E.+Bates&title=Romidepsin%3A+a+new+therapy+for+cutaneous+T-cell+lymphoma+and+a+potential+therapy+for+solid+tumors&doi=10.1586%2Fera.10.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span></div><div class="casAuthors">Grant, Cliona; Rahman, Fahd; Piekarz, Richard; Peer, Cody; Frye, Robin; Robey, Robert W.; Gardner, Erin R.; Figg, William D.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1008</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL).  Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known.  Romidepsin induces long-lasting responses.  The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia.  Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients.  Electrocardiog. (ECG) changes are common but are not assocd. with myocardial damage.  When mol. end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was assocd. with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin.  Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGXcIbdqpk7Vg90H21EOLACvtfcHk0ljYFXu1usUkZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D&md5=b28fd17c77991e4662f7c0e08d6d7297</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1586%2Fera.10.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.88%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DC.%26aulast%3DRahman%26aufirst%3DF.%26aulast%3DPiekarz%26aufirst%3DR.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DRomidepsin%253A%2520a%2520new%2520therapy%2520for%2520cutaneous%2520T-cell%2520lymphoma%2520and%2520a%2520potential%2520therapy%2520for%2520solid%2520tumors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D997%26epage%3D1008%26doi%3D10.1586%2Fera.10.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Rasheed, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prince, H. M.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors in cancer therapy</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">678</span><span class="refDoi"> DOI: 10.1517/13543784.16.5.659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1517%2F13543784.16.5.659" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=659-678&author=W.+K.+Rasheedauthor=R.+W.+Johnstoneauthor=H.+M.+Prince&title=Histone+deacetylase+inhibitors+in+cancer+therapy&doi=10.1517%2F13543784.16.5.659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.5.659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.5.659%26sid%3Dliteratum%253Aachs%26aulast%3DRasheed%26aufirst%3DW.%2BK.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DPrince%26aufirst%3DH.%2BM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D659%26epage%3D678%26doi%3D10.1517%2F13543784.16.5.659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Federico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagella, L.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors</span> <span class="citation_source-journal">J. Biomed. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">475641</span><span class="refDoi"> DOI: 10.1155/2011/475641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1155%2F2011%2F475641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21188171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FntFOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=475641&author=M.+Federicoauthor=L.+Bagella&title=Histone+deacetylase+inhibitors+in+the+treatment+of+hematological+malignancies+and+solid+tumors&doi=10.1155%2F2011%2F475641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors</span></div><div class="casAuthors">Federico Mario; Bagella Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">475641</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA.  In cancer, many of the proteins that regulate these modifications can be altered in both function and expression.  One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure.  HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators.  Given this, small molecule histone deacetylases inhibitors have been identified and developed, which not only inhibit HDACs, but can also lead to growth arrest, differentiation, and/or apoptosis in tumors both in vitro and in vivo.  Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrrh0JvwMO6N0Q2ypr7jHkfW6udTcc2ea5LO0yP-Ugrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FntFOmsA%253D%253D&md5=7e5af080ec475c293041fec4ecea6721</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1155%2F2011%2F475641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F475641%26sid%3Dliteratum%253Aachs%26aulast%3DFederico%26aufirst%3DM.%26aulast%3DBagella%26aufirst%3DL.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520hematological%2520malignancies%2520and%2520solid%2520tumors%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D475641%26doi%3D10.1155%2F2011%2F475641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="refDoi"> DOI: 10.1186/1756-8722-3-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1186%2F1756-8722-3-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20132536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=5&author=J.+Tanauthor=S.+Cangauthor=Y.+Maauthor=R.+L.+Petrilloauthor=D.+Liu&title=Novel+histone+deacetylase+inhibitors+in+clinical+trials+as+anti-cancer+agents&doi=10.1186%2F1756-8722-3-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span></div><div class="casAuthors">Tan Jiahuai; Cang Shundong; Ma Yuehua; Petrillo Richard L; Liu Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin.  Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs.  One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies.  At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies.  This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnASThrmiLG50d-O_J5C0AfW6udTcc2ebAJ-nbEG1eW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D&md5=399a6c058fd597450221aff2648d8c0f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-3-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-3-5%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DPetrillo%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DNovel%2520histone%2520deacetylase%2520inhibitors%2520in%2520clinical%2520trials%2520as%2520anti-cancer%2520agents%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D5%26doi%3D10.1186%2F1756-8722-3-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Thompson, C. A.</span><span> </span><span class="NLM_article-title">Belinostat approved for use in treating rare lymphoma</span> <span class="citation_source-journal">Am. J. Health-Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1328</span><span class="refDoi"> DOI: 10.2146/news140056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.2146%2Fnews140056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=25074945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BC2cbntlSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=1328&author=C.+A.+Thompson&title=Belinostat+approved+for+use+in+treating+rare+lymphoma&doi=10.2146%2Fnews140056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Belinostat approved for use in treating rare lymphoma</span></div><div class="casAuthors">Thompson Cheryl A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_oWMFZOhhR4USrryheKE6fW6udTcc2ebAJ-nbEG1eW7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbntlSqtg%253D%253D&md5=1a2a66024cd82c736bfbb1d284447ac6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2146%2Fnews140056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews140056%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DC.%2BA.%26atitle%3DBelinostat%2520approved%2520for%2520use%2520in%2520treating%2520rare%2520lymphoma%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2014%26volume%3D71%26spage%3D1328%26doi%3D10.2146%2Fnews140056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Panobinostat: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span><span class="refDoi"> DOI: 10.1007/s40265-015-0388-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs40265-015-0388-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=695-704&author=K.+P.+Garnock-Jones&title=Panobinostat%3A+first+global+approval&doi=10.1007%2Fs40265-015-0388-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0388-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0388-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DPanobinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D695%26epage%3D704%26doi%3D10.1007%2Fs40265-015-0388-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Gu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span> </span><span class="NLM_article-title">Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application</span> <span class="citation_source-journal">J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1000</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1016/j.jchromb.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.jchromb.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=26245362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OqurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1000&publication_year=2015&pages=181-186&author=R.+Guauthor=T.+Liuauthor=X.+Zhuauthor=H.+Ganauthor=Z.+Wuauthor=J.+Liauthor=Y.+Zhengauthor=G.+Douauthor=Z.+Meng&title=Development+and+validation+of+a+sensitive+HPLC-MS%2FMS+method+for+determination+of+chidamide+%28epidaza%29%2C+a+new+benzamide+class+of+selective+histone+deacetylase+inhibitor%2C+in+human+plasma+and+its+clinical+application&doi=10.1016%2Fj.jchromb.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application</span></div><div class="casAuthors">Gu, Ruolan; Liu, Taoyun; Zhu, Xiaoxia; Gan, Hui; Wu, Zhuona; Li, Jian; Zheng, Ying; Dou, Guifang; Meng, Zhiyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1000</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chidamide (epidaza), a new oral isotype-selective histone deacetylase inhibitor (HDACi), which is just approved in China for the treatment of recurrent or refractory peripheral T-cell lymphoma (PTCL) in Dec. 2014, is the first listed benzamide class of HDACi in the world, and is currently undergoing global clin. trials for solid tumor treatments.  Here, we report a sensitive, rapid and robust HPLC-MS/MS method for detn. of chidamide in human plasma.  Plasma sample was subjected to a simple acetonitrile protein pptn. contg. MS-275 used as an internal std. (IS).  Chromatog. was performed on a Hypersil GOLD C18 anal. column, using a gradient methanol/water mobile phase contg. 0.1% formic acid.  A tandem mass spectrometer equipped with electrospray ionization source was used as detector and operated in the pos.-ion mode.  Selected reaction monitoring (SRM) using the precursor/ product transitions (m/z) of 391.1/265.1 for chidamide and 377.1/359.2 for IS were used for quantification, resp.  Good linearity was obtained in the range of 1-1000 ng/mL.  The method gave R.  S. D.% values for precision always lower than 13.8% and R.  E.% values for accuracy between -3.7 and 9.1%.  In addn., the specificity, recovery, stability and matrix effect were satisfactory too.  The method is now being successfully applied to plasma samples as part of an ongoing chidamide phase Ib clin. trial in patients with solid tumors, and had demonstrated consistent AUClast and t1/2 results with the published phase I pharmacokinetic data, which was also analyzed by this method, thus further confirming the reproducibility and accuracy during its clin. application.  Considering the excellent performance of this method, it will continue being utilized for future clin. developments of chidamide and for routine monitoring of plasma exposure of chidamide during its clin. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriZ_cSIXuX6rVg90H21EOLACvtfcHk0lgkNbvpilBUdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OqurbN&md5=bbb4b8ad71146c3909db9f30be705645</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DGan%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDou%26aufirst%3DG.%26aulast%3DMeng%26aufirst%3DZ.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520sensitive%2520HPLC-MS%252FMS%2520method%2520for%2520determination%2520of%2520chidamide%2520%2528epidaza%2529%252C%2520a%2520new%2520benzamide%2520class%2520of%2520selective%2520histone%2520deacetylase%2520inhibitor%252C%2520in%2520human%2520plasma%2520and%2520its%2520clinical%2520application%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2015%26volume%3D1000%26spage%3D181%26epage%3D186%26doi%3D10.1016%2Fj.jchromb.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Thurn, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munster, P. N.</span><span> </span><span class="NLM_article-title">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span><span class="refDoi"> DOI: 10.2217/fon.11.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.2217%2Ffon.11.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21345145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=263-283&author=K.+T.+Thurnauthor=S.+Thomasauthor=A.+Mooreauthor=P.+N.+Munster&title=Rational+therapeutic+combinations+with+histone+deacetylase+inhibitors+for+the+treatment+of+cancer&doi=10.2217%2Ffon.11.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span></div><div class="casAuthors">Thurn, K. Ted; Thomas, Scott; Moore, Amy; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-283</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and nonhistone proteins, controlling the transcription and regulation of genes involved in cell cycle control, proliferation, survival, DNA repair and differentiation.  Unsurprisingly, HDAC expression is frequently altered in hematol. and solid tumor malignancies.  Two HDAC inhibitors (vorinostat and romidepsin) have been approved by the US FDA for the treatment of cutaneous T-cell lymphoma.  As single agents, treatment with HDAC inhibitors has demonstrated limited clin. benefit for patients with solid tumors, prompting the investigation of novel treatment combinations with other cancer therapeutics.  In this article, the rationales and clin. progress of several combinations with HDAC inhibitors are presented, including DNA-damaging chemotherapeutic agents, radiotherapy, hormonal therapies, DNA methyltransferase inhibitors and various small-mol. inhibitors.  The future application of HDAC inhibitors as a treatment for cancer is discussed, examg. current hurdles to overcome before realizing the potential of this new approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn7EKQGlvu_LVg90H21EOLACvtfcHk0lieRxUcGFgGbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D&md5=193fc07f4e19bf16fcd7ee202057ef7c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.2%26sid%3Dliteratum%253Aachs%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DRational%2520therapeutic%2520combinations%2520with%2520histone%2520deacetylase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D263%26epage%3D283%26doi%3D10.2217%2Ffon.11.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Munster, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurn, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raha, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melisko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail-Khan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minton, S. E.</span><span> </span><span class="NLM_article-title">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1828</span><span class="NLM_x">–</span> <span class="NLM_lpage">1835</span><span class="refDoi"> DOI: 10.1038/bjc.2011.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2Fbjc.2011.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21559012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1828-1835&author=P.+N.+Munsterauthor=K.+T.+Thurnauthor=S.+Thomasauthor=P.+Rahaauthor=M.+Lacevicauthor=A.+Millerauthor=M.+Meliskoauthor=R.+Ismail-Khanauthor=H.+Rugoauthor=M.+Moasserauthor=S.+E.+Minton&title=A+phase+II+study+of+the+histone+deacetylase+inhibitor+vorinostat+combined+with+tamoxifen+for+the+treatment+of+patients+with+hormone+therapy-resistant+breast+cancer&doi=10.1038%2Fbjc.2011.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span></div><div class="casAuthors">Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1828-1835</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crucial components of the estrogen receptor (ER) transcriptional complex.  Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-pos. breast cancer.  This concept was examd. in a phase II combination trial with correlative end points.  Patients with ER-pos. metastatic breast cancer progressing on endocrine therapy were treated with 400 mg of vorinostat daily for 3 of 4 wk and 20 mg tamoxifen daily, continuously.  Histone acetylation and HDAC2 expression in peripheral blood mononuclear cells were also evaluated.  In all, 43 patients (median age 56 years (31-71)) were treated, 25 (58%) received prior adjuvant tamoxifen, 29 (67%) failed one prior chemotherapy regimen, 42 (98%) progressed after one, and 23 (54%) after two aromatase inhibitors.  The objective response rate by Response Evaluation Criteria in Solid Tumors criteria was 19% and the clin. benefit rate (response or stable disease >24 wk) was 40%.  The median response duration was 10.3 mo (confidence interval: 8.1-12.4).  Histone hyperacetylation and higher baseline HDAC2 levels correlated with response.  The combination of vorinostat and tamoxifen is well tolerated and exhibits encouraging activity in reversing hormone resistance.  Correlative studies suggest that HDAC2 expression is a predictive marker and histone hyperacetylation is a useful pharmacodynamic marker for the efficacy of this combination.  British Journal of Cancer (2011) 104, 1828-1835; doi:10.1038/bjc.2011.156 www.bjcancer.com Published online 10 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDPB1YAqSmBLVg90H21EOLACvtfcHk0lgbQmV5g35sEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D&md5=15e2afd6a1b658f378e4f41ed2b15ef9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.156%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DRaha%26aufirst%3DP.%26aulast%3DLacevic%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMelisko%26aufirst%3DM.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DMoasser%26aufirst%3DM.%26aulast%3DMinton%26aufirst%3DS.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520vorinostat%2520combined%2520with%2520tamoxifen%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520hormone%2520therapy-resistant%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1828%26epage%3D1835%26doi%3D10.1038%2Fbjc.2011.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurn, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicaku, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchion, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munster, P. N.</span><span> </span><span class="NLM_article-title">Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1007/s10549-011-1364-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs10549-011-1364-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21298336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yktL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=437-447&author=S.+Thomasauthor=K.+T.+Thurnauthor=E.+Bicakuauthor=D.+C.+Marchionauthor=P.+N.+Munster&title=Addition+of+a+histone+deacetylase+inhibitor+redirects+tamoxifen-treated+breast+cancer+cells+into+apoptosis%2C+which+is+opposed+by+the+induction+of+autophagy&doi=10.1007%2Fs10549-011-1364-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy</span></div><div class="casAuthors">Thomas, Scott; Thurn, Kenneth T.; Bicaku, Elona; Marchion, Douglas C.; Muenster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">437-447</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Modulation of estrogen signaling is one of the most successful modalities for the treatment of estrogen receptor (ER)-pos. breast cancer, yet de novo and acquired resistance are frequent.  Recent data suggests that the induction of autophagy may play a considerable role in promoting tumor cell survival and resistance to anti-estrogen therapy.  Hence, bypassing autophagy may offer a novel strategy to enhance the anti-tumor efficacy of anti-estrogens.  Histone deacetylases (HDAC) are involved in the regulation of steroid hormone receptor mediated cell signaling and their inhibition potentiates the anti-tumor effects of anti-estrogens.  However, the mechanism underlying this anti-tumor activity is poorly understood.  In this report, we show that the addn. of an HDAC inhibitor redirects the response of ER-pos. breast cancer cells when treated with tamoxifen from growth arrest to apoptotic cell death.  This redirection requires functional ER signaling and is mediated by a depletion of Bcl-2 and an induction of Bax and Bak, manifesting in cytochrome C release and PARP cleavage.  With combined treatment, a subpopulation of cells is refractory to apoptosis and exhibit a strong induction of autophagy.  Inhibition of autophagy in these cells, using siRNA directed against Beclin-1 or treatment with chloroquine, further promotes the induction of apoptosis.  Thus, supporting prior reports that autophagy acts as a survival mechanism, our findings demonstrate that HDAC and autophagy inhibition directs autophagy-protected cells into apoptotic cell death, which may impair development of tamoxifen resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3q7R9fI2f2rVg90H21EOLACvtfcHk0lgbQmV5g35sEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yktL%252FN&md5=7d959ad3e2773999385c2423e44d84f4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1364-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1364-y%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DAddition%2520of%2520a%2520histone%2520deacetylase%2520inhibitor%2520redirects%2520tamoxifen-treated%2520breast%2520cancer%2520cells%2520into%2520apoptosis%252C%2520which%2520is%2520opposed%2520by%2520the%2520induction%2520of%2520autophagy%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D130%26spage%3D437%26epage%3D447%26doi%3D10.1007%2Fs10549-011-1364-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echigo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rikiishi, H.</span><span> </span><span class="NLM_article-title">Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.3892/ijo.28.5.1233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.3892%2Fijo.28.5.1233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=16596240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Cis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=1233-1241&author=T.+Satoauthor=M.+Suzukiauthor=Y.+Satoauthor=S.+Echigoauthor=H.+Rikiishi&title=Sequence-dependent+interaction+between+cisplatin+and+histone+deacetylase+inhibitors+in+human+oral+squamous+cell+carcinoma+cells&doi=10.3892%2Fijo.28.5.1233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells</span></div><div class="casAuthors">Sato, Tomonori; Suzuki, Maiko; Sato, Yoshitaro; Echigo, Seishi; Rikiishi, Hidemi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1233-1241</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Chemotherapeutic treatment with combinations of drugs is front-line therapy for many types of cancer.  Combining drugs that target different signaling pathways often lessens adverse side-effects while increasing the efficacy of treatment and reducing patient morbidity.  Histone deacetylase (HDAC) inhibitors represent a novel class of anti-neoplastic agents that act by promoting acetylation of core histones, leading in turn to the uncoiling of chromatin and activation of a variety of genes implicated in the regulation of cell survival, proliferation, differentiation, and apoptosis.  A defined scheduling protocol is described by which HDAC inhibitors facilitate the cytotoxic effectiveness of cisplatin (CDDP) in the killing of carcinoma cells.  An oral squamous cell carcinoma cell line (HSC-3) was treated with sodium butyrate (NaB), suberoylanilide hydroxamic acid (SAHA) or MS-275 on the day of, the day before, or the day after addn. of CDDP.  The IC50 (48-h assay) value of 3.48 μg/mL CDDP could be lowered to 0.41 μg/mL CDDP when concurrently combined with an HDAC inhibitor (MS-275).  The percentage of apoptosis by treatment with CDDP for 24 h, followed by NaB for an addnl. 24 h without washing was significantly greater than that obsd. in the reverse order.  Depending on the time of addn. of HDAC inhibitors, CDDP-treated cells displayed varying degrees of apoptotic responses, indicating the crit. nature of timing in the use of HDAC inhibitors.  Interestingly, expts. suggested that cells arrested at the G1/S checkpoint by CDDP were more sensitive to subsequent treatment with an HDAC inhibitor.  Moreover, these events were assocd. with an enhancement of reactive oxygen species (ROS) generation and caspase-3 activation by HDAC inhibitors.  They raise the possibility that combining these agents may represent a novel anti-neoplastic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4_pciLxCQLVg90H21EOLACvtfcHk0lgbQmV5g35sEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Cis7k%253D&md5=2b1ad821109ac4f6e98044e8eb4d1838</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3892%2Fijo.28.5.1233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.28.5.1233%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DEchigo%26aufirst%3DS.%26aulast%3DRikiishi%26aufirst%3DH.%26atitle%3DSequence-dependent%2520interaction%2520between%2520cisplatin%2520and%2520histone%2520deacetylase%2520inhibitors%2520in%2520human%2520oral%2520squamous%2520cell%2520carcinoma%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2006%26volume%3D28%26spage%3D1233%26epage%3D1241%26doi%3D10.3892%2Fijo.28.5.1233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Budman, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, V.</span><span> </span><span class="NLM_article-title">The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1224</span><span class="NLM_x">–</span> <span class="NLM_lpage">1229</span><span class="refDoi"> DOI: 10.1007/s10637-010-9467-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs10637-010-9467-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1224-1229&author=D.+R.+Budmanauthor=J.+Taiauthor=A.+Calabroauthor=V.+John&title=The+histone+deacetylase+inhibitor+panobinostat+demonstrates+marked+synergy+with+conventional+chemotherapeutic+agents+in+human+ovarian+cancer+cell+lines&doi=10.1007%2Fs10637-010-9467-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9467-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9467-6%26sid%3Dliteratum%253Aachs%26aulast%3DBudman%26aufirst%3DD.%2BR.%26aulast%3DTai%26aufirst%3DJ.%26aulast%3DCalabro%26aufirst%3DA.%26aulast%3DJohn%26aufirst%3DV.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520panobinostat%2520demonstrates%2520marked%2520synergy%2520with%2520conventional%2520chemotherapeutic%2520agents%2520in%2520human%2520ovarian%2520cancer%2520cell%2520lines%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2011%26volume%3D29%26spage%3D1224%26epage%3D1229%26doi%3D10.1007%2Fs10637-010-9467-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Sarcar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, P.</span><span> </span><span class="NLM_article-title">Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1007/s11060-010-0127-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs11060-010-0127-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20135194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGmtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=201-207&author=B.+Sarcarauthor=S.+Kahaliauthor=P.+Chinnaiyan&title=Vorinostat+enhances+the+cytotoxic+effects+of+the+topoisomerase+I+inhibitor+SN38+in+glioblastoma+cell+lines&doi=10.1007%2Fs11060-010-0127-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines</span></div><div class="casAuthors">Sarcar, Bhaswati; Kahali, Soumen; Chinnaiyan, Prakash</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-207</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clin. trials in solid tumors, including glioblastoma.  What makes these agents particularly attractive is their capacity to enhance the activity of commonly used cytotoxics in cancer therapy, including both chemotherapy and ionizing radiation.  As recent investigations suggest HDAC inhibitors may potentiate the cytotoxicity of topoisomerase inhibitors, which continue to be a commonly used class of agents in the treatment of glioblastoma, we performed preclin. studies to det. if this combination may be a promising strategy in glioblastoma.  The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.  Various treatment schedules were tested to det. optimum drug sequencing.  Induction of DNA double strand breaks (DSBs) with the combination of vorinostat and SN38 was evaluated using the neutral comet assay, and their subsequent repair was evaluated by γH2AX foci kinetics using immunofluorescent cytochem.  Vorinostat enhanced the cytotoxicity of SN38 in glioblastoma cell lines.  Optimal treatment schedules involved maximal concurrent administration of agents.  Pretreatment with either agent did not enhance cytotoxicity.  Vorinostat potentiated SN38-induced DNA DSBs and attenuated their subsequent repair.  These results indicate vorinostat enhances the cytotoxicity of SN38 in glioblastoma cell lines, suggesting this combination may be a worthwhile strategy to test in the context of a clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodef1O5fCkdbVg90H21EOLACvtfcHk0lh7peooVn8uOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGmtLbF&md5=f651fd43350809ef34a97b10ce43907b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs11060-010-0127-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-010-0127-7%26sid%3Dliteratum%253Aachs%26aulast%3DSarcar%26aufirst%3DB.%26aulast%3DKahali%26aufirst%3DS.%26aulast%3DChinnaiyan%26aufirst%3DP.%26atitle%3DVorinostat%2520enhances%2520the%2520cytotoxic%2520effects%2520of%2520the%2520topoisomerase%2520I%2520inhibitor%2520SN38%2520in%2520glioblastoma%2520cell%2520lines%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2010%26volume%3D99%26spage%3D201%26epage%3D207%26doi%3D10.1007%2Fs11060-010-0127-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Mwakwari, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrant, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyelere, A. K.</span><span> </span><span class="NLM_article-title">Macrocyclic histone deacetylase inhibitors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1440</span><span class="refDoi"> DOI: 10.2174/156802610792232079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.2174%2F156802610792232079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20536416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFajurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=1423-1440&author=S.+C.+Mwakwariauthor=V.+Patilauthor=W.+Guerrantauthor=A.+K.+Oyelere&title=Macrocyclic+histone+deacetylase+inhibitors&doi=10.2174%2F156802610792232079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic histone deacetylase inhibitors</span></div><div class="casAuthors">Mwakwari, Sandra C.; Patil, Vishal; Guerrant, William; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1423-1440</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells.  In addn., they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatol. and immunosuppressant agents.  To date, several structurally distinct small mol. HDACi have been reported including aryl hydroxamates, benzamides, short-chain fatty acids, electrophilic ketones, and macrocyclic peptides.  Macrocyclic HDACi possess the most complex cap-groups which interact with HDAC enzyme's outer rim and have demonstrated excellent HDAC inhibition potency and isoform selectivity.  This review focuses on the recent progress and current state of macrocyclic HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXzgRmfQBx27Vg90H21EOLACvtfcHk0lh7peooVn8uOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFajurrF&md5=d027b0380e04f364fb0985a350e99c60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F156802610792232079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610792232079%26sid%3Dliteratum%253Aachs%26aulast%3DMwakwari%26aufirst%3DS.%2BC.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DMacrocyclic%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D1423%26epage%3D1440%26doi%3D10.2174%2F156802610792232079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0lh7peooVn8uOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1002/med.21320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1002%2Fmed.21320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=24782318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=63-84&author=L.+Zhangauthor=Y.+Hanauthor=Q.+Jiangauthor=C.+Wangauthor=X.+Chenauthor=X.+Liauthor=F.+Xuauthor=Y.+Jiangauthor=Q.+Wangauthor=W.+Xu&title=Trend+of+histone+deacetylase+inhibitors+in+cancer+therapy%3A+isoform+selectivity+or+multitargeted+strategy&doi=10.1002%2Fmed.21320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy</span></div><div class="casAuthors">Zhang, Lei; Han, Yantao; Jiang, Qixiao; Wang, Chunbo; Chen, Xuehong; Li, Xiaoguang; Xu, Fuming; Jiang, Yuqi; Wang, Qiang; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-84</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Pharmacol. inhibition of histone deacetylases (HDACs) has been successfully applied in the treatment of a wide range of disorders, including Parkinson's disease, infection, cardiac diseases, inflammation, and esp. cancer.  HDAC inhibitors (HDACIs) have been proved to be effective antitumor agents by various stages of investigation.  At present, there are two opposite focuses of HDACI design in the cancer therapy, highly selective inhibitor strategy and dual- or multitargeted inhibitors.  The former method, which is supposed to elucidate the function of individual HDAC and provide candidate inhibitors with fewer side effects, has been widely accepted by the inhibitor developer.  The latter approach, though less practiced, has promising potential for the antitumor therapy based on HDACIs.  Effective HDACIs, some of which are in clinic anticancer research, have been developed by both methods.  In order to gain insight into HDACI design, the strategies and achievements of the two diverse methods are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm6HJUNw_9dLVg90H21EOLACvtfcHk0lg_XEhkJtcGog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M&md5=791e7d6b057c92f206c8d0d75099e021</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fmed.21320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21320%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DTrend%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520isoform%2520selectivity%2520or%2520multitargeted%2520strategy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D63%26epage%3D84%26doi%3D10.1002%2Fmed.21320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Kalin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1021/jm200773h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200773h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SrtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=639-651&author=J.+H.+Kalinauthor=K.+V.+Butlerauthor=T.+Akimovaauthor=W.+W.+Hancockauthor=A.+P.+Kozikowski&title=Second-generation+histone+deacetylase+6+inhibitors+enhance+the+immunosuppressive+effects+of+Foxp3%2B+T-regulatory+cells&doi=10.1021%2Fjm200773h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Second-Generation Histone Deacetylase 6 Inhibitors Enhance the Immunosuppressive Effects of Foxp3+ T-Regulatory Cells</span></div><div class="casAuthors">Kalin, Jay H.; Butler, Kyle V.; Akimova, Tatiana; Hancock, Wayne W.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">639-651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Second-generation Tubastatin A analogs were synthesized and evaluated for their ability to inhibit selectively histone deacetylase 6 (HDAC6).  Substitutions to the carboline cap group were well-tolerated with substitution at the 2-position of both β- and γ-carbolines being optimal for HDAC6 activity and selectivity.  Some compds. in this series were detd. to have subnanomolar activity at HDAC6 with more than 7000 fold selectivity for HDAC6 vs. HDAC1.  Selected compds. were then evaluated for their ability to augment the immunosuppressive effect of Foxp3+ regulatory T cells.  All compds. tested were found to enhance the ability of regulatory T cells to inhibit the mitotic division of effector T cells both in vitro and in vivo, suggesting that further investigation into the use of these compds. for the treatment of autoimmune disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzt2Rz2tD6ibVg90H21EOLACvtfcHk0lg_XEhkJtcGog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SrtbzM&md5=88a4f02045fdc5387970abe53ec00c7a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm200773h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200773h%26sid%3Dliteratum%253Aachs%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSecond-generation%2520histone%2520deacetylase%25206%2520inhibitors%2520enhance%2520the%2520immunosuppressive%2520effects%2520of%2520Foxp3%252B%2520T-regulatory%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D639%26epage%3D651%26doi%3D10.1021%2Fjm200773h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Mwakwari, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrant, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tekwani, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurard-Levin, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrksich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyelere, A. K.</span><span> </span><span class="NLM_article-title">Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6100</span><span class="NLM_x">–</span> <span class="NLM_lpage">6111</span><span class="refDoi"> DOI: 10.1021/jm100507q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100507q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6100-6111&author=S.+C.+Mwakwariauthor=W.+Guerrantauthor=V.+Patilauthor=S.+I.+Khanauthor=B.+L.+Tekwaniauthor=Z.+A.+Gurard-Levinauthor=M.+Mrksichauthor=A.+K.+Oyelere&title=Non-peptide+macrocyclic+histone+deacetylase+inhibitors+derived+from+tricyclic+ketolide+skeleton&doi=10.1021%2Fjm100507q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton</span></div><div class="casAuthors">Mwakwari, Sandra C.; Guerrant, William; Patil, Vishal; Khan, Shabana I.; Tekwani, Babu L.; Gurard-Levin, Zachary A.; Mrksich, Milan; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6100-6111</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase (HDAC) function is a validated therapeutic strategy for cancer treatment.  Of the several structurally distinct small mol. histone deacetylase inhibitors (HDACi) reported, macrocyclic depsipeptides possess the most complex cap groups and have demonstrated excellent HDAC inhibition potency and isoform selectivity.  Unfortunately, the development of macrocyclic depsipeptides has been hampered in part because of development problems characteristic of large peptides and the complex reaction schemes required for their synthesis.  Herein we report that tricyclic ketolide TE-802 is an excellent mimetic for the peptide backbone of macrocyclic HDACi.  Compds. derived from this template are particularly selective against HDACs 1 and 2 with nanomolar inhibitory activity.  Interrogation of the assocn. between a subset of these compds. and key HDAC isoforms, using AutoDock, enables a mol. description of the interaction between the HDAC enzyme's outer rim and the inhibitors' macrocyclic cap group that are responsible for compd. affinity and presumably isoform selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt9QPKI33jvbVg90H21EOLACvtfcHk0lg5bsxL7WZmEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D&md5=6407dc82e9fb2dab6313d32956600659</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm100507q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100507q%26sid%3Dliteratum%253Aachs%26aulast%3DMwakwari%26aufirst%3DS.%2BC.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DS.%2BI.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26aulast%3DGurard-Levin%26aufirst%3DZ.%2BA.%26aulast%3DMrksich%26aufirst%3DM.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DNon-peptide%2520macrocyclic%2520histone%2520deacetylase%2520inhibitors%2520derived%2520from%2520tricyclic%2520ketolide%2520skeleton%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6100%26epage%3D6111%26doi%3D10.1021%2Fjm100507q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W. G.</span><span> </span><span class="NLM_article-title">The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1016/j.dnarep.2011.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.dnarep.2011.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=22112863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=146-156&author=H.+Wangauthor=W.+Zhouauthor=Z.+Zhengauthor=P.+Zhangauthor=B.+Tuauthor=Q.+Heauthor=W.+G.+Zhu&title=The+HDAC+inhibitor+depsipeptide+transactivates+the+p53%2Fp21+pathway+by+inducing+DNA+damage&doi=10.1016%2Fj.dnarep.2011.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage</span></div><div class="casAuthors">Wang, Haiying; Zhou, Wen; Zheng, Zhixing; Zhang, Ping; Tu, Bo; He, Qihua; Zhu, Wei-Guo</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-156</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have been proven to be effective therapeutic agents to kill cancer cells through inhibiting HDAC activity or altering the structure of chromatin.  As a potent HDAC inhibitor, depsipeptide not only modulates histone deacetylation but also activates non-histone protein p53 to inhibit cancer cell growth.  However, the mechanism of depsipeptide-induced p53 transactivity remains unknown.  Here, we show that depsipeptide causes DNA damage through induction of reactive oxygen species (ROS) generation, as demonstrated by a comet assay and by detection of the phosphorylation of H2AX.  Depsipeptide induced oxidative stress was confirmed to relate to a disturbance in redn.-oxidn. (redox) reactions through inhibition of the transactivation of thioredoxin reductase (TrxR) in human cancer cells.  Upon treatment with depsipeptide, p53 phosphorylation at threonine 18 (Thr18) was specifically induced.  Furthermore, we also demonstrated that phosphorylation of p53 at Thr18 is required for p53 acetylation at lysine 373/382 and for p21 expression in response to depsipeptide treatment.  Our results demonstrate that depsipeptide plays an anti-neoplastic role by generating ROS to elicit p53/p21 pathway activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb4o9Q8pCXQbVg90H21EOLACvtfcHk0lg5bsxL7WZmEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVCksw%253D%253D&md5=eefbeedd5c1475560e83c20359b45cc9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2011.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2011.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DW.%2BG.%26atitle%3DThe%2520HDAC%2520inhibitor%2520depsipeptide%2520transactivates%2520the%2520p53%252Fp21%2520pathway%2520by%2520inducing%2520DNA%2520damage%26jtitle%3DDNA%2520Repair%26date%3D2012%26volume%3D11%26spage%3D146%26epage%3D156%26doi%3D10.1016%2Fj.dnarep.2011.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Development of tetrahydroisoquinoline-based hydroxamic acid serivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2823</span><span class="NLM_x">–</span> <span class="NLM_lpage">2838</span><span class="refDoi"> DOI: 10.1021/jm101605z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101605z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2823-2838&author=Y.+Zhangauthor=J.+Fengauthor=Y.+Jiaauthor=X.+Wangauthor=L.+Zhangauthor=C.+Liuauthor=H.+Fangauthor=W.+Xu&title=Development+of+tetrahydroisoquinoline-based+hydroxamic+acid+serivatives%3A+potent+histone+deacetylase+inhibitors+with+marked+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Fjm101605z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm101605z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101605z%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520tetrahydroisoquinoline-based%2520hydroxamic%2520acid%2520serivatives%253A%2520potent%2520histone%2520deacetylase%2520inhibitors%2520with%2520marked%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2823%26epage%3D2838%26doi%3D10.1021%2Fjm101605z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 45 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Kalpana Tilekar, Jessica D. Hess, Neha Upadhyay, Alessandra Lo Bianco, Markus Schweipert, Antonio Laghezza, Fulvio Loiodice, Franz-Josef Meyer-Almes, Renato J. Aguilera, Antonio Lavecchia, <span class="NLM_string-name hlFld-ContribAuthor">Ramaa C S</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolidinedione “Magic Bullets” Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (10)
                                     , 6949-6971. <a href="https://doi.org/10.1021/acs.jmedchem.1c00491" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00491</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00491%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThiazolidinedione%252B%2525E2%252580%25259CMagic%252BBullets%2525E2%252580%25259D%252BSimultaneously%252BTargeting%252BPPAR%2525CE%2525B3%252Band%252BHDACs%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BInvestigations%252Bof%252Btheir%252BIn%252BVitro%252Band%252BIn%252BVivo%252BAntitumor%252BEffects%26aulast%3DTilekar%26aufirst%3DKalpana%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D18032021%26date%3D18052021%26volume%3D64%26issue%3D10%26spage%3D6949%26epage%3D6971" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Aurélien Beato, Anthonin Gori, Benjamin Boucherle, Marine Peuchmaur, <span class="NLM_string-name hlFld-ContribAuthor">Romain Haudecoeur</span>. </span><span class="cited-content_cbyCitation_article-title">β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer’s Disease Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (3)
                                     , 1392-1422. <a href="https://doi.org/10.1021/acs.jmedchem.0c01887" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01887</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01887%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Carboline%252Bas%252Ba%252BPrivileged%252BScaffold%252Bfor%252BMultitarget%252BStrategies%252Bin%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BTherapy%26aulast%3DBeato%26aufirst%3DAur%25C3%25A9lien%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31102020%26date%3D02022021%26volume%3D64%26issue%3D3%26spage%3D1392%26epage%3D1422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ji Liu, Xin Liu, Jianqiang Qian, Chi Meng, Peng Zhu, Jiaying Hang, Yaling Wang, Biao Xiong, Xiaodong Qiu, Weizhong Zhu, Yumin Yang, Yanan Zhang, <span class="NLM_string-name hlFld-ContribAuthor">Yong Ling</span>. </span><span class="cited-content_cbyCitation_article-title">Development of pH/Glutathione-Responsive Theranostic Agents Activated by Glutathione S-Transferase π for Human Colon Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9271-9283. <a href="https://doi.org/10.1021/acs.jmedchem.0c00354" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00354</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00354&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00354%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BpH%25252FGlutathione-Responsive%252BTheranostic%252BAgents%252BActivated%252Bby%252BGlutathione%252BS-Transferase%252B%2525CF%252580%252Bfor%252BHuman%252BColon%252BCancer%26aulast%3DLiu%26aufirst%3DJi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10032020%26date%3D20082020%26date%3D05082020%26volume%3D63%26issue%3D17%26spage%3D9271%26epage%3D9283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong Ling, Yangyang Li, Rui Zhu, Jianqiang Qian, Ji Liu, Weijie Gao, Chi Meng, Jiefei Miao, Biao Xiong, Xiaodong Qiu, Changchun Ling, Hong Dai, <span class="NLM_string-name hlFld-ContribAuthor">Yanan Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways. </span><span class="cited-content_cbyCitation_journal-name">Journal of Natural Products</span><span> <strong>2019,</strong> <em>82 </em>
                                    (6)
                                     , 1442-1450. <a href="https://doi.org/10.1021/acs.jnatprod.8b00843" title="DOI URL">https://doi.org/10.1021/acs.jnatprod.8b00843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jnatprod.8b00843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jnatprod.8b00843%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Natural%2520Products%26atitle%3DHydroxamic%252BAcid%252BDerivatives%252Bof%252B%2525CE%2525B2-Carboline%25252FHydroxycinnamic%252BAcid%252BHybrids%252BInducing%252BApoptosis%252Band%252BAutophagy%252Bthrough%252Bthe%252BPI3K%25252FAkt%25252FmTOR%252BPathways%26aulast%3DLing%26aufirst%3DYong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D11102018%26date%3D23052019%26volume%3D82%26issue%3D6%26spage%3D1442%26epage%3D1450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Filipe Penteado, Eric F. Lopes, Diego Alves, Gelson Perin, Raquel G. Jacob, <span class="NLM_string-name hlFld-ContribAuthor">Eder J. Lenardão</span>. </span><span class="cited-content_cbyCitation_article-title">α-Keto Acids: Acylating Agents in Organic Synthesis. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2019,</strong> <em>119 </em>
                                    (12)
                                     , 7113-7278. <a href="https://doi.org/10.1021/acs.chemrev.8b00782" title="DOI URL">https://doi.org/10.1021/acs.chemrev.8b00782</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.8b00782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.8b00782%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3D%2525CE%2525B1-Keto%252BAcids%25253A%252BAcylating%252BAgents%252Bin%252BOrganic%252BSynthesis%26aulast%3DPenteado%26aufirst%3DFilipe%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D20122018%26date%3D16042019%26volume%3D119%26issue%3D12%26spage%3D7113%26epage%3D7278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Jie Zang, Xuewu Liang, Yongxue Huang, Yuping Jia, Xiaoyang Li, Wenfang Xu, C. James Chou, <span class="NLM_string-name hlFld-ContribAuthor">Yingjie Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (12)
                                     , 5304-5322. <a href="https://doi.org/10.1021/acs.jmedchem.8b00384" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00384</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00384%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%252BPazopanib-Based%252BHDAC%252Band%252BVEGFR%252BDual%252BInhibitors%252BTargeting%252BCancer%252BEpigenetics%252Band%252BAngiogenesis%252BSimultaneously%26aulast%3DZang%26aufirst%3DJie%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09032018%26date%3D07062018%26date%3D22052018%26volume%3D61%26issue%3D12%26spage%3D5304%26epage%3D5322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shi  Tang</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Zhuang  Xiong</span>, <span class="hlFld-ContribAuthor ">Zeqiang  Xie</span>, <span class="hlFld-ContribAuthor ">Dengke  Li</span>, <span class="hlFld-ContribAuthor ">Jinbo  Huang</span>, and <span class="hlFld-ContribAuthor ">Qiang  Zhu</span>  . </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Imidoylative Cyclization of Tryptophan-Derived Isocyanides: Access to β-Carbolines. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2017,</strong> <em>19 </em>
                                    (20)
                                     , 5577-5580. <a href="https://doi.org/10.1021/acs.orglett.7b02725" title="DOI URL">https://doi.org/10.1021/acs.orglett.7b02725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.7b02725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.7b02725%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Catalyzed%252BImidoylative%252BCyclization%252Bof%252BTryptophan-Derived%252BIsocyanides%25253A%252BAccess%252Bto%252B%2525CE%2525B2-Carbolines%26aulast%3DTang%26aufirst%3DShi%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D01092017%26date%3D05102017%26date%3D20102017%26volume%3D19%26issue%3D20%26spage%3D5577%26epage%3D5580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Luo</span>, <span class="hlFld-ContribAuthor ">Xinqiang  Song</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive overview of β-carbolines and its derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113688. <a href="https://doi.org/10.1016/j.ejmech.2021.113688" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113688</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113688&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113688%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Boverview%252Bof%252B%2525CE%2525B2-carbolines%252Band%252Bits%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DLuo%26aufirst%3DBo%26date%3D2021%26volume%3D224%26spage%3D113688" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdulrahim A.  Alzain</span>, <span class="hlFld-ContribAuthor ">Lucie  Brisson</span>, <span class="hlFld-ContribAuthor ">Pierre-Olivier  Delaye</span>, <span class="hlFld-ContribAuthor ">Mélanie  Pénichon</span>, <span class="hlFld-ContribAuthor ">Stéphanie  Chadet</span>, <span class="hlFld-ContribAuthor ">Pierre  Besson</span>, <span class="hlFld-ContribAuthor ">Stéphan  Chevalier</span>, <span class="hlFld-ContribAuthor ">Hassan  Allouchi</span>, <span class="hlFld-ContribAuthor ">Magdi A.  Mohamed</span>, <span class="hlFld-ContribAuthor ">Sébastien  Roger</span>, <span class="hlFld-ContribAuthor ">Cécile  Enguehard-Gueiffier</span>. </span><span class="cited-content_cbyCitation_article-title">Bioinspired imidazo[1,2-a:4,5-c’]dipyridines with dual antiproliferative and anti-migrative properties in human cancer cells: The SAR investigation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113258. <a href="https://doi.org/10.1016/j.ejmech.2021.113258" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113258</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113258&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113258%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBioinspired%252Bimidazo%25255B1%25252C2-a%25253A4%25252C5-c%2525E2%252580%252599%25255Ddipyridines%252Bwith%252Bdual%252Bantiproliferative%252Band%252Banti-migrative%252Bproperties%252Bin%252Bhuman%252Bcancer%252Bcells%25253A%252BThe%252BSAR%252Binvestigation%26aulast%3DAlzain%26aufirst%3DAbdulrahim%2BA.%26date%3D2021%26volume%3D218%26spage%3D113258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jay Prakash  Soni</span>, <span class="hlFld-ContribAuthor ">Yogesh  Yeole</span>, <span class="hlFld-ContribAuthor ">Nagula  Shankaraiah</span>. </span><span class="cited-content_cbyCitation_article-title">β-Carboline-based molecular hybrids as anticancer agents: a brief sketch. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (5)
                                     , 730-750. <a href="https://doi.org/10.1039/D0MD00422G" title="DOI URL">https://doi.org/10.1039/D0MD00422G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00422G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00422G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Carboline-based%252Bmolecular%252Bhybrids%252Bas%252Banticancer%252Bagents%25253A%252Ba%252Bbrief%252Bsketch%26aulast%3DSoni%26aufirst%3DJay%2BPrakash%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D5%26spage%3D730%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Hu</span>, <span class="hlFld-ContribAuthor ">Xiang  Gao</span>, <span class="hlFld-ContribAuthor ">Gang  Gao</span>, <span class="hlFld-ContribAuthor ">Yanbing  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Cao</span>, <span class="hlFld-ContribAuthor ">Dahong  Li</span>, <span class="hlFld-ContribAuthor ">Huiming  Hua</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>40 </em>, 127952. <a href="https://doi.org/10.1016/j.bmcl.2021.127952" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127952</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127952&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127952%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252B%2525CE%2525B2-carboline-%252528phenylsulfonyl%252529furoxan%252Bhybrids%252Bas%252Bpotential%252Banti-breast%252Bcancer%252Bagents%26aulast%3DHu%26aufirst%3DXu%26date%3D2021%26volume%3D40%26spage%3D127952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shams  Aaghaz</span>, <span class="hlFld-ContribAuthor ">Komal  Sharma</span>, <span class="hlFld-ContribAuthor ">Rahul  Jain</span>, <span class="hlFld-ContribAuthor ">Ahmed  Kamal</span>. </span><span class="cited-content_cbyCitation_article-title">β-Carbolines as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113321. <a href="https://doi.org/10.1016/j.ejmech.2021.113321" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113321</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113321%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Carbolines%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DAaghaz%26aufirst%3DShams%26date%3D2021%26volume%3D216%26spage%3D113321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiuru  Bi</span>, <span class="hlFld-ContribAuthor ">Luyao  Tao</span>, <span class="hlFld-ContribAuthor ">Nan  Yao</span>, <span class="hlFld-ContribAuthor ">Mingxia  Gou</span>, <span class="hlFld-ContribAuthor ">Gexin  Chen</span>, <span class="hlFld-ContribAuthor ">Xu  Meng</span>, <span class="hlFld-ContribAuthor ">Peiqing  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Selectivity-tunable oxidation of tetrahydro-β-carboline over an OMS-2 composite catalyst: preparation and catalytic performance. </span><span class="cited-content_cbyCitation_journal-name">Dalton Transactions</span><span> <strong>2021,</strong> <em>50 </em>
                                    (10)
                                     , 3682-3692. <a href="https://doi.org/10.1039/D1DT00168J" title="DOI URL">https://doi.org/10.1039/D1DT00168J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1DT00168J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1DT00168J%26sid%3Dliteratum%253Aachs%26jtitle%3DDalton%2520Transactions%26atitle%3DSelectivity-tunable%252Boxidation%252Bof%252Btetrahydro-%2525CE%2525B2-carboline%252Bover%252Ban%252BOMS-2%252Bcomposite%252Bcatalyst%25253A%252Bpreparation%252Band%252Bcatalytic%252Bperformance%26aulast%3DBi%26aufirst%3DXiuru%26date%3D2021%26date%3D2021%26volume%3D50%26issue%3D10%26spage%3D3682%26epage%3D3692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiefei  Miao</span>, <span class="hlFld-ContribAuthor ">Chi  Meng</span>, <span class="hlFld-ContribAuthor ">Hongmei  Wu</span>, <span class="hlFld-ContribAuthor ">Wenpei  Shan</span>, <span class="hlFld-ContribAuthor ">Haoran  Wang</span>, <span class="hlFld-ContribAuthor ">Changchun  Ling</span>, <span class="hlFld-ContribAuthor ">Jinlin  Zhang</span>, <span class="hlFld-ContribAuthor ">Tao  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Hybrid CHC from β-carboline and N-Hydroxyacrylamide Overcomes Drug-Resistant Hepatocellular Carcinoma by Promoting Apoptosis, DNA Damage, and Cell Cycle Arrest. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fphar.2020.626065" title="DOI URL">https://doi.org/10.3389/fphar.2020.626065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2020.626065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2020.626065%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DNovel%252BHybrid%252BCHC%252Bfrom%252B%2525CE%2525B2-carboline%252Band%252BN-Hydroxyacrylamide%252BOvercomes%252BDrug-Resistant%252BHepatocellular%252BCarcinoma%252Bby%252BPromoting%252BApoptosis%25252C%252BDNA%252BDamage%25252C%252Band%252BCell%252BCycle%252BArrest%26aulast%3DMiao%26aufirst%3DJiefei%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qin'ge  Ding</span>, <span class="hlFld-ContribAuthor ">Chunxi  Liu</span>, <span class="hlFld-ContribAuthor ">Chunlong  Zhao</span>, <span class="hlFld-ContribAuthor ">Hang  Dong</span>, <span class="hlFld-ContribAuthor ">Qifu  Xu</span>, <span class="hlFld-ContribAuthor ">C.  James Chou</span>, <span class="hlFld-ContribAuthor ">Yingjie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104235. <a href="https://doi.org/10.1016/j.bioorg.2020.104235" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104235</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104235&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104235%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bstudy%252Bof%252Bclass%252BI%252Bselective%252BHDAC%252Binhibitors%252Bwith%252BNO%252Breleasing%252Bactivity%26aulast%3DDing%26aufirst%3DQin%2527ge%26date%3D2020%26volume%3D104%26spage%3D104235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenhua  Liu</span>, <span class="hlFld-ContribAuthor ">Yuchen  Liang</span>, <span class="hlFld-ContribAuthor ">Xiaoyong  Si</span>. </span><span class="cited-content_cbyCitation_article-title">Hydroxamic acid hybrids as the potential anticancer agents: An Overview. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>205 </em>, 112679. <a href="https://doi.org/10.1016/j.ejmech.2020.112679" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112679</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112679%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHydroxamic%252Bacid%252Bhybrids%252Bas%252Bthe%252Bpotential%252Banticancer%252Bagents%25253A%252BAn%252BOverview%26aulast%3DLiu%26aufirst%3DWenhua%26date%3D2020%26volume%3D205%26spage%3D112679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manpreet  Singh</span>, <span class="hlFld-ContribAuthor ">Vaishali</span>, <span class="hlFld-ContribAuthor ">Sunit  Kumar</span>, <span class="hlFld-ContribAuthor ">Rahul  Jamra</span>, <span class="hlFld-ContribAuthor ">Satyendra K.  Pandey</span>, <span class="hlFld-ContribAuthor ">Virender  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">A metal-free approach towards synthesis of β-carboline C1 substituted Pyrido(2,3-c)carbazole derivatives (nitramarine analogues) through A3-coupling and estimation of their light emitting properties. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2020,</strong> <em>76 </em>
                                    (47)
                                     , 131640. <a href="https://doi.org/10.1016/j.tet.2020.131640" title="DOI URL">https://doi.org/10.1016/j.tet.2020.131640</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2020.131640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2020.131640%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DA%252Bmetal-free%252Bapproach%252Btowards%252Bsynthesis%252Bof%252B%2525CE%2525B2-carboline%252BC1%252Bsubstituted%252BPyrido%2525282%25252C3-c%252529carbazole%252Bderivatives%252B%252528nitramarine%252Banalogues%252529%252Bthrough%252BA3-coupling%252Band%252Bestimation%252Bof%252Btheir%252Blight%252Bemitting%252Bproperties%26aulast%3DSingh%26aufirst%3DManpreet%26date%3D2020%26volume%3D76%26issue%3D47%26spage%3D131640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rui  Cai</span>, <span class="hlFld-ContribAuthor ">Li  Zhu</span>, <span class="hlFld-ContribAuthor ">Pengfei  Wang</span>, <span class="hlFld-ContribAuthor ">Yu  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Bimetallic Catalyzed N-arylation Used in Synthesis of Novel β-carbolines Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Letters in Drug Design & Discovery</span><span> <strong>2020,</strong> <em>17 </em>
                                    (5)
                                     , 520-525. <a href="https://doi.org/10.2174/1570180815666181025124615" title="DOI URL">https://doi.org/10.2174/1570180815666181025124615</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570180815666181025124615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570180815666181025124615%26sid%3Dliteratum%253Aachs%26jtitle%3DLetters%2520in%2520Drug%2520Design%2520%2526%2520Discovery%26atitle%3DBimetallic%252BCatalyzed%252BN-arylation%252BUsed%252Bin%252BSynthesis%252Bof%252BNovel%252B%2525CE%2525B2-carbolines%252BDerivatives%26aulast%3DCai%26aufirst%3DRui%26date%3D2020%26volume%3D17%26issue%3D5%26spage%3D520%26epage%3D525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Srinath  Santhanam</span>, <span class="hlFld-ContribAuthor ">Abinaya  Ramu</span>, <span class="hlFld-ContribAuthor ">Baskar  Baburaj</span>, <span class="hlFld-ContribAuthor ">Balasubramanian  Kalpatu Kuppusamy</span>. </span><span class="cited-content_cbyCitation_article-title">Application of metal free aromatization to total synthesis of perlolyrin, flazin, eudistomin U and harmane. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2020,</strong> <em>57 </em>
                                    (5)
                                     , 2121-2127. <a href="https://doi.org/10.1002/jhet.3931" title="DOI URL">https://doi.org/10.1002/jhet.3931</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.3931&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.3931%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DApplication%252Bof%252Bmetal%252Bfree%252Baromatization%252Bto%252Btotal%252Bsynthesis%252Bof%252Bperlolyrin%25252C%252Bflazin%25252C%252Beudistomin%252BU%252Band%252Bharmane%26aulast%3DSanthanam%26aufirst%3DSrinath%26date%3D2020%26volume%3D57%26issue%3D5%26spage%3D2121%26epage%3D2127" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Feifei  Yang</span>, <span class="hlFld-ContribAuthor ">Lina  Han</span>, <span class="hlFld-ContribAuthor ">Na  Zhao</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>, <span class="hlFld-ContribAuthor ">Di  Ge</span>, <span class="hlFld-ContribAuthor ">Hua  Zhang</span>, <span class="hlFld-ContribAuthor ">Yihua  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of thiophene-based hydroxamate derivatives as HDACis with antitumor activities. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2020,</strong> <em>12 </em>
                                    (8)
                                     , 655-672. <a href="https://doi.org/10.4155/fmc-2019-0343" title="DOI URL">https://doi.org/10.4155/fmc-2019-0343</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2019-0343&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2019-0343%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bthiophene-based%252Bhydroxamate%252Bderivatives%252Bas%252BHDACis%252Bwith%252Bantitumor%252Bactivities%26aulast%3DYang%26aufirst%3DFeifei%26date%3D2020%26volume%3D12%26issue%3D8%26spage%3D655%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Bi-Qun  Zou</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Ling  Huang</span>, <span class="hlFld-ContribAuthor ">Ye  Zhang</span>, <span class="hlFld-ContribAuthor ">Ming-Xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Shu-Long  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">High in vitro and in vivo antitumor activities of luminecent platinum(II) complexes with jatrorrhizine derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>183 </em>, 111727. <a href="https://doi.org/10.1016/j.ejmech.2019.111727" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111727</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111727%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DHigh%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bantitumor%252Bactivities%252Bof%252Bluminecent%252Bplatinum%252528II%252529%252Bcomplexes%252Bwith%252Bjatrorrhizine%252Bderivatives%26aulast%3DQin%26aufirst%3DQi-Pin%26date%3D2019%26volume%3D183%26spage%3D111727" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biao  Xiong</span>, <span class="hlFld-ContribAuthor ">Shi  Chen</span>, <span class="hlFld-ContribAuthor ">Peng  Zhu</span>, <span class="hlFld-ContribAuthor ">Meiling  Huang</span>, <span class="hlFld-ContribAuthor ">Weijie  Gao</span>, <span class="hlFld-ContribAuthor ">Rui  Zhu</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Qian</span>, <span class="hlFld-ContribAuthor ">Yanfu  Peng</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Dai</span>, <span class="hlFld-ContribAuthor ">Yong  Ling</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Novel Thiazolyl Substituted Bis-pyrazole Oxime Derivatives with Potent Antitumor Activities by Selectively Inducing Apoptosis and ROS in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry</span><span> <strong>2019,</strong> <em>15 </em>
                                    (7)
                                     , 743-754. <a href="https://doi.org/10.2174/1573406414666180827112724" title="DOI URL">https://doi.org/10.2174/1573406414666180827112724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1573406414666180827112724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1573406414666180827112724%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BNovel%252BThiazolyl%252BSubstituted%252BBis-pyrazole%252BOxime%252BDerivatives%252Bwith%252BPotent%252BAntitumor%252BActivities%252Bby%252BSelectively%252BInducing%252BApoptosis%252Band%252BROS%252Bin%252BCancer%252BCells%26aulast%3DXiong%26aufirst%3DBiao%26date%3D2019%26volume%3D15%26issue%3D7%26spage%3D743%26epage%3D754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Manuela Ribeiro  Panice</span>, <span class="hlFld-ContribAuthor ">Susana M.M.  Lopes</span>, <span class="hlFld-ContribAuthor ">Mariana Cecchetto  Figueiredo</span>, <span class="hlFld-ContribAuthor ">Ana Lucia T.  Goes Ruiz</span>, <span class="hlFld-ContribAuthor ">Mary Ann  Foglio</span>, <span class="hlFld-ContribAuthor ">Anelise S.  Nazari Formagio</span>, <span class="hlFld-ContribAuthor ">Maria Helena  Sarragiotto</span>, <span class="hlFld-ContribAuthor ">Teresa M.V.D.  Pinho e Melo</span>. </span><span class="cited-content_cbyCitation_article-title">New 3-tetrazolyl-β-carbolines and β-carboline-3-carboxylates with anti-cancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 123-132. <a href="https://doi.org/10.1016/j.ejmech.2019.05.085" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.085</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.085%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNew%252B3-tetrazolyl-%2525CE%2525B2-carbolines%252Band%252B%2525CE%2525B2-carboline-3-carboxylates%252Bwith%252Banti-cancer%252Bactivity%26aulast%3DPanice%26aufirst%3DManuela%2BRibeiro%26date%3D2019%26volume%3D179%26spage%3D123%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Javier  Recio</span>, <span class="hlFld-ContribAuthor ">Adrián  Pérez-Redondo</span>, <span class="hlFld-ContribAuthor ">Julio  Alvarez-Builla</span>, <span class="hlFld-ContribAuthor ">Carolina  Burgos</span>. </span><span class="cited-content_cbyCitation_article-title">Access to 2-substituted 1-pyridin-3-yl-β-carboline derivatives by intramolecular radical cyclization-ring opening-S
              N
              Ar substitution. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (18)
                                     , 3300-3304. <a href="https://doi.org/10.1039/C9QO00944B" title="DOI URL">https://doi.org/10.1039/C9QO00944B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00944B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00944B%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DAccess%252Bto%252B2-substituted%252B1-pyridin-3-yl-%2525CE%2525B2-carboline%252Bderivatives%252Bby%252Bintramolecular%252Bradical%252Bcyclization-ring%252Bopening-S%252BN%252BAr%252Bsubstitution%26aulast%3DRecio%26aufirst%3DJavier%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D18%26spage%3D3300%26epage%3D3304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fan  Yun</span>, <span class="hlFld-ContribAuthor ">Chunhui  Cheng</span>, <span class="hlFld-ContribAuthor ">Sadeeq  Ullah</span>, <span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Mohamed Reda  Zahi</span>, <span class="hlFld-ContribAuthor ">Qipeng  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 195-207. <a href="https://doi.org/10.1016/j.ejmech.2019.05.007" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.007%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThioether-based%252B2-aminobenzamide%252Bderivatives%25253A%252BNovel%252BHDAC%252Binhibitors%252Bwith%252Bpotent%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bantitumor%252Bactivity%26aulast%3DYun%26aufirst%3DFan%26date%3D2019%26volume%3D176%26spage%3D195%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ding-Yi  Fu</span>, <span class="hlFld-ContribAuthor ">Ya-Rong  Xue</span>, <span class="hlFld-ContribAuthor ">Xianghui  Yu</span>, <span class="hlFld-ContribAuthor ">Yuqing  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">Anti-virus reagents targeting the capsid protein assembly. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2019,</strong> <em>7 </em>
                                    (21)
                                     , 3331-3340. <a href="https://doi.org/10.1039/C8TB02954G" title="DOI URL">https://doi.org/10.1039/C8TB02954G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8TB02954G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8TB02954G%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DAnti-virus%252Breagents%252Btargeting%252Bthe%252Bcapsid%252Bprotein%252Bassembly%26aulast%3DFu%26aufirst%3DDing-Yi%26date%3D2019%26date%3D2019%26volume%3D7%26issue%3D21%26spage%3D3331%26epage%3D3340" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rong  Wang</span>, <span class="hlFld-ContribAuthor ">Liang  Li</span>, <span class="hlFld-ContribAuthor ">Aijun  Duan</span>, <span class="hlFld-ContribAuthor ">Yi  Li</span>, <span class="hlFld-ContribAuthor ">Xiujun  Liu</span>, <span class="hlFld-ContribAuthor ">Qingfang  Miao</span>, <span class="hlFld-ContribAuthor ">Jianhua  Gong</span>, <span class="hlFld-ContribAuthor ">Yongsu  Zhen</span>. </span><span class="cited-content_cbyCitation_article-title">Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. </span><span class="cited-content_cbyCitation_journal-name">Cancer Letters</span><span> <strong>2019,</strong> <em>448 </em>, 84-93. <a href="https://doi.org/10.1016/j.canlet.2019.02.002" title="DOI URL">https://doi.org/10.1016/j.canlet.2019.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.canlet.2019.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.canlet.2019.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Letters%26atitle%3DCrizotinib%252Benhances%252Banti-CD30-LDM%252Binduced%252Bantitumor%252Befficacy%252Bin%252BNPM-ALK%252Bpositive%252Banaplastic%252Blarge%252Bcell%252Blymphoma%26aulast%3DWang%26aufirst%3DRong%26date%3D2019%26volume%3D448%26spage%3D84%26epage%3D93" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ling</span>, <span class="hlFld-ContribAuthor ">Wei-Jie  Gao</span>, <span class="hlFld-ContribAuthor ">Changchun  Ling</span>, <span class="hlFld-ContribAuthor ">Ji  Liu</span>, <span class="hlFld-ContribAuthor ">Chi  Meng</span>, <span class="hlFld-ContribAuthor ">Jianqiang  Qian</span>, <span class="hlFld-ContribAuthor ">Siqun  Liu</span>, <span class="hlFld-ContribAuthor ">Huiling  Gan</span>, <span class="hlFld-ContribAuthor ">Hongmei  Wu</span>, <span class="hlFld-ContribAuthor ">Jinhua  Tao</span>, <span class="hlFld-ContribAuthor ">Hong  Dai</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>168 </em>, 515-526. <a href="https://doi.org/10.1016/j.ejmech.2019.02.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.02.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.02.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.02.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3D%2525CE%2525B2-Carboline%252Band%252BN-hydroxycinnamamide%252Bhybrids%252Bas%252Banticancer%252Bagents%252Bfor%252Bdrug-resistant%252Bhepatocellular%252Bcarcinoma%26aulast%3DLing%26aufirst%3DYong%26date%3D2019%26volume%3D168%26spage%3D515%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ziquan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan  Sun</span>, <span class="hlFld-ContribAuthor ">Lilin  Wang</span>, <span class="hlFld-ContribAuthor ">Xuan  Chen</span>, <span class="hlFld-ContribAuthor ">Yanpei  Sun</span>, <span class="hlFld-ContribAuthor ">Long  Lin</span>, <span class="hlFld-ContribAuthor ">Yulin  Tang</span>, <span class="hlFld-ContribAuthor ">Fei  Li</span>, <span class="hlFld-ContribAuthor ">Dongyin  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Organic base-promoted efficient dehydrogenative/decarboxylative aromatization of tetrahydro-β-carbolines into β-carbolines under air. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2019,</strong> <em>60 </em>
                                    (11)
                                     , 800-804. <a href="https://doi.org/10.1016/j.tetlet.2019.02.020" title="DOI URL">https://doi.org/10.1016/j.tetlet.2019.02.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2019.02.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2019.02.020%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DOrganic%252Bbase-promoted%252Befficient%252Bdehydrogenative%25252Fdecarboxylative%252Baromatization%252Bof%252Btetrahydro-%2525CE%2525B2-carbolines%252Binto%252B%2525CE%2525B2-carbolines%252Bunder%252Bair%26aulast%3DZhao%26aufirst%3DZiquan%26date%3D2019%26volume%3D60%26issue%3D11%26spage%3D800%26epage%3D804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed A  Abdelsalam</span>, <span class="hlFld-ContribAuthor ">Omaima M  AboulWafa</span>, <span class="hlFld-ContribAuthor ">El-Sayed AM  Badawey</span>, <span class="hlFld-ContribAuthor ">Mai S  El-Shoukrofy</span>, <span class="hlFld-ContribAuthor ">Mostafa M  El-Miligy</span>, <span class="hlFld-ContribAuthor ">Noha  Gouda</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of some β-carboline derivatives as multi-target anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (24)
                                     , 2791-2814. <a href="https://doi.org/10.4155/fmc-2018-0226" title="DOI URL">https://doi.org/10.4155/fmc-2018-0226</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2018-0226&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2018-0226%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bsome%252B%2525CE%2525B2-carboline%252Bderivatives%252Bas%252Bmulti-target%252Banticancer%252Bagents%26aulast%3DAbdelsalam%26aufirst%3DMohamed%2BA%26date%3D2018%26volume%3D10%26issue%3D24%26spage%3D2791%26epage%3D2814" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi-Pin  Qin</span>, <span class="hlFld-ContribAuthor ">Shu-Long  Wang</span>, <span class="hlFld-ContribAuthor ">Ming-Xiong  Tan</span>, <span class="hlFld-ContribAuthor ">Zhen-Feng  Wang</span>, <span class="hlFld-ContribAuthor ">Dong-Mei  Luo</span>, <span class="hlFld-ContribAuthor ">Bi-Qun  Zou</span>, <span class="hlFld-ContribAuthor ">Yan-Cheng  Liu</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Yao</span>, <span class="hlFld-ContribAuthor ">Hong  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel tacrine platinum(II) complexes display high anticancer activity via inhibition of telomerase activity, dysfunction of mitochondria, and activation of the p53 signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 106-122. <a href="https://doi.org/10.1016/j.ejmech.2018.09.008" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.008%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Btacrine%252Bplatinum%252528II%252529%252Bcomplexes%252Bdisplay%252Bhigh%252Banticancer%252Bactivity%252Bvia%252Binhibition%252Bof%252Btelomerase%252Bactivity%25252C%252Bdysfunction%252Bof%252Bmitochondria%25252C%252Band%252Bactivation%252Bof%252Bthe%252Bp53%252Bsignaling%252Bpathway%26aulast%3DQin%26aufirst%3DQi-Pin%26date%3D2018%26volume%3D158%26spage%3D106%26epage%3D122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sunil  Gaikwad</span>, <span class="hlFld-ContribAuthor ">Dayanand  Kamble</span>, <span class="hlFld-ContribAuthor ">Pradeep  Lokhande</span>. </span><span class="cited-content_cbyCitation_article-title">Iodine-catalyzed chemoselective dehydrogenation and aromatization of tetrahydro-β-carbolines: A short synthesis of Kumujian-C, Eudistomin-U, Norharmane, Harmane Harmalan and Isoeudistomine-M. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (25)
                                     , 2387-2392. <a href="https://doi.org/10.1016/j.tetlet.2018.04.043" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.04.043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.04.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.04.043%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DIodine-catalyzed%252Bchemoselective%252Bdehydrogenation%252Band%252Baromatization%252Bof%252Btetrahydro-%2525CE%2525B2-carbolines%25253A%252BA%252Bshort%252Bsynthesis%252Bof%252BKumujian-C%25252C%252BEudistomin-U%25252C%252BNorharmane%25252C%252BHarmane%252BHarmalan%252Band%252BIsoeudistomine-M%26aulast%3DGaikwad%26aufirst%3DSunil%26date%3D2018%26volume%3D59%26issue%3D25%26spage%3D2387%26epage%3D2392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie-Fei  Miao</span>, <span class="hlFld-ContribAuthor ">Yan-Fu  Peng</span>, <span class="hlFld-ContribAuthor ">Shi  Chen</span>, <span class="hlFld-ContribAuthor ">Wei-Jie  Gao</span>, <span class="hlFld-ContribAuthor ">Qiu-Xing  Yang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhu</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Jinhua  Tao</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Ling</span>. </span><span class="cited-content_cbyCitation_article-title">A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2018,</strong> <em>824 </em>, 78-88. <a href="https://doi.org/10.1016/j.ejphar.2018.02.004" title="DOI URL">https://doi.org/10.1016/j.ejphar.2018.02.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2018.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2018.02.004%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DA%252Bnovel%252Bharmine%252Bderivative%25252C%252BN-%2525284-%252528hydroxycarbamoyl%252529benzyl%252529-1-%2525284-%252Bmethoxyphenyl%252529-9H-pyrido%25255B3%25252C4-b%25255Dindole-3-carboxamide%252B%252528HBC%252529%25252C%252Bas%252Bhistone%252Bdeacetylase%252Binhibitor%25253A%252Bin%252Bvitro%252Bantiproliferation%25252C%252Bapoptosis%252Binduction%25252C%252Bcell%252Bcycle%252Barrest%25252C%252Band%252Bantimetastatic%252Beffects%26aulast%3DMiao%26aufirst%3DJie-Fei%26date%3D2018%26volume%3D824%26spage%3D78%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hong  Dai</span>, <span class="hlFld-ContribAuthor ">Shushan  Ge</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Shi  Chen</span>, <span class="hlFld-ContribAuthor ">Meiling  Huang</span>, <span class="hlFld-ContribAuthor ">Jiaying  Yang</span>, <span class="hlFld-ContribAuthor ">Siyu  Sun</span>, <span class="hlFld-ContribAuthor ">Yong  Ling</span>, <span class="hlFld-ContribAuthor ">Yujun  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>143 </em>, 1066-1076. <a href="https://doi.org/10.1016/j.ejmech.2017.11.098" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.11.098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.11.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.11.098%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252Bbis-pyrazole%252Bderivatives%252Bas%252Bantitumor%252Bagents%252Bwith%252Bpotent%252Bapoptosis%252Binduction%252Beffects%252Band%252BDNA%252Bdamage%26aulast%3DDai%26aufirst%3DHong%26date%3D2018%26volume%3D143%26spage%3D1066%26epage%3D1076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ling</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Qiuxing  Yang</span>, <span class="hlFld-ContribAuthor ">Peng  Zhu</span>, <span class="hlFld-ContribAuthor ">Jiefei  Miao</span>, <span class="hlFld-ContribAuthor ">Weijie  Gao</span>, <span class="hlFld-ContribAuthor ">Yanfu  Peng</span>, <span class="hlFld-ContribAuthor ">Jiaying  Yang</span>, <span class="hlFld-ContribAuthor ">Kun  Xu</span>, <span class="hlFld-ContribAuthor ">Biao  Xiong</span>, <span class="hlFld-ContribAuthor ">Gongqing  Liu</span>, <span class="hlFld-ContribAuthor ">Jinhua  Tao</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Qing  Zhu</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with antiproliferative and antimetastatic activities in human cancer cells. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>144 </em>, 398-409. <a href="https://doi.org/10.1016/j.ejmech.2017.12.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.12.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.12.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.12.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bnovel%252B%2525CE%2525B2-carboline-based%252Bhydroxamate%252Bderivatives%252Bas%252BHDAC%252Binhibitors%252Bwith%252Bantiproliferative%252Band%252Bantimetastatic%252Bactivities%252Bin%252Bhuman%252Bcancer%252Bcells%26aulast%3DLing%26aufirst%3DYong%26date%3D2018%26volume%3D144%26spage%3D398%26epage%3D409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sumit  Kumar</span>, <span class="hlFld-ContribAuthor ">Amandeep  Singh</span>, <span class="hlFld-ContribAuthor ">Kewal  Kumar</span>, <span class="hlFld-ContribAuthor ">Vipan  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Recent insights into synthetic β -carbolines with anti-cancer activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 48-73. <a href="https://doi.org/10.1016/j.ejmech.2017.05.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Binsights%252Binto%252Bsynthetic%252B%2525CE%2525B2%252B-carbolines%252Bwith%252Banti-cancer%252Bactivities%26aulast%3DKumar%26aufirst%3DSumit%26date%3D2017%26volume%3D142%26spage%3D48%26epage%3D73" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shiv  Dhiman</span>, <span class="hlFld-ContribAuthor ">Steven  Rhodes</span>, <span class="hlFld-ContribAuthor ">Dalip  Kumar</span>, <span class="hlFld-ContribAuthor ">Anil  Kumar</span>, <span class="hlFld-ContribAuthor ">Mukund  Jha</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-Catalyzed Tandem Imine Formation, Sonogashira Coupling and Intramolecular Hydroamination: A Facile Synthesis of 3-Aryl-γ−carbolines. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2017,</strong> <em>2 </em>
                                    (28)
                                     , 8922-8926. <a href="https://doi.org/10.1002/slct.201702025" title="DOI URL">https://doi.org/10.1002/slct.201702025</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.201702025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.201702025%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DCopper-Catalyzed%252BTandem%252BImine%252BFormation%25252C%252BSonogashira%252BCoupling%252Band%252BIntramolecular%252BHydroamination%25253A%252BA%252BFacile%252BSynthesis%252Bof%252B3-Aryl-%2525CE%2525B3%2525E2%252588%252592carbolines%26aulast%3DDhiman%26aufirst%3DShiv%26date%3D2017%26date%3D2017%26volume%3D2%26issue%3D28%26spage%3D8922%26epage%3D8926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Veena D.  Yadav</span>, <span class="hlFld-ContribAuthor ">Kumkum  Srivastava</span>, <span class="hlFld-ContribAuthor ">Renu  Tripathi</span>, <span class="hlFld-ContribAuthor ">Sanjay  Batra</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of β-carboline-fused 1,4-oxazepines and their assessment as antiplasmodial agents. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2017,</strong> <em>73 </em>
                                    (38)
                                     , 5680-5689. <a href="https://doi.org/10.1016/j.tet.2017.08.003" title="DOI URL">https://doi.org/10.1016/j.tet.2017.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2017.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2017.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B2-carboline-fused%252B1%25252C4-oxazepines%252Band%252Btheir%252Bassessment%252Bas%252Bantiplasmodial%252Bagents%26aulast%3DYadav%26aufirst%3DVeena%2BD.%26date%3D2017%26volume%3D73%26issue%3D38%26spage%3D5680%26epage%3D5689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sierra D.  Durham</span>, <span class="hlFld-ContribAuthor ">Brianna  Sierra</span>, <span class="hlFld-ContribAuthor ">Maximillian J.  Gomez</span>, <span class="hlFld-ContribAuthor ">Jennifer K.  Tran</span>, <span class="hlFld-ContribAuthor ">Marc O.  Anderson</span>, <span class="hlFld-ContribAuthor ">Nick A.  Whittington-Davis</span>, <span class="hlFld-ContribAuthor ">Scott  Eagon</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of β-carbolines via a silver-mediated oxidation of tetrahydro-β-carbolines. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2017,</strong> <em>58 </em>
                                    (28)
                                     , 2747-2750. <a href="https://doi.org/10.1016/j.tetlet.2017.05.098" title="DOI URL">https://doi.org/10.1016/j.tetlet.2017.05.098</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2017.05.098&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2017.05.098%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSynthesis%252Bof%252B%2525CE%2525B2-carbolines%252Bvia%252Ba%252Bsilver-mediated%252Boxidation%252Bof%252Btetrahydro-%2525CE%2525B2-carbolines%26aulast%3DDurham%26aufirst%3DSierra%2BD.%26date%3D2017%26volume%3D58%26issue%3D28%26spage%3D2747%26epage%3D2750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong  Ling</span>, <span class="hlFld-ContribAuthor ">Jiao  Feng</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Yanfu  Peng</span>, <span class="hlFld-ContribAuthor ">Tingting  Wang</span>, <span class="hlFld-ContribAuthor ">Xiang  Ge</span>, <span class="hlFld-ContribAuthor ">Qibing  Xu</span>, <span class="hlFld-ContribAuthor ">Xinyang  Wang</span>, <span class="hlFld-ContribAuthor ">Hong  Dai</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of C3-Substituted β-Carboline-Based Histone Deacetylase Inhibitors with Potent Antitumor Activities. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (9)
                                     , 646-651. <a href="https://doi.org/10.1002/cmdc.201700133" title="DOI URL">https://doi.org/10.1002/cmdc.201700133</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700133&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700133%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BC3-Substituted%252B%2525CE%2525B2-Carboline-Based%252BHistone%252BDeacetylase%252BInhibitors%252Bwith%252BPotent%252BAntitumor%252BActivities%26aulast%3DLing%26aufirst%3DYong%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D9%26spage%3D646%26epage%3D651" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heron F.  Vieira Torquato</span>, <span class="hlFld-ContribAuthor ">Antonio C.  Ribeiro-Filho</span>, <span class="hlFld-ContribAuthor ">Marcus V.  Buri</span>, <span class="hlFld-ContribAuthor ">Roberto T.  Araújo Júnior</span>, <span class="hlFld-ContribAuthor ">Renata  Pimenta</span>, <span class="hlFld-ContribAuthor ">José Salvador R.  de Oliveira</span>, <span class="hlFld-ContribAuthor ">Valdir C.  Filho</span>, <span class="hlFld-ContribAuthor ">Antonio  Macho</span>, <span class="hlFld-ContribAuthor ">Edgar J.  Paredes-Gamero</span>, <span class="hlFld-ContribAuthor ">Domingos T.  de Oliveira Martins</span>. </span><span class="cited-content_cbyCitation_article-title">Canthin-6-one induces cell death, cell cycle arrest and differentiation in human myeloid leukemia cells. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - General Subjects</span><span> <strong>2017,</strong> <em>1861 </em>
                                    (4)
                                     , 958-967. <a href="https://doi.org/10.1016/j.bbagen.2017.01.033" title="DOI URL">https://doi.org/10.1016/j.bbagen.2017.01.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbagen.2017.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbagen.2017.01.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520General%2520Subjects%26atitle%3DCanthin-6-one%252Binduces%252Bcell%252Bdeath%25252C%252Bcell%252Bcycle%252Barrest%252Band%252Bdifferentiation%252Bin%252Bhuman%252Bmyeloid%252Bleukemia%252Bcells%26aulast%3DVieira%2BTorquato%26aufirst%3DHeron%2BF.%26date%3D2017%26volume%3D1861%26issue%3D4%26spage%3D958%26epage%3D967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ji  Liu</span>, <span class="hlFld-ContribAuthor ">Tingting  Wang</span>, <span class="hlFld-ContribAuthor ">Xinyang  Wang</span>, <span class="hlFld-ContribAuthor ">Lin  Luo</span>, <span class="hlFld-ContribAuthor ">Jing  Guo</span>, <span class="hlFld-ContribAuthor ">Yanfu  Peng</span>, <span class="hlFld-ContribAuthor ">Qibing  Xu</span>, <span class="hlFld-ContribAuthor ">Jiefei  Miao</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Ling</span>. </span><span class="cited-content_cbyCitation_article-title">Development of novel β-carboline-based hydroxamate derivatives as HDAC inhibitors with DNA damage and apoptosis inducing abilities. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2017,</strong> <em>8 </em>
                                    (6)
                                     , 1213-1219. <a href="https://doi.org/10.1039/C6MD00681G" title="DOI URL">https://doi.org/10.1039/C6MD00681G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6MD00681G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6MD00681G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDevelopment%252Bof%252Bnovel%252B%2525CE%2525B2-carboline-based%252Bhydroxamate%252Bderivatives%252Bas%252BHDAC%252Binhibitors%252Bwith%252BDNA%252Bdamage%252Band%252Bapoptosis%252Binducing%252Babilities%26aulast%3DLiu%26aufirst%3DJi%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D6%26spage%3D1213%26epage%3D1219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nisha  Devi</span>, <span class="hlFld-ContribAuthor ">Dharmender  Singh</span>, <span class="hlFld-ContribAuthor ">Gurpreet  Kaur</span>, <span class="hlFld-ContribAuthor ">Satbir  Mor</span>, <span class="hlFld-ContribAuthor ">V. P. R. Kishore  Putta</span>, <span class="hlFld-ContribAuthor ">Saibabu  Polina</span>, <span class="hlFld-ContribAuthor ">Chandi C.  Malakar</span>, <span class="hlFld-ContribAuthor ">Virender  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">In(OTf)
              3
              assisted synthesis of β-carboline C-3 tethered imidazo[1,2-a]azine derivatives. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2017,</strong> <em>41 </em>
                                    (3)
                                     , 1082-1093. <a href="https://doi.org/10.1039/C6NJ03210A" title="DOI URL">https://doi.org/10.1039/C6NJ03210A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6NJ03210A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6NJ03210A%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DIn%252528OTf%252529%252B3%252Bassisted%252Bsynthesis%252Bof%252B%2525CE%2525B2-carboline%252BC-3%252Btethered%252Bimidazo%25255B1%25252C2-a%25255Dazine%252Bderivatives%26aulast%3DDevi%26aufirst%3DNisha%26date%3D2017%26date%3D2017%26volume%3D41%26issue%3D3%26spage%3D1082%26epage%3D1093" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi-Bing  Xu</span>, <span class="hlFld-ContribAuthor ">Xiang-Fan  Chen</span>, <span class="hlFld-ContribAuthor ">Jiao  Feng</span>, <span class="hlFld-ContribAuthor ">Jie-Fei  Miao</span>, <span class="hlFld-ContribAuthor ">Ji  Liu</span>, <span class="hlFld-ContribAuthor ">Feng-Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Bi-Xi  Niu</span>, <span class="hlFld-ContribAuthor ">Jin-Yang  Cai</span>, <span class="hlFld-ContribAuthor ">Chao  Huang</span>, <span class="hlFld-ContribAuthor ">Yanan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Ling</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of hybrids of β-carboline and salicylic acid as potential anticancer and apoptosis inducing agents. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2016,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep36238" title="DOI URL">https://doi.org/10.1038/srep36238</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep36238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep36238%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bhybrids%252Bof%252B%2525CE%2525B2-carboline%252Band%252Bsalicylic%252Bacid%252Bas%252Bpotential%252Banticancer%252Band%252Bapoptosis%252Binducing%252Bagents%26aulast%3DXu%26aufirst%3DQi-Bing%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shivalinga  Kolle</span>, <span class="hlFld-ContribAuthor ">Sanjay  Batra</span>. </span><span class="cited-content_cbyCitation_article-title">β-Carboline-directed decarboxylative acylation of ortho-C(sp
              2
              )–H of the aryl ring of aryl(β-carbolin-1-yl)methanones with α-ketoacids under palladium catalysis. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (56)
                                     , 50658-50665. <a href="https://doi.org/10.1039/C6RA11811A" title="DOI URL">https://doi.org/10.1039/C6RA11811A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA11811A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA11811A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3D%2525CE%2525B2-Carboline-directed%252Bdecarboxylative%252Bacylation%252Bof%252Bortho-C%252528sp%252B2%252B%252529%2525E2%252580%252593H%252Bof%252Bthe%252Baryl%252Bring%252Bof%252Baryl%252528%2525CE%2525B2-carbolin-1-yl%252529methanones%252Bwith%252B%2525CE%2525B1-ketoacids%252Bunder%252Bpalladium%252Bcatalysis%26aulast%3DKolle%26aufirst%3DShivalinga%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D56%26spage%3D50658%26epage%3D50665" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0013.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative β-carboline derivatives, HDAC inhibitor SAHA, and designed β-carboline/hydroxamic acid hybrids <b>5a</b>–<b>o</b> and <b>11a</b>–<b>j</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0011.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Procedure to Obtain Compounds <b>5a</b>–<b>o</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>H<sup>+</sup> or OH<sup>–</sup>, RCHO, reflux, 2–4 h, 81–86%.</p><p><span class="fn-label">Scheme b</span>KMnO<sub>4</sub>, DMF, reflux, 6 h, 60–70%.</p><p><span class="fn-label">Scheme c</span>Ethyl chloroformate, <i>N</i>-methylmorpholine, NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe, rt, 5–8 h, 71–83%.</p><p class="last"><span class="fn-label">Scheme d</span>NH<sub>2</sub>OK, MeOH, rt, 10–15 h, 68–77%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0012.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Procedure to Obtain Compounds <b>11a</b>–<b>j</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>SOCl<sub>2</sub>, MeOH, 0 °C, 1h, and then reflux 6 h, 90%.</p><p><span class="fn-label">Scheme b</span>CH<sub>3</sub>I, NaH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2–4 h, 81–86%.</p><p><span class="fn-label">Scheme c</span>NH<sub>2</sub>–NH<sub>2</sub>·H<sub>2</sub>O, CH<sub>3</sub>OH, 0 °C, 1h, 90–95%.</p><p><span class="fn-label">Scheme d</span>NaNO<sub>2</sub>, CH<sub>3</sub>OH, 0 °C, 6 h, 73–80%.</p><p><span class="fn-label">Scheme e</span>NH<sub>2</sub>(CH<sub>2</sub>)<sub><i>n</i></sub>COOMe, toluene, reflux, 1 h, 77–85%.</p><p class="last"><span class="fn-label">Scheme f</span>NH<sub>2</sub>OK, MeOH, 63–75%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Inhibition of cell proliferation (%) of target compounds <b>5a</b>–<b>o</b> against HCT116, SW620, and LOVO cell lines after incubation for 48 h at a concentration of 25 μM. Data are expressed as means ± SD of each compound from three separate measurements.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Immunoblot analysis of the expression of the acetylation for histone H3 and α-tubulin in vitro. (A) HCT116 cells were treated with <b>11c</b> and SAHA for 48 h at the indicated concentrations. Cell lysates were prepared and subjected to SDS-PAGE and immunoblot analysis using anti-acetyl-histone H3 (Ac-H3), anti-acetyl-α-tubulin (Ac-α-tubulin), and anti-β-actin antibodies, respectively. β-Actin was used as the loading control. (B) Quantitative analysis. The relative levels of Ac-H3 and Ac-α-tubulin used to control β-actin were determined by densimetric scanning. The data are expressed as means ± SD of three separate experiments. *, <i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Inhibitory effects of <b>11c</b> and SAHA on the proliferation of HCT116 and IEC-18 cells. Cells were incubated with the indicated concentrations of tested compounds for 48 h. Cell proliferation was assessed using the MTT assay. Data are means + SD of the inhibition (%) from three independent experiments.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compound <b>11c</b> induces HCT116 cell apoptosis in vitro. HCT116 cells were incubated with the indicated concentrations of <b>11c</b> or SAHA (5.0 μM) for 48 h, and the cells were stained with FITC-Annexin V/PI, followed by flow cytometry analysis. (A) Flow cytometry analysis. (B) Quantitative analysis of apoptotic cells. Data are expressed as means ± SD of the percentages of apoptotic cells from three independent experiments. *, <i>P</i> < 0.01 vs control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Expression of (A) Bax, Bcl-2, (C) cleaved caspase 3, PARP, and (A and C) β-actin was examined by Western blot analysis. HCT116 cells were incubated with or without <b>11c</b> and SAHA at the indicated concentrations for 48 h, and the levels of protein expression were detected using specific antibodies. Data shown are representative images of each protein for three separate experiments. Quantitative analysis of (B) Bax and Bcl-2 and (D) cleaved caspase 3 and PARP. The relative levels of each protein compared to that of control β-actin were determined by densimetric scanning. Data are expressed as means ± SD from three separate experiments. *, <i>P</i> < 0.01 vs respective control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Immunoblot analysis of the expression of DNA damage and DNA-damage response p53 signaling pathway events in vitro. (A and C) HCT116 cells were treated with vehicle (control), different doses of <b>11c</b>, <b>11h</b>, harmine, or SAHA and then were homogenized; their lysates were subjected to immunoblot analysis using anti-H2AXS139ph, anti-phospho-p53 (ser15), anti-p53, anti-p21, and anti-β-actin antibodies. β-Actin was used as the control. (B and D) Quantitative analysis. The levels of each signaling event relative to those of control β-actin were determined by densimetric scanning. The data are expressed as means ± SD from three separate experiments. *, <i>P</i> < 0.01 vs respective control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0009.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Expression profile of p53 in shRNA control and shRNA p53 HCT116 cell lines by Western blot in vitro. β-Actin was used as control. (B) Quantitative analysis. (C and D) Effects of SAHA or <b>11c</b> treatment on the shRNA control and shRNA p53 HCT116 colorectal cancer cell growth for 48 h at a wide range of concentrations. The data are expressed as means ± SD of three duplicate experiments. *, <i>P</i> < 0.01 vs respective control.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/medium/jm-2015-01052d_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Inhibitory effects of <b>11c</b> on the growth of an implanted HCT116 xenograft in nude mice. BALB/c nude mice were subcutaneously inoculated with HCT116 cells. After establishment of solid tumor, the mice were randomized and treated with solvent control, SAHA, or <b>11c</b> at the indicated doses, respectively. The growth of tumors was measured longitudinally. Data are expressed as means (SD of tumor volumes at each time point for each group of mice; <i>n</i> = 6 per group). *, <i>P</i> < 0.01 vs control group; #, <i>P</i> < 0.05 vs SAHA group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2015/jmcmar.2015.58.issue-23/acs.jmedchem.5b01052/20151204/images/large/jm-2015-01052d_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01052&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i89">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63122" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63122" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 37 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Kim, J. H.</span><span> </span><span class="NLM_article-title">Chemotherapy for colorectal cancer in the elderly</span> <span class="citation_source-journal">World J. Gastroenterol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">5158</span><span class="NLM_x">–</span> <span class="NLM_lpage">5166</span><span class="refDoi"> DOI: 10.3748/wjg.v21.i17.5158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.3748%2Fwjg.v21.i17.5158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=25954089" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFaktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=5158-5166&author=J.+H.+Kim&title=Chemotherapy+for+colorectal+cancer+in+the+elderly&doi=10.3748%2Fwjg.v21.i17.5158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Chemotherapy for colorectal cancer in the elderly</span></div><div class="casAuthors">Kim, Jung Han</div><div class="citationInfo"><span class="NLM_cas:title">World Journal of Gastroenterology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5158-5166</span>CODEN:
                <span class="NLM_cas:coden">WJGAF2</span>;
        ISSN:<span class="NLM_cas:issn">2219-2840</span>.
    
            (<span class="NLM_cas:orgname">Baishideng Publishing Group Inc.</span>)
        </div><div class="casAbstract">A review.  Colorectal cancer (CRC) is one of the leading causes of cancer-related death in the elderly.  However, elderly patients with CRC tend to be under-presented in clin. trials and undertreated in clin. practice.  Advanced age alone should not be the only criteria to preclude effective therapy in elderly patients with CRC.  The best guide about optimal cancer treatment can be provided by comprehensive geriatric assessment.  Elderly patients with stage  colon cancer can enjoy the same benefit from adjuvant chemotherapy with 5-fluorouracil/leucovorin or capecitabine as younger patients, without a substantial increase in toxicity.  With conflicting results of retrospective studies and a lack of data available from randomized studies, combined modality treatment should be used with great caution in elderly patients with locally advanced rectal cancer.  Combination chemotherapy can be considered for older patients with metastatic CRC.  For elderly patients who are frail or vulnerable, however, monotherapy or a stopand- go strategy may be desirable.  The use of targeted therapies in older patients with metastatic CRC appears to be promising in view of their better efficacy and toxicity.  Treatment should be individualized based on the nature of the disease, the physiol. or functional status, and the patient's preference.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd3RvF6ygpALVg90H21EOLACvtfcHk0lhmykpjDmca8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFaktrrI&md5=e89c264b4fe5633ef1a406d8402e7491</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3748%2Fwjg.v21.i17.5158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3748%252Fwjg.v21.i17.5158%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DJ.%2BH.%26atitle%3DChemotherapy%2520for%2520colorectal%2520cancer%2520in%2520the%2520elderly%26jtitle%3DWorld%2520J.%2520Gastroenterol.%26date%3D2015%26volume%3D21%26spage%3D5158%26epage%3D5166%26doi%3D10.3748%2Fwjg.v21.i17.5158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Fakih, M. G.</span><span> </span><span class="NLM_article-title">Metastatic colorectal cancer: current state and future directions</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1809</span><span class="NLM_x">–</span> <span class="NLM_lpage">1824</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.7633</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1200%2FJCO.2014.59.7633" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=25918280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1eisb3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1809-1824&author=M.+G.+Fakih&title=Metastatic+colorectal+cancer%3A+current+state+and+future+directions&doi=10.1200%2FJCO.2014.59.7633"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Metastatic colorectal cancer: current state and future direction</span></div><div class="casAuthors">Fakih, Marwan G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1809-1824</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Substantial improvements have been made in the management of metastatic colorectal cancer over the last two decades.  The overall survival of patients diagnosed with unresectable metastatic colorectal cancer has increased from approx. 1 yr during the era of fluoropyrimidine monotherapy to more than 30 mo with the integration of multiple cytotoxic agents and targeted therapies.  More effective therapeutic combinations have increased the rate of curative-intent surgical resections, resulting in median survival in this subgroup that exceed 5 years.  Here we review the landscape of systemic therapies for unresectable metastatic colorectal cancer during the current era of targeted therapies, review the effects of RAS and BRAF mutations on clin. decision making, and reflect on future directions for the treatment of metastatic colorectal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0_vqdnGQXi7Vg90H21EOLACvtfcHk0liuPGOk_Wmg3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1eisb3L&md5=c9c27ec937920458df9394eaceecb345</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.7633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.7633%26sid%3Dliteratum%253Aachs%26aulast%3DFakih%26aufirst%3DM.%2BG.%26atitle%3DMetastatic%2520colorectal%2520cancer%253A%2520current%2520state%2520and%2520future%2520directions%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1809%26epage%3D1824%26doi%3D10.1200%2FJCO.2014.59.7633" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Musso, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dallavalle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zunino, F.</span><span> </span><span class="NLM_article-title">Perspectives in the development of hybrid bifunctional antitumour agents</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">96</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="refDoi"> DOI: 10.1016/j.bcp.2015.06.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.bcp.2015.06.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2015&pages=297&author=L.+Mussoauthor=S.+Dallavalleauthor=F.+Zunino&title=Perspectives+in+the+development+of+hybrid+bifunctional+antitumour+agents&doi=10.1016%2Fj.bcp.2015.06.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2015.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2015.06.006%26sid%3Dliteratum%253Aachs%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DDallavalle%26aufirst%3DS.%26aulast%3DZunino%26aufirst%3DF.%26atitle%3DPerspectives%2520in%2520the%2520development%2520of%2520hybrid%2520bifunctional%2520antitumour%2520agents%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2015%26volume%3D96%26spage%3D297%26doi%3D10.1016%2Fj.bcp.2015.06.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Patel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gadewar, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, D. K.</span><span> </span><span class="NLM_article-title">A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ’’Harmine’’</span> <span class="citation_source-journal">Asian Pac. J. Trop. Biomed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">664</span><span class="refDoi"> DOI: 10.1016/S2221-1691(12)60116-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2FS2221-1691%2812%2960116-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=23569990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ent73E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2012&pages=660-664&author=K.+Patelauthor=M.+Gadewarauthor=R.+Tripathiauthor=S.+K.+Prasadauthor=D.+K.+Patel&title=A+review+on+medicinal+importance%2C+pharmacological+activity+and+bioanalytical+aspects+of+beta-carboline+alkaloid+%E2%80%99%E2%80%99Harmine%E2%80%99%E2%80%99&doi=10.1016%2FS2221-1691%2812%2960116-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid "Harmine"</span></div><div class="casAuthors">Patel, K.; Gadewar, M.; Tripathi, R.; Prasad, S. K.; Patel, Dinesh Kumar</div><div class="citationInfo"><span class="NLM_cas:title">Asian Pacific Journal of Tropical Biomedicine</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">660-664</span>CODEN:
                <span class="NLM_cas:coden">APJTC7</span>;
        ISSN:<span class="NLM_cas:issn">2221-1691</span>.
    
            (<span class="NLM_cas:orgname">Asian Pacific Tropical Medicine Press</span>)
        </div><div class="casAbstract">A review.  Harmine, a beta-carboline alkaloid, is widely distributed in the plants, marine creatures, insects, mammalians as well as in human tissues and body fluids.  Harmine was originally isolated from seeds of Peganum harmal in 1847 having a core indole structure and a pyridine ring.  Harmine has various types of pharmacol. activities such as antimicrobial, antifungal, antitumor, cytotoxic, antiplasmodial, antioxidant, antimutagenic, antigenotoxic and hallucinogenic properties.  It acts on gamma-aminobutyric acid type A and monoamine oxidase A or B receptor, enhances insulin sensitivity and also produces vasorelaxant effect.  Harmine prevents bone loss by suppressing osteoclastogenesis.  The current review gives an overview on pharmacol. activity and anal. techniques of harmine, which may be useful for researchers to explore the hidden potential of harmine and will also help in developing new drugs for the treatment of various diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphYIg7jC3SRrVg90H21EOLACvtfcHk0liuPGOk_Wmg3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ent73E&md5=0faccc657b181ef34db4d839fa2487ef</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS2221-1691%2812%2960116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS2221-1691%252812%252960116-6%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DK.%26aulast%3DGadewar%26aufirst%3DM.%26aulast%3DTripathi%26aufirst%3DR.%26aulast%3DPrasad%26aufirst%3DS.%2BK.%26aulast%3DPatel%26aufirst%3DD.%2BK.%26atitle%3DA%2520review%2520on%2520medicinal%2520importance%252C%2520pharmacological%2520activity%2520and%2520bioanalytical%2520aspects%2520of%2520beta-carboline%2520alkaloid%2520%25E2%2580%2599%25E2%2580%2599Harmine%25E2%2580%2599%25E2%2580%2599%26jtitle%3DAsian%2520Pac.%2520J.%2520Trop.%2520Biomed.%26date%3D2012%26volume%3D2%26spage%3D660%26epage%3D664%26doi%3D10.1016%2FS2221-1691%2812%2960116-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Song, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kesuma, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, R. Z.</span><span> </span><span class="NLM_article-title">Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">317</span><span class="NLM_x">, </span> <span class="NLM_fpage">128</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2004.03.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.bbrc.2004.03.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=15047157" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisVKmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=317&publication_year=2004&pages=128-132&author=Y.+Songauthor=D.+Kesumaauthor=J.+Wangauthor=Y.+Dengauthor=J.+Duanauthor=J.+H.+Wangauthor=R.+Z.+Qi&title=Specific+inhibition+of+cyclin-dependent+kinases+and+cell+proliferation+by+harmine&doi=10.1016%2Fj.bbrc.2004.03.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine</span></div><div class="casAuthors">Song, Yongcheng; Kesuma, Djohan; Wang, Jian; Deng, Yu; Duan, Jinao; Wang, Jerry H.; Qi, Robert Z.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">317</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">128-132</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science</span>)
        </div><div class="casAbstract">As key regulators of the cell proliferation cycle, cyclin-dependent kinases (CDKs) are attractive targets for the development of anti-tumor drugs.  In the present study, harmine was identified from a collection of herbal compds. to be a specific inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, and Cdk5/p25 with IC50 values at low micromoles.  It displayed little effect on other serine/threonine and tyrosine kinases tested.  The CDK inhibition by harmine is competitive with ATP-Mg2+, suggesting that it binds to the ATP-Mg2+-binding pocket of CDKs.  In cytotoxicity assays, harmine exhibited a strong inhibitory effect on the growth and proliferation of carcinoma cells whereas it had no significant effect on quiescent fibroblasts.  Further, harmine was found to block DNA replication in the carcinoma cells.  Taken together, harmine is a selective inhibitor of CDKs and cell proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9drfO7NpUHrVg90H21EOLACvtfcHk0lig6qpc086s7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisVKmt74%253D&md5=1a88a183ab790612a3e4c3d7c147eca6</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2004.03.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2004.03.019%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKesuma%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%2BH.%26aulast%3DQi%26aufirst%3DR.%2BZ.%26atitle%3DSpecific%2520inhibition%2520of%2520cyclin-dependent%2520kinases%2520and%2520cell%2520proliferation%2520by%2520harmine%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D317%26spage%3D128%26epage%3D132%26doi%3D10.1016%2Fj.bbrc.2004.03.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Frédérick, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruyère, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vancraeynest, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reniers, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinguet, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pochet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backlund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masereel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wouters, J.</span><span> </span><span class="NLM_article-title">Novel trisubstituted harmine derivatives with original in vitro anticancer activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6489</span><span class="NLM_x">–</span> <span class="NLM_lpage">6501</span><span class="refDoi"> DOI: 10.1021/jm300542e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300542e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6489-6501&author=R.+Fr%C3%A9d%C3%A9rickauthor=C.+Bruy%C3%A8reauthor=C.+Vancraeynestauthor=J.+Reniersauthor=C.+Meinguetauthor=L.+Pochetauthor=A.+Backlundauthor=B.+Masereelauthor=R.+Kissauthor=J.+Wouters&title=Novel+trisubstituted+harmine+derivatives+with+original+in+vitro+anticancer+activity&doi=10.1021%2Fjm300542e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1021%2Fjm300542e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300542e%26sid%3Dliteratum%253Aachs%26aulast%3DFr%25C3%25A9d%25C3%25A9rick%26aufirst%3DR.%26aulast%3DBruy%25C3%25A8re%26aufirst%3DC.%26aulast%3DVancraeynest%26aufirst%3DC.%26aulast%3DReniers%26aufirst%3DJ.%26aulast%3DMeinguet%26aufirst%3DC.%26aulast%3DPochet%26aufirst%3DL.%26aulast%3DBacklund%26aufirst%3DA.%26aulast%3DMasereel%26aufirst%3DB.%26aulast%3DKiss%26aufirst%3DR.%26aulast%3DWouters%26aufirst%3DJ.%26atitle%3DNovel%2520trisubstituted%2520harmine%2520derivatives%2520with%2520original%2520in%2520vitro%2520anticancer%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6489%26epage%3D6501%26doi%3D10.1021%2Fjm300542e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baudy-Floc’h, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ju, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S.</span><span> </span><span class="NLM_article-title">Synthesis and cytotoxic activities of beta-carboline amino acid ester conjugates</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">6998</span><span class="NLM_x">–</span> <span class="NLM_lpage">7010</span><span class="refDoi"> DOI: 10.1016/j.bmc.2006.06.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.bmc.2006.06.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=6998-7010&author=M.+Zhaoauthor=L.+Biauthor=W.+Wangauthor=C.+Wangauthor=M.+Baudy-Floc%E2%80%99hauthor=J.+Juauthor=S.+Peng&title=Synthesis+and+cytotoxic+activities+of+beta-carboline+amino+acid+ester+conjugates&doi=10.1016%2Fj.bmc.2006.06.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.06.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.06.021%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DBi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DBaudy-Floc%25E2%2580%2599h%26aufirst%3DM.%26aulast%3DJu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520cytotoxic%2520activities%2520of%2520beta-carboline%2520amino%2520acid%2520ester%2520conjugates%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D6998%26epage%3D7010%26doi%3D10.1016%2Fj.bmc.2006.06.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">He, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liao, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, R. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, L. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, Z. W.</span><span> </span><span class="NLM_article-title">Ruthenium-arene-beta-carboline complexes as potent inhibitors of cyclin-dependent kinase 1: synthesis, characterization and anticancer mechanism studies</span> <span class="citation_source-journal">Chem. - Eur. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">12152</span><span class="NLM_x">–</span> <span class="NLM_lpage">12160</span><span class="refDoi"> DOI: 10.1002/chem.201301389</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1002%2Fchem.201301389" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=23878093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=12152-12160&author=L.+Heauthor=S.+Y.+Liaoauthor=C.+P.+Tanauthor=R.+R.+Yeauthor=Y.+W.+Xuauthor=M.+Zhaoauthor=L.+N.+Jiauthor=Z.+W.+Mao&title=Ruthenium-arene-beta-carboline+complexes+as+potent+inhibitors+of+cyclin-dependent+kinase+1%3A+synthesis%2C+characterization+and+anticancer+mechanism+studies&doi=10.1002%2Fchem.201301389"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Ruthenium-Arene-β-Carboline Complexes as Potent Inhibitors of Cyclin-Dependent Kinase 1: Synthesis, Characterization and Anticancer Mechanism Studies</span></div><div class="casAuthors">He, Liang; Liao, Si-Yan; Tan, Cai-Ping; Ye, Rui-Rong; Xu, Yu-Wen; Zhao, Meng; Ji, Liang-Nian; Mao, Zong-Wan</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - A European Journal</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">12152-12160</span>CODEN:
                <span class="NLM_cas:coden">CEUJED</span>;
        ISSN:<span class="NLM_cas:issn">0947-6539</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Ru(II)-arene complexes, [(η6-arene)Ru(L)Cl]PF6 (1-6, arene = benzene or p-cymene; L = bidentate β-carboline deriv., an indole alkaloid with potential cyclin-dependent kinases (CDKs) inhibitory activities), are prepd. from [(η6-arene)RuCl2]2 and L.  All the complexes were fully characterized by classical anal. methods, and three were characterized by x-ray crystallog.  Hydrolytic studies show that β-carboline ligands play a vital role in their aq. behavior.  These complexes are highly active in vitro, with the most active complex 6 displaying a 3-12-fold higher anticancer activity than cisplatin against several cancer cell lines.  The complexes are able to overcome cross-resistance to cisplatin, and show much lower cytotoxicity against normal cells.  Complexes 1-6 may directly target CDK1, because they can block cells in the G2M phase, down-regulate the expression of CDK1 and cyclin B1, and inhibit CDK1/cyclin B in vitro.  Further mechanism studies show that the complexes can effectively induce apoptosis through mitochondrial-related pathways and intracellular reactive O species (ROS) elevation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6h10BlYuFK7Vg90H21EOLACvtfcHk0lig6qpc086s7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjtbnK&md5=fb2b63894c4f96209d60c1b4e8266e9a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fchem.201301389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fchem.201301389%26sid%3Dliteratum%253Aachs%26aulast%3DHe%26aufirst%3DL.%26aulast%3DLiao%26aufirst%3DS.%2BY.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DYe%26aufirst%3DR.%2BR.%26aulast%3DXu%26aufirst%3DY.%2BW.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DJi%26aufirst%3DL.%2BN.%26aulast%3DMao%26aufirst%3DZ.%2BW.%26atitle%3DRuthenium-arene-beta-carboline%2520complexes%2520as%2520potent%2520inhibitors%2520of%2520cyclin-dependent%2520kinase%25201%253A%2520synthesis%252C%2520characterization%2520and%2520anticancer%2520mechanism%2520studies%26jtitle%3DChem.%2520-%2520Eur.%2520J.%26date%3D2013%26volume%3D19%26spage%3D12152%26epage%3D12160%26doi%3D10.1002%2Fchem.201301389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Han, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Si, S.</span><span> </span><span class="NLM_article-title">A series of beta-carboline derivatives inhibit the kinase activity of PLKs</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e46546</span><span class="refDoi"> DOI: 10.1371/journal.pone.0046546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1371%2Fjournal.pone.0046546" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e46546&author=X.+Hanauthor=J.+Zhangauthor=L.+Guoauthor=R.+Caoauthor=Y.+Liauthor=N.+Liauthor=Q.+Maauthor=J.+Wuauthor=Y.+Wangauthor=S.+Si&title=A+series+of+beta-carboline+derivatives+inhibit+the+kinase+activity+of+PLKs&doi=10.1371%2Fjournal.pone.0046546"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0046546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0046546%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DS.%26atitle%3DA%2520series%2520of%2520beta-carboline%2520derivatives%2520inhibit%2520the%2520kinase%2520activity%2520of%2520PLKs%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De46546%26doi%3D10.1371%2Fjournal.pone.0046546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Herraiz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzalez, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ancin-Azpilicueta, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aran, V. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guillen, H.</span><span> </span><span class="NLM_article-title">beta-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)</span> <span class="citation_source-journal">Food Chem. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">845</span><span class="refDoi"> DOI: 10.1016/j.fct.2009.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.fct.2009.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20036304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXit1OrtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2010&pages=839-845&author=T.+Herraizauthor=D.+Gonzalezauthor=C.+Ancin-Azpilicuetaauthor=V.+J.+Aranauthor=H.+Guillen&title=beta-Carboline+alkaloids+in+Peganum+harmala+and+inhibition+of+human+monoamine+oxidase+%28MAO%29&doi=10.1016%2Fj.fct.2009.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">β-Carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO)</span></div><div class="casAuthors">Herraiz, T.; Gonzalez, D.; Ancin-Azpilicueta, C.; Aran, V. J.; Guillen, H.</div><div class="citationInfo"><span class="NLM_cas:title">Food and Chemical Toxicology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-845</span>CODEN:
                <span class="NLM_cas:coden">FCTOD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-6915</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Peganum harmala L. is a multipurpose medicinal plant increasingly used for psychoactive recreational purposes (Ayahuasca analog).  Harmaline, harmine, harmalol, harmol, and tetrahydroharmine were identified and quantified as the main β-carboline alkaloids in P. harmala exts.  Seeds and roots contained the highest levels of alkaloids with low levels in stems and leaves, and absence in flowers.  Harmine and harmaline accumulated in dry seeds at 4.3 and 5.6% (wt./wt.), resp., harmalol at 0.6%, and tetrahydroharmine at 0.1% (wt./wt.).  Roots contained harmine and harmol with 2.0 and 1.4% (wt./wt.), resp.  Seed exts. were potent reversible and competitive inhibitors of human monoamine oxidase (MAO-A) with an IC50 of 27 μg/l whereas root exts. strongly inhibited MAO-A with an IC50 of 159 μg/l.  In contrast, they were poor inhibitors of MAO-B.  Inhibition of MAO-A by seed exts. was quant. attributed to harmaline and harmine whereas inhibition by root exts. came from harmine with no addnl. interferences.  Stems and leaves exts. were poor inhibitors of MAO.  The potent inhibition of MAO-A by seed and root exts. of P. harmala contg. β-carbolines should contribute to the psychopharmacol. and toxicol. effects of this plant and could be the basis for its purported antidepressant actions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj_9T1Mqk4U7Vg90H21EOLACvtfcHk0ljYjZixEw4NLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXit1OrtLk%253D&md5=34d13b816d538df99ff19d421ec22519</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.fct.2009.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.fct.2009.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DHerraiz%26aufirst%3DT.%26aulast%3DGonzalez%26aufirst%3DD.%26aulast%3DAncin-Azpilicueta%26aufirst%3DC.%26aulast%3DAran%26aufirst%3DV.%2BJ.%26aulast%3DGuillen%26aufirst%3DH.%26atitle%3Dbeta-Carboline%2520alkaloids%2520in%2520Peganum%2520harmala%2520and%2520inhibition%2520of%2520human%2520monoamine%2520oxidase%2520%2528MAO%2529%26jtitle%3DFood%2520Chem.%2520Toxicol.%26date%3D2010%26volume%3D48%26spage%3D839%26epage%3D845%26doi%3D10.1016%2Fj.fct.2009.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kamal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narasimha Rao, M. P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swapna, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Srinivasulu, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagul, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaik, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullagiri, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovvuri, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, V. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidyasagar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagesh, N.</span><span> </span><span class="NLM_article-title">Synthesis of beta-carboline-benzimidazole conjugates using lanthanum nitrate as a catalyst and their biological evaluation</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2370</span><span class="NLM_x">–</span> <span class="NLM_lpage">2387</span><span class="refDoi"> DOI: 10.1039/c3ob42236d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1039%2Fc3ob42236d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2014&pages=2370-2387&author=A.+Kamalauthor=M.+P.+N.+Narasimha+Raoauthor=P.+Swapnaauthor=V.+Srinivasuluauthor=C.+Bagulauthor=A.+B.+Shaikauthor=K.+Mullagiriauthor=J.+Kovvuriauthor=V.+S.+Reddyauthor=K.+Vidyasagarauthor=N.+Nagesh&title=Synthesis+of+beta-carboline-benzimidazole+conjugates+using+lanthanum+nitrate+as+a+catalyst+and+their+biological+evaluation&doi=10.1039%2Fc3ob42236d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1039%2Fc3ob42236d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc3ob42236d%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DA.%26aulast%3DNarasimha%2BRao%26aufirst%3DM.%2BP.%2BN.%26aulast%3DSwapna%26aufirst%3DP.%26aulast%3DSrinivasulu%26aufirst%3DV.%26aulast%3DBagul%26aufirst%3DC.%26aulast%3DShaik%26aufirst%3DA.%2BB.%26aulast%3DMullagiri%26aufirst%3DK.%26aulast%3DKovvuri%26aufirst%3DJ.%26aulast%3DReddy%26aufirst%3DV.%2BS.%26aulast%3DVidyasagar%26aufirst%3DK.%26aulast%3DNagesh%26aufirst%3DN.%26atitle%3DSynthesis%2520of%2520beta-carboline-benzimidazole%2520conjugates%2520using%2520lanthanum%2520nitrate%2520as%2520a%2520catalyst%2520and%2520their%2520biological%2520evaluation%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2014%26volume%3D12%26spage%3D2370%26epage%3D2387%26doi%3D10.1039%2Fc3ob42236d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Wu, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris-Natschke, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. Q.</span><span> </span><span class="NLM_article-title">Novel N-(3-carboxyl-9-benzyl-beta-carboline-1-yl)ethylamino acids: Synthesis, anti-tumor evaluation, intercalating determination, 3D QSAR analysis and docking investigation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">4153</span><span class="NLM_x">–</span> <span class="NLM_lpage">4161</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2009.05.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.ejmech.2009.05.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2009&pages=4153-4161&author=J.+H.+Wuauthor=M.+Zhaoauthor=K.+D.+Qianauthor=K.+H.+Leeauthor=S.+Morris-Natschkeauthor=S.+Q.+Peng&title=Novel+N-%283-carboxyl-9-benzyl-beta-carboline-1-yl%29ethylamino+acids%3A+Synthesis%2C+anti-tumor+evaluation%2C+intercalating+determination%2C+3D+QSAR+analysis+and+docking+investigation&doi=10.1016%2Fj.ejmech.2009.05.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2009.05.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2009.05.006%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%2BH.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DQian%26aufirst%3DK.%2BD.%26aulast%3DLee%26aufirst%3DK.%2BH.%26aulast%3DMorris-Natschke%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BQ.%26atitle%3DNovel%2520N-%25283-carboxyl-9-benzyl-beta-carboline-1-yl%2529ethylamino%2520acids%253A%2520Synthesis%252C%2520anti-tumor%2520evaluation%252C%2520intercalating%2520determination%252C%25203D%2520QSAR%2520analysis%2520and%2520docking%2520investigation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2009%26volume%3D44%26spage%3D4153%26epage%3D4161%26doi%3D10.1016%2Fj.ejmech.2009.05.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Sobhani, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebrahimi, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mahmoudian, M.</span><span> </span><span class="NLM_article-title">An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids</span> <span class="citation_source-journal">J. Pharm. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">19</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=12042115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BD38zhs1antw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2002&pages=19-23&author=A.+M.+Sobhaniauthor=S.+A.+Ebrahimiauthor=M.+Mahmoudian&title=An+in+vitro+evaluation+of+human+DNA+topoisomerase+I+inhibition+by+Peganum+harmala+L.+seeds+extract+and+its+beta-carboline+alkaloids"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids</span></div><div class="casAuthors">Sobhani Armin Madadkar; Ebrahimi Sultan-Ahmad; Mahmoudian Massoud</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-23</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Peganum harmala L. (Zygophyllaceae) seeds extract is one of the main components of an ethnobotanical preparation used in the treatment of neoplasms in Iran.  Cytotoxic effects of P. harmala extract on cancerous cell-lines have been reported before. beta-carbolines like harmaline and harmine are the major alkaloids present in the seeds of the P. harmala.  Considering reports concerning DNA topoisomerase inhibition by other beta-carbolines like harmane, we have used DNA relaxation assays to investigate topoisomerase I inhibitory activity of P. harmala seeds extract and its beta-carboline alkaloids to further inspecting the mechanism of its cytotoxic activity.  METHODS:  Harmine and harmaline contents of the extract were determined using an HPTLC method.  DNA topoisomerase I enzyme needed for investigating inhibitory effect of the compounds using DNA relaxation assay, was partially purified from the human placenta.  DNA relaxation assay is based on the conversion of a supercoiled plasmid substrate to its relaxed form by the catalytic activity of the enzyme.  The supercoiled substrate and its relaxed product can be easily distinguished using agarose gel electrophoresis, since the relaxed topological isomers of DNA migrate more slowly than supercoiled species.  RESULTS:  Using HPTLC method, it was found that each gram of dried extract contained 55.5 and 79.0 mg of harmine and harmaline respectively.  In the DNA relaxation assay, order of potency was harmine > harmane > harmaline > extract.  The most active compound was harmine with IC50 value of 13.5 +/- 1.7 microg/ml.  CONCLUSIONS:  Our in vitro findings demonstrate that P. harmala seeds extract do inhibit human DNA topoisomerase I and based on the results of HPTLC analysis, it appears that the biological activity of the extract can be explained by its beta-carboline content.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTco1bQOg25AENHe_gFldTbfW6udTcc2eb3zMOQYjKQYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38zhs1antw%253D%253D&md5=9a28f3bbbc901f48c665505be4e98b2a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSobhani%26aufirst%3DA.%2BM.%26aulast%3DEbrahimi%26aufirst%3DS.%2BA.%26aulast%3DMahmoudian%26aufirst%3DM.%26atitle%3DAn%2520in%2520vitro%2520evaluation%2520of%2520human%2520DNA%2520topoisomerase%2520I%2520inhibition%2520by%2520Peganum%2520harmala%2520L.%2520seeds%2520extract%2520and%2520its%2520beta-carboline%2520alkaloids%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2002%26volume%3D5%26spage%3D19%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yang, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, E.</span><span> </span><span class="NLM_article-title">HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5310</span><span class="NLM_x">–</span> <span class="NLM_lpage">5318</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2Fsj.onc.1210599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=17694074" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFekurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5310-5318&author=X.+J.+Yangauthor=E.+Seto&title=HATs+and+HDACs%3A+from+structure%2C+function+and+regulation+to+novel+strategies+for+therapy+and+prevention&doi=10.1038%2Fsj.onc.1210599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention</span></div><div class="casAuthors">Yang, X.-J.; Seto, E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5310-5318</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The acetylation of the ε-NH2 group of a Lys residue was 1st discovered with histones in 1968, but the responsible enzymes, histone acetyltransferases (HATs) and histone deacetylases (HDACs), were not identified until the mid-1990s.  In the past decade, knowledge about this modification has exploded, with targets rapidly expanding from histones to transcription factors and other nuclear proteins, and then to the cytoskeleton, metabolic enzymes, and signaling regulators in the cytoplasm.  Thus, protein Lys acetylation has emerged as a major post-translational modification to rival phosphorylation.  Here, various aspects of the enzymes governing Lys acetylation, esp. about their intimate links to cancer are reviewed.  For central themes are highlighted: (1) multisubunit enzymic complexes; (2) non-histone substrates in diverse cellular processes; (3) interplay of Lys acetylation with other regulatory mechanisms, such as noncoding RNA-mediated gene silencing and activation; and (4) novel therapeutic strategies and preventive measures to combat cancer and other human diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuGSkc-b3umrVg90H21EOLACvtfcHk0liZpSFLUq_kRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFekurc%253D&md5=de49d71791356a55d90fd797cbecaf4b</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210599%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHATs%2520and%2520HDACs%253A%2520from%2520structure%252C%2520function%2520and%2520regulation%2520to%2520novel%2520strategies%2520for%2520therapy%2520and%2520prevention%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5310%26epage%3D5318%26doi%3D10.1038%2Fsj.onc.1210599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Gryder, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sodji, Q. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyelere, A. K.</span><span> </span><span class="NLM_article-title">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">505</span><span class="NLM_x">–</span> <span class="NLM_lpage">524</span><span class="refDoi"> DOI: 10.4155/fmc.12.3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.4155%2Ffmc.12.3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=22416777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=505-524&author=B.+E.+Gryderauthor=Q.+H.+Sodjiauthor=A.+K.+Oyelere&title=Targeted+cancer+therapy%3A+giving+histone+deacetylase+inhibitors+all+they+need+to+succeed&doi=10.4155%2Ffmc.12.3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed</span></div><div class="casAuthors">Gryder, Berkley E.; Sodji, Quaovi H.; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-524</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACis) have now emerged as a powerful new class of small-mol. therapeutics acting through the regulation of the acetylation states of histone proteins (a form of epigenetic modulation) and other non-histone protein targets.  Over 490 clin. trials have been initiated in the last 10 years, culminating in the approval of two structurally distinct HDACis-SAHA (vorinostat, Zolinza) and FK228 (romidepsin, Istodax).  However, the current HDACis have serious limitations, including ineffectively low concns. in solid tumors and cardiac toxicity, which is hindering their progress in the clinic.  Herein, we review the primary paradigms being pursued to overcome these hindrances, including HDAC isoform selectivity, localized administration, and targeting cap groups to achieve selective tissue and cell type distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWwrW1IVCIULVg90H21EOLACvtfcHk0liZpSFLUq_kRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktVajsL8%253D&md5=234080d1b0862680a68062a03afee20c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.4155%2Ffmc.12.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.12.3%26sid%3Dliteratum%253Aachs%26aulast%3DGryder%26aufirst%3DB.%2BE.%26aulast%3DSodji%26aufirst%3DQ.%2BH.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520cancer%2520therapy%253A%2520giving%2520histone%2520deacetylase%2520inhibitors%2520all%2520they%2520need%2520to%2520succeed%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D505%26epage%3D524%26doi%3D10.4155%2Ffmc.12.3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiloh, A.</span><span> </span><span class="NLM_article-title">Deacetylation of p53 modulates its effect on cell growth and apoptosis</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">377</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span><span class="refDoi"> DOI: 10.1038/35042612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2F35042612" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2000&pages=377-381&author=W.+Guauthor=J.+Luoauthor=F.+Suauthor=D.+Chenauthor=A.+Shiloh&title=Deacetylation+of+p53+modulates+its+effect+on+cell+growth+and+apoptosis&doi=10.1038%2F35042612"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2F35042612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35042612%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DW.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DShiloh%26aufirst%3DA.%26atitle%3DDeacetylation%2520of%2520p53%2520modulates%2520its%2520effect%2520on%2520cell%2520growth%2520and%2520apoptosis%26jtitle%3DNature%26date%3D2000%26volume%3D408%26spage%3D377%26epage%3D381%26doi%3D10.1038%2F35042612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Grant, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Easley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Vorinostat</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span><span class="refDoi"> DOI: 10.1038/nrd2227</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2Fnrd2227" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=17269160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=21-22&author=S.+Grantauthor=C.+Easleyauthor=P.+Kirkpatrick&title=Vorinostat&doi=10.1038%2Fnrd2227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat</span></div><div class="casAuthors">Grant, Steven; Easley, Chris; Kirkpatrick, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">21-22</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYtFgooxRrcbVg90H21EOLACvtfcHk0lgtqybPiitMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlGktbfK&md5=4017dcf775971088e24fca37e8a369af</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnrd2227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2227%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%26aulast%3DEasley%26aufirst%3DC.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DVorinostat%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D21%26epage%3D22%26doi%3D10.1038%2Fnrd2227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Grant, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piekarz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robey, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figg, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">997</span><span class="NLM_x">–</span> <span class="NLM_lpage">1008</span><span class="refDoi"> DOI: 10.1586/era.10.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1586%2Fera.10.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20645688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=997-1008&author=C.+Grantauthor=F.+Rahmanauthor=R.+Piekarzauthor=C.+Peerauthor=R.+Fryeauthor=R.+W.+Robeyauthor=E.+R.+Gardnerauthor=W.+D.+Figgauthor=S.+E.+Bates&title=Romidepsin%3A+a+new+therapy+for+cutaneous+T-cell+lymphoma+and+a+potential+therapy+for+solid+tumors&doi=10.1586%2Fera.10.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors</span></div><div class="casAuthors">Grant, Cliona; Rahman, Fahd; Piekarz, Richard; Peer, Cody; Frye, Robin; Robey, Robert W.; Gardner, Erin R.; Figg, William D.; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">997-1008</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL).  Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known.  Romidepsin induces long-lasting responses.  The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia.  Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients.  Electrocardiog. (ECG) changes are common but are not assocd. with myocardial damage.  When mol. end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was assocd. with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin.  Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhGXcIbdqpk7Vg90H21EOLACvtfcHk0lgtqybPiitMMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFWqs74%253D&md5=b28fd17c77991e4662f7c0e08d6d7297</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1586%2Fera.10.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252Fera.10.88%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DC.%26aulast%3DRahman%26aufirst%3DF.%26aulast%3DPiekarz%26aufirst%3DR.%26aulast%3DPeer%26aufirst%3DC.%26aulast%3DFrye%26aufirst%3DR.%26aulast%3DRobey%26aufirst%3DR.%2BW.%26aulast%3DGardner%26aufirst%3DE.%2BR.%26aulast%3DFigg%26aufirst%3DW.%2BD.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DRomidepsin%253A%2520a%2520new%2520therapy%2520for%2520cutaneous%2520T-cell%2520lymphoma%2520and%2520a%2520potential%2520therapy%2520for%2520solid%2520tumors%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2010%26volume%3D10%26spage%3D997%26epage%3D1008%26doi%3D10.1586%2Fera.10.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Rasheed, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnstone, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prince, H. M.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors in cancer therapy</span> <span class="citation_source-journal">Expert Opin. Invest. Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">659</span><span class="NLM_x">–</span> <span class="NLM_lpage">678</span><span class="refDoi"> DOI: 10.1517/13543784.16.5.659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1517%2F13543784.16.5.659" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2007&pages=659-678&author=W.+K.+Rasheedauthor=R.+W.+Johnstoneauthor=H.+M.+Prince&title=Histone+deacetylase+inhibitors+in+cancer+therapy&doi=10.1517%2F13543784.16.5.659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1517%2F13543784.16.5.659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.16.5.659%26sid%3Dliteratum%253Aachs%26aulast%3DRasheed%26aufirst%3DW.%2BK.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26aulast%3DPrince%26aufirst%3DH.%2BM.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520in%2520cancer%2520therapy%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2007%26volume%3D16%26spage%3D659%26epage%3D678%26doi%3D10.1517%2F13543784.16.5.659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Federico, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagella, L.</span><span> </span><span class="NLM_article-title">Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors</span> <span class="citation_source-journal">J. Biomed. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">475641</span><span class="refDoi"> DOI: 10.1155/2011/475641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1155%2F2011%2F475641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21188171" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BC3M%252FntFOmsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=475641&author=M.+Federicoauthor=L.+Bagella&title=Histone+deacetylase+inhibitors+in+the+treatment+of+hematological+malignancies+and+solid+tumors&doi=10.1155%2F2011%2F475641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors</span></div><div class="casAuthors">Federico Mario; Bagella Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">475641</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA.  In cancer, many of the proteins that regulate these modifications can be altered in both function and expression.  One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure.  HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators.  Given this, small molecule histone deacetylases inhibitors have been identified and developed, which not only inhibit HDACs, but can also lead to growth arrest, differentiation, and/or apoptosis in tumors both in vitro and in vivo.  Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRrrh0JvwMO6N0Q2ypr7jHkfW6udTcc2eaKws339tZkv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M%252FntFOmsA%253D%253D&md5=7e5af080ec475c293041fec4ecea6721</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1155%2F2011%2F475641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F475641%26sid%3Dliteratum%253Aachs%26aulast%3DFederico%26aufirst%3DM.%26aulast%3DBagella%26aufirst%3DL.%26atitle%3DHistone%2520deacetylase%2520inhibitors%2520in%2520the%2520treatment%2520of%2520hematological%2520malignancies%2520and%2520solid%2520tumors%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D475641%26doi%3D10.1155%2F2011%2F475641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrillo, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, D.</span><span> </span><span class="NLM_article-title">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span> <span class="citation_source-journal">J. Hematol. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="refDoi"> DOI: 10.1186/1756-8722-3-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1186%2F1756-8722-3-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20132536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2010&pages=5&author=J.+Tanauthor=S.+Cangauthor=Y.+Maauthor=R.+L.+Petrilloauthor=D.+Liu&title=Novel+histone+deacetylase+inhibitors+in+clinical+trials+as+anti-cancer+agents&doi=10.1186%2F1756-8722-3-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents</span></div><div class="casAuthors">Tan Jiahuai; Cang Shundong; Ma Yuehua; Petrillo Richard L; Liu Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of hematology & oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) can regulate expression of tumor suppressor genes and activities of transcriptional factors involved in both cancer initiation and progression through alteration of either DNA or the structural components of chromatin.  Recently, the role of gene repression through modulation such as acetylation in cancer patients has been clinically validated with several inhibitors of HDACs.  One of the HDAC inhibitors, vorinostat, has been approved by FDA for treating cutaneous T-cell lymphoma (CTCL) for patients with progressive, persistent, or recurrent disease on or following two systemic therapies.  Other inhibitors, for example, FK228, PXD101, PCI-24781, ITF2357, MGCD0103, MS-275, valproic acid and LBH589 have also demonstrated therapeutic potential as monotherapy or combination with other anti-tumor drugs in CTCL and other malignancies.  At least 80 clinical trials are underway, testing more than eleven different HDAC inhibitory agents including both hematological and solid malignancies.  This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQnASThrmiLG50d-O_J5C0AfW6udTcc2eaKws339tZkv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3c7jtFejtg%253D%253D&md5=399a6c058fd597450221aff2648d8c0f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-3-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-3-5%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DCang%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DPetrillo%26aufirst%3DR.%2BL.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DNovel%2520histone%2520deacetylase%2520inhibitors%2520in%2520clinical%2520trials%2520as%2520anti-cancer%2520agents%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2010%26volume%3D3%26spage%3D5%26doi%3D10.1186%2F1756-8722-3-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Thompson, C. A.</span><span> </span><span class="NLM_article-title">Belinostat approved for use in treating rare lymphoma</span> <span class="citation_source-journal">Am. J. Health-Syst. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">1328</span><span class="refDoi"> DOI: 10.2146/news140056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.2146%2Fnews140056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=25074945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A280%3ADC%252BC2cbntlSqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=1328&author=C.+A.+Thompson&title=Belinostat+approved+for+use+in+treating+rare+lymphoma&doi=10.2146%2Fnews140056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Belinostat approved for use in treating rare lymphoma</span></div><div class="casAuthors">Thompson Cheryl A</div><div class="citationInfo"><span class="NLM_cas:title">American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1328</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_oWMFZOhhR4USrryheKE6fW6udTcc2eaKws339tZkv7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cbntlSqtg%253D%253D&md5=1a2a66024cd82c736bfbb1d284447ac6</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.2146%2Fnews140056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2146%252Fnews140056%26sid%3Dliteratum%253Aachs%26aulast%3DThompson%26aufirst%3DC.%2BA.%26atitle%3DBelinostat%2520approved%2520for%2520use%2520in%2520treating%2520rare%2520lymphoma%26jtitle%3DAm.%2520J.%2520Health-Syst.%2520Pharm.%26date%3D2014%26volume%3D71%26spage%3D1328%26doi%3D10.2146%2Fnews140056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Garnock-Jones, K. P.</span><span> </span><span class="NLM_article-title">Panobinostat: first global approval</span> <span class="citation_source-journal">Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">75</span><span class="NLM_x">, </span> <span class="NLM_fpage">695</span><span class="NLM_x">–</span> <span class="NLM_lpage">704</span><span class="refDoi"> DOI: 10.1007/s40265-015-0388-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs40265-015-0388-8" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=695-704&author=K.+P.+Garnock-Jones&title=Panobinostat%3A+first+global+approval&doi=10.1007%2Fs40265-015-0388-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1007%2Fs40265-015-0388-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-015-0388-8%26sid%3Dliteratum%253Aachs%26aulast%3DGarnock-Jones%26aufirst%3DK.%2BP.%26atitle%3DPanobinostat%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2015%26volume%3D75%26spage%3D695%26epage%3D704%26doi%3D10.1007%2Fs40265-015-0388-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Gu, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dou, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, Z.</span><span> </span><span class="NLM_article-title">Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application</span> <span class="citation_source-journal">J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1000</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">186</span><span class="refDoi"> DOI: 10.1016/j.jchromb.2015.07.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.jchromb.2015.07.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=26245362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1OqurbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1000&publication_year=2015&pages=181-186&author=R.+Guauthor=T.+Liuauthor=X.+Zhuauthor=H.+Ganauthor=Z.+Wuauthor=J.+Liauthor=Y.+Zhengauthor=G.+Douauthor=Z.+Meng&title=Development+and+validation+of+a+sensitive+HPLC-MS%2FMS+method+for+determination+of+chidamide+%28epidaza%29%2C+a+new+benzamide+class+of+selective+histone+deacetylase+inhibitor%2C+in+human+plasma+and+its+clinical+application&doi=10.1016%2Fj.jchromb.2015.07.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application</span></div><div class="casAuthors">Gu, Ruolan; Liu, Taoyun; Zhu, Xiaoxia; Gan, Hui; Wu, Zhuona; Li, Jian; Zheng, Ying; Dou, Guifang; Meng, Zhiyun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1000</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-186</span>CODEN:
                <span class="NLM_cas:coden">JCBAAI</span>;
        ISSN:<span class="NLM_cas:issn">1570-0232</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Chidamide (epidaza), a new oral isotype-selective histone deacetylase inhibitor (HDACi), which is just approved in China for the treatment of recurrent or refractory peripheral T-cell lymphoma (PTCL) in Dec. 2014, is the first listed benzamide class of HDACi in the world, and is currently undergoing global clin. trials for solid tumor treatments.  Here, we report a sensitive, rapid and robust HPLC-MS/MS method for detn. of chidamide in human plasma.  Plasma sample was subjected to a simple acetonitrile protein pptn. contg. MS-275 used as an internal std. (IS).  Chromatog. was performed on a Hypersil GOLD C18 anal. column, using a gradient methanol/water mobile phase contg. 0.1% formic acid.  A tandem mass spectrometer equipped with electrospray ionization source was used as detector and operated in the pos.-ion mode.  Selected reaction monitoring (SRM) using the precursor/ product transitions (m/z) of 391.1/265.1 for chidamide and 377.1/359.2 for IS were used for quantification, resp.  Good linearity was obtained in the range of 1-1000 ng/mL.  The method gave R.  S. D.% values for precision always lower than 13.8% and R.  E.% values for accuracy between -3.7 and 9.1%.  In addn., the specificity, recovery, stability and matrix effect were satisfactory too.  The method is now being successfully applied to plasma samples as part of an ongoing chidamide phase Ib clin. trial in patients with solid tumors, and had demonstrated consistent AUClast and t1/2 results with the published phase I pharmacokinetic data, which was also analyzed by this method, thus further confirming the reproducibility and accuracy during its clin. application.  Considering the excellent performance of this method, it will continue being utilized for future clin. developments of chidamide and for routine monitoring of plasma exposure of chidamide during its clin. therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriZ_cSIXuX6rVg90H21EOLACvtfcHk0liIKdVlYEDMCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1OqurbN&md5=bbb4b8ad71146c3909db9f30be705645</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.jchromb.2015.07.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jchromb.2015.07.001%26sid%3Dliteratum%253Aachs%26aulast%3DGu%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DGan%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DDou%26aufirst%3DG.%26aulast%3DMeng%26aufirst%3DZ.%26atitle%3DDevelopment%2520and%2520validation%2520of%2520a%2520sensitive%2520HPLC-MS%252FMS%2520method%2520for%2520determination%2520of%2520chidamide%2520%2528epidaza%2529%252C%2520a%2520new%2520benzamide%2520class%2520of%2520selective%2520histone%2520deacetylase%2520inhibitor%252C%2520in%2520human%2520plasma%2520and%2520its%2520clinical%2520application%26jtitle%3DJ.%2520Chromatogr.%2520B%253A%2520Anal.%2520Technol.%2520Biomed.%2520Life%2520Sci.%26date%3D2015%26volume%3D1000%26spage%3D181%26epage%3D186%26doi%3D10.1016%2Fj.jchromb.2015.07.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Thurn, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munster, P. N.</span><span> </span><span class="NLM_article-title">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span> <span class="citation_source-journal">Future Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span><span class="refDoi"> DOI: 10.2217/fon.11.2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.2217%2Ffon.11.2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21345145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=263-283&author=K.+T.+Thurnauthor=S.+Thomasauthor=A.+Mooreauthor=P.+N.+Munster&title=Rational+therapeutic+combinations+with+histone+deacetylase+inhibitors+for+the+treatment+of+cancer&doi=10.2217%2Ffon.11.2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer</span></div><div class="casAuthors">Thurn, K. Ted; Thomas, Scott; Moore, Amy; Munster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Future Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">263-283</span>CODEN:
                <span class="NLM_cas:coden">FOUNBN</span>;
        ISSN:<span class="NLM_cas:issn">1479-6694</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) regulate the acetylation of a variety of histone and nonhistone proteins, controlling the transcription and regulation of genes involved in cell cycle control, proliferation, survival, DNA repair and differentiation.  Unsurprisingly, HDAC expression is frequently altered in hematol. and solid tumor malignancies.  Two HDAC inhibitors (vorinostat and romidepsin) have been approved by the US FDA for the treatment of cutaneous T-cell lymphoma.  As single agents, treatment with HDAC inhibitors has demonstrated limited clin. benefit for patients with solid tumors, prompting the investigation of novel treatment combinations with other cancer therapeutics.  In this article, the rationales and clin. progress of several combinations with HDAC inhibitors are presented, including DNA-damaging chemotherapeutic agents, radiotherapy, hormonal therapies, DNA methyltransferase inhibitors and various small-mol. inhibitors.  The future application of HDAC inhibitors as a treatment for cancer is discussed, examg. current hurdles to overcome before realizing the potential of this new approach.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqn7EKQGlvu_LVg90H21EOLACvtfcHk0ljF07d_b4USSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXisVWlurs%253D&md5=193fc07f4e19bf16fcd7ee202057ef7c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2217%2Ffon.11.2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffon.11.2%26sid%3Dliteratum%253Aachs%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DRational%2520therapeutic%2520combinations%2520with%2520histone%2520deacetylase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DFuture%2520Oncol.%26date%3D2011%26volume%3D7%26spage%3D263%26epage%3D283%26doi%3D10.2217%2Ffon.11.2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Munster, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurn, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raha, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lacevic, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melisko, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail-Khan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rugo, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moasser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minton, S. E.</span><span> </span><span class="NLM_article-title">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1828</span><span class="NLM_x">–</span> <span class="NLM_lpage">1835</span><span class="refDoi"> DOI: 10.1038/bjc.2011.156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1038%2Fbjc.2011.156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21559012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2011&pages=1828-1835&author=P.+N.+Munsterauthor=K.+T.+Thurnauthor=S.+Thomasauthor=P.+Rahaauthor=M.+Lacevicauthor=A.+Millerauthor=M.+Meliskoauthor=R.+Ismail-Khanauthor=H.+Rugoauthor=M.+Moasserauthor=S.+E.+Minton&title=A+phase+II+study+of+the+histone+deacetylase+inhibitor+vorinostat+combined+with+tamoxifen+for+the+treatment+of+patients+with+hormone+therapy-resistant+breast+cancer&doi=10.1038%2Fbjc.2011.156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer</span></div><div class="casAuthors">Munster, P. N.; Thurn, K. T.; Thomas, S.; Raha, P.; Lacevic, M.; Miller, A.; Melisko, M.; Ismail-Khan, R.; Rugo, H.; Moasser, M.; Minton, S. E.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1828-1835</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crucial components of the estrogen receptor (ER) transcriptional complex.  Preclinically, HDAC inhibitors can reverse tamoxifen/aromatase inhibitor resistance in hormone receptor-pos. breast cancer.  This concept was examd. in a phase II combination trial with correlative end points.  Patients with ER-pos. metastatic breast cancer progressing on endocrine therapy were treated with 400 mg of vorinostat daily for 3 of 4 wk and 20 mg tamoxifen daily, continuously.  Histone acetylation and HDAC2 expression in peripheral blood mononuclear cells were also evaluated.  In all, 43 patients (median age 56 years (31-71)) were treated, 25 (58%) received prior adjuvant tamoxifen, 29 (67%) failed one prior chemotherapy regimen, 42 (98%) progressed after one, and 23 (54%) after two aromatase inhibitors.  The objective response rate by Response Evaluation Criteria in Solid Tumors criteria was 19% and the clin. benefit rate (response or stable disease >24 wk) was 40%.  The median response duration was 10.3 mo (confidence interval: 8.1-12.4).  Histone hyperacetylation and higher baseline HDAC2 levels correlated with response.  The combination of vorinostat and tamoxifen is well tolerated and exhibits encouraging activity in reversing hormone resistance.  Correlative studies suggest that HDAC2 expression is a predictive marker and histone hyperacetylation is a useful pharmacodynamic marker for the efficacy of this combination.  British Journal of Cancer (2011) 104, 1828-1835; doi:10.1038/bjc.2011.156 www.bjcancer.com Published online 10 May 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDPB1YAqSmBLVg90H21EOLACvtfcHk0ljF07d_b4USSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXntV2hsbg%253D&md5=15e2afd6a1b658f378e4f41ed2b15ef9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.156%26sid%3Dliteratum%253Aachs%26aulast%3DMunster%26aufirst%3DP.%2BN.%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DRaha%26aufirst%3DP.%26aulast%3DLacevic%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DA.%26aulast%3DMelisko%26aufirst%3DM.%26aulast%3DIsmail-Khan%26aufirst%3DR.%26aulast%3DRugo%26aufirst%3DH.%26aulast%3DMoasser%26aufirst%3DM.%26aulast%3DMinton%26aufirst%3DS.%2BE.%26atitle%3DA%2520phase%2520II%2520study%2520of%2520the%2520histone%2520deacetylase%2520inhibitor%2520vorinostat%2520combined%2520with%2520tamoxifen%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520hormone%2520therapy-resistant%2520breast%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2011%26volume%3D104%26spage%3D1828%26epage%3D1835%26doi%3D10.1038%2Fbjc.2011.156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Thomas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thurn, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bicaku, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marchion, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munster, P. N.</span><span> </span><span class="NLM_article-title">Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy</span> <span class="citation_source-journal">Breast Cancer Res. Treat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">437</span><span class="NLM_x">–</span> <span class="NLM_lpage">447</span><span class="refDoi"> DOI: 10.1007/s10549-011-1364-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs10549-011-1364-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=21298336" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1yktL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2011&pages=437-447&author=S.+Thomasauthor=K.+T.+Thurnauthor=E.+Bicakuauthor=D.+C.+Marchionauthor=P.+N.+Munster&title=Addition+of+a+histone+deacetylase+inhibitor+redirects+tamoxifen-treated+breast+cancer+cells+into+apoptosis%2C+which+is+opposed+by+the+induction+of+autophagy&doi=10.1007%2Fs10549-011-1364-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy</span></div><div class="casAuthors">Thomas, Scott; Thurn, Kenneth T.; Bicaku, Elona; Marchion, Douglas C.; Muenster, Pamela N.</div><div class="citationInfo"><span class="NLM_cas:title">Breast Cancer Research and Treatment</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">437-447</span>CODEN:
                <span class="NLM_cas:coden">BCTRD6</span>;
        ISSN:<span class="NLM_cas:issn">0167-6806</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Modulation of estrogen signaling is one of the most successful modalities for the treatment of estrogen receptor (ER)-pos. breast cancer, yet de novo and acquired resistance are frequent.  Recent data suggests that the induction of autophagy may play a considerable role in promoting tumor cell survival and resistance to anti-estrogen therapy.  Hence, bypassing autophagy may offer a novel strategy to enhance the anti-tumor efficacy of anti-estrogens.  Histone deacetylases (HDAC) are involved in the regulation of steroid hormone receptor mediated cell signaling and their inhibition potentiates the anti-tumor effects of anti-estrogens.  However, the mechanism underlying this anti-tumor activity is poorly understood.  In this report, we show that the addn. of an HDAC inhibitor redirects the response of ER-pos. breast cancer cells when treated with tamoxifen from growth arrest to apoptotic cell death.  This redirection requires functional ER signaling and is mediated by a depletion of Bcl-2 and an induction of Bax and Bak, manifesting in cytochrome C release and PARP cleavage.  With combined treatment, a subpopulation of cells is refractory to apoptosis and exhibit a strong induction of autophagy.  Inhibition of autophagy in these cells, using siRNA directed against Beclin-1 or treatment with chloroquine, further promotes the induction of apoptosis.  Thus, supporting prior reports that autophagy acts as a survival mechanism, our findings demonstrate that HDAC and autophagy inhibition directs autophagy-protected cells into apoptotic cell death, which may impair development of tamoxifen resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3q7R9fI2f2rVg90H21EOLACvtfcHk0ljCjl1DymPPSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1yktL%252FN&md5=7d959ad3e2773999385c2423e44d84f4</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2Fs10549-011-1364-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10549-011-1364-y%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DS.%26aulast%3DThurn%26aufirst%3DK.%2BT.%26aulast%3DBicaku%26aufirst%3DE.%26aulast%3DMarchion%26aufirst%3DD.%2BC.%26aulast%3DMunster%26aufirst%3DP.%2BN.%26atitle%3DAddition%2520of%2520a%2520histone%2520deacetylase%2520inhibitor%2520redirects%2520tamoxifen-treated%2520breast%2520cancer%2520cells%2520into%2520apoptosis%252C%2520which%2520is%2520opposed%2520by%2520the%2520induction%2520of%2520autophagy%26jtitle%3DBreast%2520Cancer%2520Res.%2520Treat.%26date%3D2011%26volume%3D130%26spage%3D437%26epage%3D447%26doi%3D10.1007%2Fs10549-011-1364-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Sato, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echigo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rikiishi, H.</span><span> </span><span class="NLM_article-title">Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">1233</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.3892/ijo.28.5.1233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.3892%2Fijo.28.5.1233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=16596240" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BD28Xks1Cis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2006&pages=1233-1241&author=T.+Satoauthor=M.+Suzukiauthor=Y.+Satoauthor=S.+Echigoauthor=H.+Rikiishi&title=Sequence-dependent+interaction+between+cisplatin+and+histone+deacetylase+inhibitors+in+human+oral+squamous+cell+carcinoma+cells&doi=10.3892%2Fijo.28.5.1233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells</span></div><div class="casAuthors">Sato, Tomonori; Suzuki, Maiko; Sato, Yoshitaro; Echigo, Seishi; Rikiishi, Hidemi</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1233-1241</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Chemotherapeutic treatment with combinations of drugs is front-line therapy for many types of cancer.  Combining drugs that target different signaling pathways often lessens adverse side-effects while increasing the efficacy of treatment and reducing patient morbidity.  Histone deacetylase (HDAC) inhibitors represent a novel class of anti-neoplastic agents that act by promoting acetylation of core histones, leading in turn to the uncoiling of chromatin and activation of a variety of genes implicated in the regulation of cell survival, proliferation, differentiation, and apoptosis.  A defined scheduling protocol is described by which HDAC inhibitors facilitate the cytotoxic effectiveness of cisplatin (CDDP) in the killing of carcinoma cells.  An oral squamous cell carcinoma cell line (HSC-3) was treated with sodium butyrate (NaB), suberoylanilide hydroxamic acid (SAHA) or MS-275 on the day of, the day before, or the day after addn. of CDDP.  The IC50 (48-h assay) value of 3.48 μg/mL CDDP could be lowered to 0.41 μg/mL CDDP when concurrently combined with an HDAC inhibitor (MS-275).  The percentage of apoptosis by treatment with CDDP for 24 h, followed by NaB for an addnl. 24 h without washing was significantly greater than that obsd. in the reverse order.  Depending on the time of addn. of HDAC inhibitors, CDDP-treated cells displayed varying degrees of apoptotic responses, indicating the crit. nature of timing in the use of HDAC inhibitors.  Interestingly, expts. suggested that cells arrested at the G1/S checkpoint by CDDP were more sensitive to subsequent treatment with an HDAC inhibitor.  Moreover, these events were assocd. with an enhancement of reactive oxygen species (ROS) generation and caspase-3 activation by HDAC inhibitors.  They raise the possibility that combining these agents may represent a novel anti-neoplastic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoP4_pciLxCQLVg90H21EOLACvtfcHk0ljCjl1DymPPSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xks1Cis7k%253D&md5=2b1ad821109ac4f6e98044e8eb4d1838</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.3892%2Fijo.28.5.1233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.28.5.1233%26sid%3Dliteratum%253Aachs%26aulast%3DSato%26aufirst%3DT.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DY.%26aulast%3DEchigo%26aufirst%3DS.%26aulast%3DRikiishi%26aufirst%3DH.%26atitle%3DSequence-dependent%2520interaction%2520between%2520cisplatin%2520and%2520histone%2520deacetylase%2520inhibitors%2520in%2520human%2520oral%2520squamous%2520cell%2520carcinoma%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2006%26volume%3D28%26spage%3D1233%26epage%3D1241%26doi%3D10.3892%2Fijo.28.5.1233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Budman, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Calabro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">John, V.</span><span> </span><span class="NLM_article-title">The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1224</span><span class="NLM_x">–</span> <span class="NLM_lpage">1229</span><span class="refDoi"> DOI: 10.1007/s10637-010-9467-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs10637-010-9467-6" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1224-1229&author=D.+R.+Budmanauthor=J.+Taiauthor=A.+Calabroauthor=V.+John&title=The+histone+deacetylase+inhibitor+panobinostat+demonstrates+marked+synergy+with+conventional+chemotherapeutic+agents+in+human+ovarian+cancer+cell+lines&doi=10.1007%2Fs10637-010-9467-6"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1007%2Fs10637-010-9467-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-010-9467-6%26sid%3Dliteratum%253Aachs%26aulast%3DBudman%26aufirst%3DD.%2BR.%26aulast%3DTai%26aufirst%3DJ.%26aulast%3DCalabro%26aufirst%3DA.%26aulast%3DJohn%26aufirst%3DV.%26atitle%3DThe%2520histone%2520deacetylase%2520inhibitor%2520panobinostat%2520demonstrates%2520marked%2520synergy%2520with%2520conventional%2520chemotherapeutic%2520agents%2520in%2520human%2520ovarian%2520cancer%2520cell%2520lines%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2011%26volume%3D29%26spage%3D1224%26epage%3D1229%26doi%3D10.1007%2Fs10637-010-9467-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Sarcar, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kahali, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnaiyan, P.</span><span> </span><span class="NLM_article-title">Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines</span> <span class="citation_source-journal">J. Neuro-Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">99</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1007/s11060-010-0127-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1007%2Fs11060-010-0127-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20135194" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVGmtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2010&pages=201-207&author=B.+Sarcarauthor=S.+Kahaliauthor=P.+Chinnaiyan&title=Vorinostat+enhances+the+cytotoxic+effects+of+the+topoisomerase+I+inhibitor+SN38+in+glioblastoma+cell+lines&doi=10.1007%2Fs11060-010-0127-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines</span></div><div class="casAuthors">Sarcar, Bhaswati; Kahali, Soumen; Chinnaiyan, Prakash</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuro-Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-207</span>CODEN:
                <span class="NLM_cas:coden">JNODD2</span>;
        ISSN:<span class="NLM_cas:issn">0167-594X</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors represent a promising class of anti-cancer agents that are actively being evaluated in the context of clin. trials in solid tumors, including glioblastoma.  What makes these agents particularly attractive is their capacity to enhance the activity of commonly used cytotoxics in cancer therapy, including both chemotherapy and ionizing radiation.  As recent investigations suggest HDAC inhibitors may potentiate the cytotoxicity of topoisomerase inhibitors, which continue to be a commonly used class of agents in the treatment of glioblastoma, we performed preclin. studies to det. if this combination may be a promising strategy in glioblastoma.  The effects of the HDAC inhibitor vorinostat and SN38, which is the active metabolite of the topoisomerase I inhibitor CPT-11, was evaluated using the clonogenic assay.  Various treatment schedules were tested to det. optimum drug sequencing.  Induction of DNA double strand breaks (DSBs) with the combination of vorinostat and SN38 was evaluated using the neutral comet assay, and their subsequent repair was evaluated by γH2AX foci kinetics using immunofluorescent cytochem.  Vorinostat enhanced the cytotoxicity of SN38 in glioblastoma cell lines.  Optimal treatment schedules involved maximal concurrent administration of agents.  Pretreatment with either agent did not enhance cytotoxicity.  Vorinostat potentiated SN38-induced DNA DSBs and attenuated their subsequent repair.  These results indicate vorinostat enhances the cytotoxicity of SN38 in glioblastoma cell lines, suggesting this combination may be a worthwhile strategy to test in the context of a clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodef1O5fCkdbVg90H21EOLACvtfcHk0ljCjl1DymPPSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVGmtLbF&md5=f651fd43350809ef34a97b10ce43907b</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs11060-010-0127-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11060-010-0127-7%26sid%3Dliteratum%253Aachs%26aulast%3DSarcar%26aufirst%3DB.%26aulast%3DKahali%26aufirst%3DS.%26aulast%3DChinnaiyan%26aufirst%3DP.%26atitle%3DVorinostat%2520enhances%2520the%2520cytotoxic%2520effects%2520of%2520the%2520topoisomerase%2520I%2520inhibitor%2520SN38%2520in%2520glioblastoma%2520cell%2520lines%26jtitle%3DJ.%2520Neuro-Oncol.%26date%3D2010%26volume%3D99%26spage%3D201%26epage%3D207%26doi%3D10.1007%2Fs11060-010-0127-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Mwakwari, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrant, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyelere, A. K.</span><span> </span><span class="NLM_article-title">Macrocyclic histone deacetylase inhibitors</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1423</span><span class="NLM_x">–</span> <span class="NLM_lpage">1440</span><span class="refDoi"> DOI: 10.2174/156802610792232079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.2174%2F156802610792232079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20536416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFajurrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=1423-1440&author=S.+C.+Mwakwariauthor=V.+Patilauthor=W.+Guerrantauthor=A.+K.+Oyelere&title=Macrocyclic+histone+deacetylase+inhibitors&doi=10.2174%2F156802610792232079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Macrocyclic histone deacetylase inhibitors</span></div><div class="casAuthors">Mwakwari, Sandra C.; Patil, Vishal; Guerrant, William; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1423-1440</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase inhibitors (HDACi) are an emerging class of novel anti-cancer drugs that cause growth arrest, differentiation, and apoptosis of tumor cells.  In addn., they have shown promise as anti-parasitic, anti-neurodegenerative, anti-rheumatol. and immunosuppressant agents.  To date, several structurally distinct small mol. HDACi have been reported including aryl hydroxamates, benzamides, short-chain fatty acids, electrophilic ketones, and macrocyclic peptides.  Macrocyclic HDACi possess the most complex cap-groups which interact with HDAC enzyme's outer rim and have demonstrated excellent HDAC inhibition potency and isoform selectivity.  This review focuses on the recent progress and current state of macrocyclic HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXzgRmfQBx27Vg90H21EOLACvtfcHk0lhCJXHSqrXqlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFajurrF&md5=d027b0380e04f364fb0985a350e99c60</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F156802610792232079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802610792232079%26sid%3Dliteratum%253Aachs%26aulast%3DMwakwari%26aufirst%3DS.%2BC.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DMacrocyclic%2520histone%2520deacetylase%2520inhibitors%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D1423%26epage%3D1440%26doi%3D10.2174%2F156802610792232079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Lai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atoyan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forrester, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zifcak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DellaRocca, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhai, H. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munger, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keegan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepicelli, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, C.</span><span> </span><span class="NLM_article-title">CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">3647</span><span class="NLM_x">–</span> <span class="NLM_lpage">3656</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1158%2F0008-5472.CAN-09-3360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=20388807" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=3647-3656&author=C.+J.+Laiauthor=R.+Baoauthor=X.+Taoauthor=J.+Wangauthor=R.+Atoyanauthor=H.+Quauthor=D.+G.+Wangauthor=L.+Yinauthor=M.+Samsonauthor=J.+Forresterauthor=B.+Zifcakauthor=G.+X.+Xuauthor=S.+DellaRoccaauthor=H.+X.+Zhaiauthor=X.+Caiauthor=W.+E.+Mungerauthor=M.+Keeganauthor=C.+V.+Pepicelliauthor=C.+Qian&title=CUDC-101%2C+a+multitargeted+inhibitor+of+histone+deacetylase%2C+epidermal+growth+factor+receptor%2C+and+human+epidermal+growth+factor+receptor+2%2C+exerts+potent+anticancer+activity&doi=10.1158%2F0008-5472.CAN-09-3360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity</span></div><div class="casAuthors">Lai, Cheng-Jung; Bao, Rudi; Tao, Xu; Wang, Jing; Atoyan, Ruzanna; Qu, Hui; Wang, Da-Gong; Yin, Ling; Samson, Maria; Forrester, Jeffrey; Zifcak, Brian; Xu, Guang-Xin; DellaRocca, Steven; Zhai, Hai-Xiao; Cai, Xiong; Munger, William E.; Keegan, Mitchell; Pepicelli, Carmen V.; Qian, Changgeng</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3647-3656</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase inhibitors have recently become important therapeutics for a variety of cancers.  However, due to the heterogeneous and dynamic nature of tumors, the effectiveness of these agents is often hindered by poor response rates and acquired drug resistance.  To overcome these limitations, we created a novel small mol., CUDC-101, which simultaneously inhibits histone deacetylase and the receptor kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) in cancer cells.  Because of its integrated histone deacetylase inhibition, CUDC-101 synergistically blocked key regulators of EGFR/HER2 signaling pathways, also attenuating multiple compensatory pathways, such as AKT, HER3, and MET, which enable cancer cells to escape the effects of conventional EGFR/HER2 inhibitors.  CUDC-101 displayed potent antiproliferative and proapoptotic activities against cultured and implanted tumor cells that are sensitive or resistant to several approved single-targeted drugs.  Our results show that CUDC-101 has the potential to dramatically improve the treatment of heterogeneous and drug-resistant tumors that cannot be controlled with single-target agents.  Further, they provide a framework to create individual small mols. that simultaneously antagonize multiple biochem. distinct oncogenic targets, suggesting a general paradigm to surpass conventional, single-target cancer therapeutics.  Cancer Res; 70(9); 3647-56.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrscJsyultc3bVg90H21EOLACvtfcHk0lhCJXHSqrXqlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlens7o%253D&md5=bc30667b0890e3c505c9608de6fa0c68</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3360%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DC.%2BJ.%26aulast%3DBao%26aufirst%3DR.%26aulast%3DTao%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DQu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DYin%26aufirst%3DL.%26aulast%3DSamson%26aufirst%3DM.%26aulast%3DForrester%26aufirst%3DJ.%26aulast%3DZifcak%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DG.%2BX.%26aulast%3DDellaRocca%26aufirst%3DS.%26aulast%3DZhai%26aufirst%3DH.%2BX.%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMunger%26aufirst%3DW.%2BE.%26aulast%3DKeegan%26aufirst%3DM.%26aulast%3DPepicelli%26aufirst%3DC.%2BV.%26aulast%3DQian%26aufirst%3DC.%26atitle%3DCUDC-101%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520histone%2520deacetylase%252C%2520epidermal%2520growth%2520factor%2520receptor%252C%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%252C%2520exerts%2520potent%2520anticancer%2520activity%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D3647%26epage%3D3656%26doi%3D10.1158%2F0008-5472.CAN-09-3360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Trend of histone deacetylase inhibitors in cancer therapy: isoform selectivity or multitargeted strategy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">63</span><span class="NLM_x">–</span> <span class="NLM_lpage">84</span><span class="refDoi"> DOI: 10.1002/med.21320</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1002%2Fmed.21320" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=24782318" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=63-84&author=L.+Zhangauthor=Y.+Hanauthor=Q.+Jiangauthor=C.+Wangauthor=X.+Chenauthor=X.+Liauthor=F.+Xuauthor=Y.+Jiangauthor=Q.+Wangauthor=W.+Xu&title=Trend+of+histone+deacetylase+inhibitors+in+cancer+therapy%3A+isoform+selectivity+or+multitargeted+strategy&doi=10.1002%2Fmed.21320"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy</span></div><div class="casAuthors">Zhang, Lei; Han, Yantao; Jiang, Qixiao; Wang, Chunbo; Chen, Xuehong; Li, Xiaoguang; Xu, Fuming; Jiang, Yuqi; Wang, Qiang; Xu, Wenfang</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">63-84</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Pharmacol. inhibition of histone deacetylases (HDACs) has been successfully applied in the treatment of a wide range of disorders, including Parkinson's disease, infection, cardiac diseases, inflammation, and esp. cancer.  HDAC inhibitors (HDACIs) have been proved to be effective antitumor agents by various stages of investigation.  At present, there are two opposite focuses of HDACI design in the cancer therapy, highly selective inhibitor strategy and dual- or multitargeted inhibitors.  The former method, which is supposed to elucidate the function of individual HDAC and provide candidate inhibitors with fewer side effects, has been widely accepted by the inhibitor developer.  The latter approach, though less practiced, has promising potential for the antitumor therapy based on HDACIs.  Effective HDACIs, some of which are in clinic anticancer research, have been developed by both methods.  In order to gain insight into HDACI design, the strategies and achievements of the two diverse methods are reviewed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm6HJUNw_9dLVg90H21EOLACvtfcHk0lhCJXHSqrXqlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVClsb3M&md5=791e7d6b057c92f206c8d0d75099e021</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fmed.21320&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21320%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DTrend%2520of%2520histone%2520deacetylase%2520inhibitors%2520in%2520cancer%2520therapy%253A%2520isoform%2520selectivity%2520or%2520multitargeted%2520strategy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2015%26volume%3D35%26spage%3D63%26epage%3D84%26doi%3D10.1002%2Fmed.21320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Kalin, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler, K. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akimova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hancock, W. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kozikowski, A. P.</span><span> </span><span class="NLM_article-title">Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">651</span><span class="refDoi"> DOI: 10.1021/jm200773h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200773h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1SrtbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=639-651&author=J.+H.+Kalinauthor=K.+V.+Butlerauthor=T.+Akimovaauthor=W.+W.+Hancockauthor=A.+P.+Kozikowski&title=Second-generation+histone+deacetylase+6+inhibitors+enhance+the+immunosuppressive+effects+of+Foxp3%2B+T-regulatory+cells&doi=10.1021%2Fjm200773h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Second-Generation Histone Deacetylase 6 Inhibitors Enhance the Immunosuppressive Effects of Foxp3+ T-Regulatory Cells</span></div><div class="casAuthors">Kalin, Jay H.; Butler, Kyle V.; Akimova, Tatiana; Hancock, Wayne W.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">639-651</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Second-generation Tubastatin A analogs were synthesized and evaluated for their ability to inhibit selectively histone deacetylase 6 (HDAC6).  Substitutions to the carboline cap group were well-tolerated with substitution at the 2-position of both β- and γ-carbolines being optimal for HDAC6 activity and selectivity.  Some compds. in this series were detd. to have subnanomolar activity at HDAC6 with more than 7000 fold selectivity for HDAC6 vs. HDAC1.  Selected compds. were then evaluated for their ability to augment the immunosuppressive effect of Foxp3+ regulatory T cells.  All compds. tested were found to enhance the ability of regulatory T cells to inhibit the mitotic division of effector T cells both in vitro and in vivo, suggesting that further investigation into the use of these compds. for the treatment of autoimmune disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzt2Rz2tD6ibVg90H21EOLACvtfcHk0lheqoRHXllMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1SrtbzM&md5=88a4f02045fdc5387970abe53ec00c7a</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm200773h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200773h%26sid%3Dliteratum%253Aachs%26aulast%3DKalin%26aufirst%3DJ.%2BH.%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DAkimova%26aufirst%3DT.%26aulast%3DHancock%26aufirst%3DW.%2BW.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSecond-generation%2520histone%2520deacetylase%25206%2520inhibitors%2520enhance%2520the%2520immunosuppressive%2520effects%2520of%2520Foxp3%252B%2520T-regulatory%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D639%26epage%3D651%26doi%3D10.1021%2Fjm200773h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Mwakwari, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerrant, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patil, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tekwani, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurard-Levin, Z. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mrksich, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oyelere, A. K.</span><span> </span><span class="NLM_article-title">Non-peptide macrocyclic histone deacetylase inhibitors derived from tricyclic ketolide skeleton</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6100</span><span class="NLM_x">–</span> <span class="NLM_lpage">6111</span><span class="refDoi"> DOI: 10.1021/jm100507q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100507q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6100-6111&author=S.+C.+Mwakwariauthor=W.+Guerrantauthor=V.+Patilauthor=S.+I.+Khanauthor=B.+L.+Tekwaniauthor=Z.+A.+Gurard-Levinauthor=M.+Mrksichauthor=A.+K.+Oyelere&title=Non-peptide+macrocyclic+histone+deacetylase+inhibitors+derived+from+tricyclic+ketolide+skeleton&doi=10.1021%2Fjm100507q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton</span></div><div class="casAuthors">Mwakwari, Sandra C.; Guerrant, William; Patil, Vishal; Khan, Shabana I.; Tekwani, Babu L.; Gurard-Levin, Zachary A.; Mrksich, Milan; Oyelere, Adegboyega K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">6100-6111</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase (HDAC) function is a validated therapeutic strategy for cancer treatment.  Of the several structurally distinct small mol. histone deacetylase inhibitors (HDACi) reported, macrocyclic depsipeptides possess the most complex cap groups and have demonstrated excellent HDAC inhibition potency and isoform selectivity.  Unfortunately, the development of macrocyclic depsipeptides has been hampered in part because of development problems characteristic of large peptides and the complex reaction schemes required for their synthesis.  Herein we report that tricyclic ketolide TE-802 is an excellent mimetic for the peptide backbone of macrocyclic HDACi.  Compds. derived from this template are particularly selective against HDACs 1 and 2 with nanomolar inhibitory activity.  Interrogation of the assocn. between a subset of these compds. and key HDAC isoforms, using AutoDock, enables a mol. description of the interaction between the HDAC enzyme's outer rim and the inhibitors' macrocyclic cap group that are responsible for compd. affinity and presumably isoform selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqt9QPKI33jvbVg90H21EOLACvtfcHk0lheqoRHXllMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsV2mtLk%253D&md5=6407dc82e9fb2dab6313d32956600659</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm100507q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100507q%26sid%3Dliteratum%253Aachs%26aulast%3DMwakwari%26aufirst%3DS.%2BC.%26aulast%3DGuerrant%26aufirst%3DW.%26aulast%3DPatil%26aufirst%3DV.%26aulast%3DKhan%26aufirst%3DS.%2BI.%26aulast%3DTekwani%26aufirst%3DB.%2BL.%26aulast%3DGurard-Levin%26aufirst%3DZ.%2BA.%26aulast%3DMrksich%26aufirst%3DM.%26aulast%3DOyelere%26aufirst%3DA.%2BK.%26atitle%3DNon-peptide%2520macrocyclic%2520histone%2520deacetylase%2520inhibitors%2520derived%2520from%2520tricyclic%2520ketolide%2520skeleton%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6100%26epage%3D6111%26doi%3D10.1021%2Fjm100507q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, W. G.</span><span> </span><span class="NLM_article-title">The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage</span> <span class="citation_source-journal">DNA Repair</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">156</span><span class="refDoi"> DOI: 10.1016/j.dnarep.2011.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=10.1016%2Fj.dnarep.2011.10.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=22112863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;key=1%3ACAS%3A528%3ADC%252BC38XotVCksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=146-156&author=H.+Wangauthor=W.+Zhouauthor=Z.+Zhengauthor=P.+Zhangauthor=B.+Tuauthor=Q.+Heauthor=W.+G.+Zhu&title=The+HDAC+inhibitor+depsipeptide+transactivates+the+p53%2Fp21+pathway+by+inducing+DNA+damage&doi=10.1016%2Fj.dnarep.2011.10.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC inhibitor depsipeptide transactivates the p53/p21 pathway by inducing DNA damage</span></div><div class="casAuthors">Wang, Haiying; Zhou, Wen; Zheng, Zhixing; Zhang, Ping; Tu, Bo; He, Qihua; Zhu, Wei-Guo</div><div class="citationInfo"><span class="NLM_cas:title">DNA Repair</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-156</span>CODEN:
                <span class="NLM_cas:coden">DRNEAR</span>;
        ISSN:<span class="NLM_cas:issn">1568-7864</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have been proven to be effective therapeutic agents to kill cancer cells through inhibiting HDAC activity or altering the structure of chromatin.  As a potent HDAC inhibitor, depsipeptide not only modulates histone deacetylation but also activates non-histone protein p53 to inhibit cancer cell growth.  However, the mechanism of depsipeptide-induced p53 transactivity remains unknown.  Here, we show that depsipeptide causes DNA damage through induction of reactive oxygen species (ROS) generation, as demonstrated by a comet assay and by detection of the phosphorylation of H2AX.  Depsipeptide induced oxidative stress was confirmed to relate to a disturbance in redn.-oxidn. (redox) reactions through inhibition of the transactivation of thioredoxin reductase (TrxR) in human cancer cells.  Upon treatment with depsipeptide, p53 phosphorylation at threonine 18 (Thr18) was specifically induced.  Furthermore, we also demonstrated that phosphorylation of p53 at Thr18 is required for p53 acetylation at lysine 373/382 and for p21 expression in response to depsipeptide treatment.  Our results demonstrate that depsipeptide plays an anti-neoplastic role by generating ROS to elicit p53/p21 pathway activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb4o9Q8pCXQbVg90H21EOLACvtfcHk0lhhlHgoCnzKpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XotVCksw%253D%253D&md5=eefbeedd5c1475560e83c20359b45cc9</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.dnarep.2011.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.dnarep.2011.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZheng%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DTu%26aufirst%3DB.%26aulast%3DHe%26aufirst%3DQ.%26aulast%3DZhu%26aufirst%3DW.%2BG.%26atitle%3DThe%2520HDAC%2520inhibitor%2520depsipeptide%2520transactivates%2520the%2520p53%252Fp21%2520pathway%2520by%2520inducing%2520DNA%2520damage%26jtitle%3DDNA%2520Repair%26date%3D2012%26volume%3D11%26spage%3D146%26epage%3D156%26doi%3D10.1016%2Fj.dnarep.2011.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span> </span><span class="NLM_article-title">Development of tetrahydroisoquinoline-based hydroxamic acid serivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2823</span><span class="NLM_x">–</span> <span class="NLM_lpage">2838</span><span class="refDoi"> DOI: 10.1021/jm101605z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101605z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2823-2838&author=Y.+Zhangauthor=J.+Fengauthor=Y.+Jiaauthor=X.+Wangauthor=L.+Zhangauthor=C.+Liuauthor=H.+Fangauthor=W.+Xu&title=Development+of+tetrahydroisoquinoline-based+hydroxamic+acid+serivatives%3A+potent+histone+deacetylase+inhibitors+with+marked+in+vitro+and+in+vivo+antitumor+activities&doi=10.1021%2Fjm101605z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm101605z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101605z%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520tetrahydroisoquinoline-based%2520hydroxamic%2520acid%2520serivatives%253A%2520potent%2520histone%2520deacetylase%2520inhibitors%2520with%2520marked%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2823%26epage%3D2838%26doi%3D10.1021%2Fjm101605z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-NOTES-d2022e6467-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i85"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01052">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48051"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01052">10.1021/acs.jmedchem.5b01052</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental details pertaining to pharmacokinetic studies. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Structures for compounds <b>5a</b>–<b>o</b> and <b>11a</b>–<b>j</b>. (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_001.pdf">jm5b01052_si_001.pdf (57.42 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01052/suppl_file/jm5b01052_si_002.csv">jm5b01052_si_002.csv (1.47 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01052&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01052%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2015.58.issue-23%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01052" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67996c3aba413d76","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
